HIV Surveillance Report (example)

National HIV Surveillance System (NHSS)

Attachment 5.
HIV Surveillance Report

Volume 33

Diagnoses of
HIV Infection in
the United States and
Dependent Areas, 2020

The HIV Surveillance Report is published annually by the Division of HIV Prevention, National Center
for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC),
U.S. Department of Health and Human Services, Atlanta, Georgia.
Data are presented for diagnoses of HIV infection reported to CDC through December 2021.
The HIV Surveillance Report is not copyrighted and may be used and reproduced without permission.
Citation of the source is, however, appreciated.
Suggested citation
Centers for Disease Control and Prevention. HIV Surveillance Report, 2020; vol. 33. 
http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2022. Accessed [date].
On the Web: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
Confidential information, referrals, and educational material on HIV infection
CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form
Acknowledgments
This report was prepared by the following CDC staff and contractors of the Division of HIV Prevention,
National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: André Dailey, Zanetta Gant, Jianmin
Li, Shruthi Nagaraju, Faith Elenwa, Sonia Singh, Joseph E. Logan, Anna Satcher Johnson, Shacara Johnson
Lyons, Michael Friend (editing and desktop publishing), Azfar Siddiqi (science review), and the Chief of the
HIV Surveillance Branch, Angela L. Hernandez.
The following are acknowledged for their contributions to the report (including graphics) and report website:
Prevention Communications Branch (Web and Consumer Services Team); the Division of Communication
Services, Mikaelyn Benson, Deirdre Launt, Meredith Newlove, Cesar Rivera (Design Team).
Publication of this report would not have been possible without the contributions of the state and territorial
health departments and the HIV surveillance programs that provided surveillance data to CDC.


HIV Surveillance Report

2

Vol. 33

Contents
Contents

Commentary
National Profile
Special Focus Profiles
Gay, Bisexual, and Other Men Who Have Sex With Men
Persons Who Inject Drugs
Transgender Persons
Women
Persons Aged 13–24 Years
Children Aged <13 Years
Technical Notes
References
Additional Resources
Suggested Readings
COVID-19 Suggested Readings
Figures in the National Profile
Section 1 Diagnoses of HIV Infection
1 Rates of diagnoses of HIV infection among persons aged ≥ 13 years, 2020 (COVID-19 pandemic)—United
States and 6 dependent areas
2 Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by gender, 2020 (COVID-19
pandemic)—United States and 6 dependent areas
3 Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by age at diagnosis, 2020 (COVID19 pandemic)—United States and 6 dependent areas
4 Rates and disparities of diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics,
2020 (COVID-19 pandemic)—United States
5 Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by race/ethnicity, 2020 (COVID-19
pandemic)—United States and 6 dependent areas
6 Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by sex assigned at birth and
transmission category, 2020 (COVID-19 pandemic)—United Sates and 6 dependent areas
Section 2 Deaths after a Diagnosis of HIV Infection
7 Rates of deaths of persons aged ≥ 13 years with diagnosed HIV infection, 2020—United States and
6 dependent areas
8 Percentages of deaths among persons aged ≥ 13 years with diagnosed HIV infection, by selected
characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
9 Rates and disparities of deaths of persons aged ≥ 13 years with diagnosed HIV infection, by selected
characteristics, 2020 (COVID-19 pandemic)—United States
Section 3 Persons Living with Diagnosed HIV Infection (Prevalence)
10 Rates of persons aged ≥ 13 years living with diagnosed HIV infection, year-end 2020 (COVID-19 pandemic)—
United States and 6 dependent areas
11 Percentages of persons aged ≥ 13 years living with diagnosed HIV infection, by sex assigned at birth and race/
ethnicity, year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas
Figures in the Special Focus Profiles
Section 1 Gay, Bisexual, and Other Men Who Have Sex With Men
12 Percentages of diagnoses of HIV infection among men who have sex with men, by selected characteristics,
2020 (COVID-19 pandemic)—United States and 6 dependent areas
13 Percentages of diagnoses of HIV infection among men who have sex with men, by age group and race/
ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
14 Diagnoses of HIV infection among men who have sex with men, by region of residence and race/ethnicity,
2020 (COVID-19 pandemic)—United States and 6 dependent areas

HIV Surveillance Report

3

8
10
23
23
26
30
34
39
43
48
56
57
57
58

11
12
12
14
15
15

16
18
19

20
21

25
25
26

Vol. 33

Section 2 Persons Who Inject Drugs
Percentages of diagnoses of HIV infection among persons who inject drugs, by selected characteristics, 2020
(COVID-19 pandemic)—United States and 6 dependent areas
16 Percentages of diagnoses of HIV infection among persons who inject drugs, by sex assigned at birth and race/
ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
17 Diagnoses of HIV infection among persons who inject drugs, by region and race/ethnicity, 2020 (COVID-19
pandemic)—United States and 6 dependent areas
Section 3 Transgender Persons
18 Percentages of diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13
years, by selected characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
19 Percentages of diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13
years, by gender and race/ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
20 Percentages of diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13
years, by gender and exposure category, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
Section 4 Women
21 Rates of diagnoses of HIV infection among females aged ≥ 13 years, 2020 (COVID-19 pandemic)—United
States and 6 dependent areas
22 Percentages of diagnoses of HIV infection and population among females aged ≥ 13 years, by race/ethnicity,
2020 (COVID-19 pandemic)—United States
23 Rates and disparities of diagnoses of HIV infection among females aged ≥ 13 years, by selected characteristics,
2020 (COVID-19 pandemic)—United States and 6 dependent areas
24 Percentages of diagnoses of HIV infection among females aged ≥ 13 years, by transmission category and race/
ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
25 Rates of diagnoses of HIV infection among females aged ≥ 13 years, by race/ethnicity and region, 2020
(COVID-19 pandemic)—United States
Section 5 Persons Aged 13–24 Years
26 Percentages of diagnoses of HIV infection among persons aged 13–24 years, by selected characteristics, 2020
(COVID-19 pandemic)—United States and 6 dependent areas
27 Percentages of diagnoses of HIV infection among persons aged 13–24 years, by sex assigned at birth and
transmission category, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
28 Rates and disparities of diagnoses of HIV infection among persons aged 13–24 years, by selected
characteristics, 2020 (COVID-19 pandemic)—United States
Section 6 Children Aged < 13 Years
29 Diagnoses of perinatally acquired HIV infection among children born during 2019—United States and 6
dependent areas
30 Time of maternal HIV testing among children with diagnosed perinatally acquired HV infection and children
exposed to HIV, birth years 2016–2019—United States and Puerto Rico
31 Percentages of diagnoses of HIV infection among children, by race/ethnicity, 2020 (COVID-19 pandemic)—
United States and 6 dependent areas
32 Rates of children living with diagnosed HIV infection, year-end 2020 (COVID-19 pandemic)—United States
and 6 dependent areas
33 Persons living with diagnosed, perinatally acquired HIV infection, year-end 2020 (COVID-19 pandemic)—
United States and 6 dependent areas
Tables in the National Profile
Section 1 Diagnoses of HIV Infection
1a Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States
1b Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States and
6 dependent areas
2a Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—
United States
2b Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—
United States and 6 dependent areas
15


HIV Surveillance Report

4

28
29
30

32
33
34

35
36
37
38
39

41
41
42

43
44
45
46
47

59
60
61
62

Vol. 33

3a Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, sex assigned at birth, and
63
selected characteristics, 2016–2020—United States
3b Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, sex assigned at birth, and
64
selected characteristics, 2016–2020—United States and 6 dependent areas
4a Diagnoses of HIV infection among transgender and additional gender identity persons, by year of diagnosis
65
and selected characteristics, 2016–2020—United States
4b Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13 years, by year 67
of diagnosis and selected characteristics, 2016–2020—United States and 6 dependent areas
5a Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and 69
male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–
2020—United States
5b Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and 73
male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–
2020—United States and 6 dependent areas
6a Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/
77
ethnicity, and selected characteristics, 2016–2020—United States
6b Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/
81
ethnicity, and selected characteristics, 2016–2020—United States and 6 dependent areas
7a Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ 85
ethnicity, and selected characteristics, 2016–2020—United States
7b Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ 89
ethnicity, and selected characteristics, 2016–2020—United States and 6 dependent areas
8a Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, sex assigned at birth, and
93
selected characteristics, 2020 (COVID-19 pandemic)—United States
8b Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, sex assigned at birth, and
94
selected characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
9a Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–
95
2020—United States
9b Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–
95
2020—United States and 6 dependent areas
10a Diagnoses of HIV infection among Hispanic/Latino persons aged ≥ 13 years, by place of birth and transmission 96
category, 2020 (COVID-19 pandemic)—United States and 6 dependent areas
10b Diagnoses of HIV infection among Hispanic/Latino transgender and additional gender identity persons aged
97
≥ 13 years, by place of birth and exposure category, 2020 (COVID 19 pandemic)—United States and
6 dependent areas
Section 2 Deaths after a Diagnosis of HIV Infection
11a Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020— 98
United States
11b Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020— 100
United States and 6 dependent areas
12a Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID- 102
19 pandemic)—United States
12b Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID- 104
19 pandemic)—United States and 6 dependent areas
13a Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and 106
selected characteristics, 2016–2020—United States
13b Death of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and
108
selected characteristics, 2016–2020—United States and 6 dependent areas
14a Deaths of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by 110
year of death and selected characteristics, 2016–2020—United States
14b Deaths of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by 112
year of death and selected characteristics, 2016–2020—United States and 6 dependent areas

HIV Surveillance Report

5

Vol. 33

Section 3 Persons Living with Diagnosed HIV Infection (Prevalence)
15a Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States
15b Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States
and 6 dependent areas
16a Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020
(COVID-19 pandemic)—United States
16b Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020
(COVID-19 pandemic)—United States and 6 dependent areas
17a Persons aged ≥ 13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected
characteristics, 2016–2020—United States
17b Persons aged ≥ 13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected
characteristics, 2016–2020—United States and 6 dependent areas
18a Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by
year and selected characteristics, 2016–2020—United States
18b Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by
year and selected characteristics, 2016–2020—United States and 6 dependent areas
19a Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year, sex assigned at birth, and
selected characteristics, year-end 2020 (COVID-19 pandemic)—United States
19b Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year, sex assigned at birth, and
selected characteristics, year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas
20
21
22

114
116
118
120
122
124
126
128
130
131

Section 4 Data by Area of Residence
Diagnoses of HIV infection, 2020, and persons living with diagnosed HIV infection (prevalence), year-end
132
2020, by area of residence—United States and 6 dependent areas
Persons aged ≥ 13 years living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 133
2020 (COVID-19 pandemic)—United States and 6 dependent areas
Diagnoses of HIV infection, 2020, and persons living with diagnosed HIV infection (prevalence), year-end
135
2020, by metropolitan statistical area of residence—United States and Puerto Rico

Web Addresses for Reports of State and Local HIV Surveillance
Appendix
A1 Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2019 and 2020—Ending the
HIV Epidemic Phase I jurisdictions
A2 Persons aged ≥ 13 years living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end
2020 (COVID-19 pandemic)—Ending the HIV Epidemic Phase I jurisdictions


HIV Surveillance Report

6

138
139
140
142

Vol. 33

Guide to Acronyms and Initialisms
AGI

additional gender identity

AIDS

acquired immunodeficiency syndrome

CDC

Centers for Disease Control and Prevention

COVID-19 coronavirus disease 2019
EHE

Ending the HIV Epidemic in the U.S.

HHS

U.S. Department of Health and Human Services

HIV

human immunodeficiency virus

IDU

injection drug use

MMSC

male-to-male sexual contact

MSA

metropolitan statistical area

MSM

gay, bisexual, and other men who have sex with men

NHAS

National HIV/AIDS Strategy

NHSS

National HIV Surveillance System

NIR

no identified risk factor

OI

opportunistic illness

OMB

Office of Management and Budget

PrEP

preexposure prophylaxis

PWID

persons who inject drugs

SDOH

social determinants of health

HIV Surveillance Report

7

Vol. 33

OVERVIEW
The Centers for Disease Control and Prevention (CDC) collects, analyzes, and disseminates surveillance data
on HIV infection; these data are one of the nation’s primary sources of information on HIV in the United States.
The annual surveillance report, published by CDC, summarizes information about diagnosed HIV infection in
the United States and dependent areas. HIV surveillance data are used by CDC and their public health partners
in other federal agencies, health departments, nonprofit organizations, academic institutions, and the public to
help focus prevention efforts; plan services; allocate resources; develop policy; detect, monitor, and intervene
in HIV clusters; and monitor trends in HIV infection. Data in this report may be used to achieve national goals,
such as those laid out in the National HIV/AIDS Strategy [1], Healthy People 2030 [2], and the Ending the HIV
Epidemic in the U.S. (EHE) initiative [3].

IMPACT OF COVID-19 PANDEMIC
For this report, due to the impact of the COVID-19 pandemic on HIV testing in the United States during 2020,
HIV diagnosis, death, and prevalence trends through 2020 are not discussed in the Commentary [4–7]. The overall number of HIV diagnoses in the United States in 2020 (30,403) was 17% lower than in 2019 (36,585) (Figure
A, Table 1a). The steep reduction in diagnoses in 2020 is likely due to disruptions in clinical care services,
patient hesitancy in accessing clinical services, and shortages in HIV testing reagents/materials, which causes
concern regarding underdiagnosis [5–7]. Although state/local health departments developed innovative strategies for HIV-related testing (self-tests) and care services (telehealth) during the COVID-19 pandemic, these
strategies did not make up for declines in laboratory reporting because self-test results are not routinely reported
to health departments or CDC [8, 9]. In addition, telehealth visits might not have included orders for laboratory
testing during periods of strict social distancing or patients may have been reluctant to complete testing.

HIV Surveillance Report

8

Vol. 33

As the COVID-19 pandemic is still ongoing, more time and data are needed to accurately assess COVID-19’s
impact on HIV in the United States. Data for the year 2020 should be interpreted with caution due to the impact
of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. To emphasize the need for caution, tables presenting data for the year 2020 include
“COVID-19 pandemic” in the title, and the 2020 column is highlighted in tables that provide multiple years of
data. Assessment of trends in HIV diagnoses, deaths, and prevalence that include the year 2020 is discouraged.
See COVID-19 suggested readings for additional information on COVID-19 and HIV.
Figure A. Diagnoses of HIV infection, 2016–2020—United States

Note. Diagnoses of HIV infection reported to CDC through December 2021. The annual number of HIV diagnoses in 2020 was
17% lower than 2019. The decline in 2020 was larger than the average yearly decline (2%–3%) observed during 2016–2019.

Numbers, percentages, and rates of diagnoses of HIV infection during 2020 are based on data from all 50 states,
the District of Columbia, and 6 U.S. dependent areas (American Samoa, Guam, the Northern Mariana Islands,
Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands). Data for stage 3 (AIDS) are available via Atlas
Plus (for 1985 through the most recent year) and in the Stage 3 (AIDS) classification slide set (for cumulative
data through the most recent year).

REPORT CHANGES
• Terminology for gender and transmission category labels were updated.
• Risk factor data for transgender and additional gender identity persons have been added. Data are presented using the exposure category classification, which is meant to convey all the known ways the person
could have been exposed to HIV. (See Technical Notes for more information on exposure category.)
• Tables that present data for transgender persons include additional gender identity (AGI); a new table
presents diagnoses of HIV infection by exposure category and place of birth (Table 10b).
• National Profile and Special Focus Profile sections now include absolute and relative disparity measures.


HIV Surveillance Report

9

Vol. 33

Data presented in this report are based on case data reported to CDC through December 31, 2021, and allows
for a 12-month reporting delay and assessment of diagnosis, death, and prevalence for the year 2020. The
statements in this section, unless otherwise indicated, are based on 12 or more cases. All rates are per
100,000 population.
When presenting rates by race/ethnicity, data are only provided for the United States (50 states and the District
of Columbia) because denominator data are not available by race/ethnicity for all U.S. dependencies.
Please use caution when interpreting data for AGI persons, transgender men, American Indian/Alaska Native
and Native Hawaiian/other Pacific Islander persons as many percentages and/or rates were based on
small numbers.
For disparity measures, reference groups are based on the rate of the lowest group with more than five percent
of cases.
Deaths of persons with diagnosed HIV infection may be due to any cause (i.e., may or may not be related to HIV
infection). Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021.
Important note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic
on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
Please read all titles and footnotes carefully to ensure a complete understanding of the displayed data. See Technical Notes for information on definitions and data specifications.

HIV Surveillance Report

10

Vol. 33

DIAGNOSES
Diagnoses of HIV infection
In 2020, in the United States and 6 dependent areas, there were 30,692 diagnoses of HIV infection (persons
aged ≥ 13 years: 30,635) (Tables 1b, 3b). The overall HIV diagnosis rate was 9.2 (persons aged ≥ 13 years: 10.9)
(Figure 1).
Figure 1. Rates of diagnoses of HIV infection among persons aged ≥ 13 years, 2020 (COVID-19 pandemic)—
United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates incomplete reporting.

HIV diagnosis percentages and/or rates among persons aged ≥ 13 years were as follows:
• Gender (Figure 2):
○ Male: 80%
○ Female: 18%
○ Transgender woman/girl: 2%
○ Transgender man/boy: < 1%
○ AGI: < 1%


HIV Surveillance Report

11

Vol. 33

Figure 2. Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by gender, 2020 (COVID19 pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.

• Age group (Figure 3):
○ 13–24 years: 20%
○ 25–34 years: 37%
○ 35–44 years: 20%
○ 45–54 years: 13%
○ ≥ 55 years: 10%
For additional data by 5-year age groups, see Table 3b.
Figure 3. Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by age at diagnosis,
2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.


HIV Surveillance Report

12

Vol. 33

• Rates (U.S. only) (Figure 4):
○ Highest: persons aged 25–34 years (24.4)
○ Lowest: persons aged ≥ 55 years (3.2)
For additional data by 5-year age groups, see Table 3a.
▪ Disparities by age group:
‣ Absolute disparity (rate difference)—If persons aged 25–34 years had the same rate as persons aged
≥ 55 years, 21 cases per 100,000 population would have been prevented.
‣ Relative disparity (rate ratio)—Persons aged 25–34 years had a rate that was 7.6 times as high as
persons aged ≥ 55 years.
• Rates (U.S. only) (Figure 4):
○ Highest: Black/African American (37.4)
○ Lowest: Asian (3.8)
▪ Disparities by race/ethnicity:
‣ Absolute disparity (rate difference)—If Black/African American persons aged ≥ 13 years had the
same rate as White persons aged ≥ 13 years (4.6), 33 cases per 100,000 population would have been
prevented.
‣ Relative disparity (rate ratio)—Black/African American persons aged ≥ 13 years had a rate that was
8.1 times as high as White persons aged ≥ 13 years.
• Rates (U.S. only) (Figure 4):
○ Highest: South (14.7)
○ Lowest: Midwest (7.2)
▪ Disparities by region:
‣ Absolute disparities (rate difference): if the South had the same rate as the Midwest, 8 cases per
100,000 population would have been prevented.
‣ Relative disparities (rate ratio): the South had a rate that was 2.0 times as high as the Midwest.


HIV Surveillance Report

13

Vol. 33

Figure 4. Rates and disparities of diagnoses of HIV infection among persons aged ≥ 13 years, by selected
characteristics, 2020 (COVID-19 pandemic)—United States

Note. Rates are per 100,000 population. Data for 2020 should be interpreted with caution due to the impact of the COVID-19
pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Absolute
disparity measures the difference between rates in groups with the highest rates and a reference group
(Ratehighest group − Ratereference group). Relative disparity (rate ratio) measures the rates in groups with the highest rates divided
by a reference group (Ratehighest group ÷ Ratereference group).
a Hispanic/Latino persons can be of any race.

• Race/ethnicity (Figure 5):
○ American Indian/Alaska Native: 1%
○ Asian: 2%
○ Black/African American: 42%
○ Hispanic/Latino: 27%
○ Native Hawaiian/other Pacific Islander: < 1%
○ White: 26%
○ Multiracial: 3%


HIV Surveillance Report

14

Vol. 33

Figure 5. Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by race/ethnicity,
2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Sex assigned at birth and transmission category—highest percentages (Figure 6, Table 1b):
○ Overall: infections attributed to male-to-male sexual contact (MMSC) (68%)
○ Among male sex at birth: MMSC (83%)
○ Among female sex at birth: heterosexual contact (83%)
Figure 6. Percentages of diagnoses of HIV infection among persons aged ≥ 13 years, by sex assigned at birth
and transmission category, 2020 (COVID-19 pandemic)—United Sates and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. See section D4 in Technical Notes for
more information on transmission categories.


HIV Surveillance Report

15

Vol. 33

• Gender and exposure category—highest percentages (Table 4b):
○ Among transgender women: sexual contact (90%)
○ Among transgender men: sexual contact (73%)
○ Among AGI: sexual contact (82%)
• Region of residence, all persons (Table 1b):
○ Northeast: 14%
○ Midwest: 13%
○ South: 51%
○ West: 21%
○ U.S. dependent areas: 1%

DEATHS
Deaths of persons with diagnosed HIV infection
In 2020, in the United States and 6 dependent areas, there were 18,493 deaths among persons with diagnosed
HIV infection (persons aged ≥ 13 years: 18,489) (Tables 12b). The overall rate of deaths was 5.6 (persons aged
≥ 13 years: 6.6) (Figure 7).
Figure 7. Rates of deaths of persons aged ≥ 13 years with diagnosed HIV infection, 2020—United States and
6 dependent areas

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary
and based on deaths reported to CDC as of December 2021. Asterisk (*) indicates incomplete reporting. Data for 2020 should
be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and
case surveillance activities in state/local jurisdictions.


HIV Surveillance Report

16

Vol. 33

Deaths of persons aged ≥ 13 years with a diagnosis of HIV infection percentages and/or rates were as follows:
• Gender, all persons (Table 11b):
○ Male: 74%
○ Female: 24%
○ Transgender woman/girl: 1%
○ Transgender man/boy: <1%
○ AGI: 0%
• Age group (Figure 8):
○ 13–24 years: 1%
○ 25–34 years: 6%
○ 35–44 years: 11%
○ 45–54 years: 20%
○ ≥ 55 years: 62%%
For additional data by 5-year age groups, see Table 11b.
• Race/ethnicity (Figure 8):
○ American Indian/Alaska Native: <1%
○ Asian: 1%
○ Black/African American: 43%
○ Hispanic/Latino: 19%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 30%
○ Multiracial: 7%


HIV Surveillance Report

17

Vol. 33

Figure 8. Percentages of deaths among persons aged ≥ 13 years with diagnosed HIV infection, by selected
characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary
and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the
impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/
local jurisdictions.
a Includes Asian/Pacific Islander legacy cases.
b Hispanic/Latino persons can be of any race.

• Rates (U.S. only) (Figure 9):
○ Highest: persons aged ≥ 55 years (11.5)
○ Lowest: persons aged 13–24 years (0.3)
For additional rates by age group, see Table 11a.
▪ Disparities by age group:
‣ Absolute disparity (rate difference)—If persons aged ≥ 55 years had the same rate as persons aged
25–34 years, 9 cases per 100,000 population would have been prevented.
‣ Relative disparity (rate ratio)—Persons aged ≥ 55 years had a rate that was 4.4 times as high as persons aged 25–34 years.
• Rates (U.S. only) (Figure 9):
○ Highest: Multiracial (25.7)
○ Lowest: Asian (0.6)
▪ Disparities by race/ethnicity:
‣ Absolute disparity (rate difference)—If multiracial persons aged ≥ 13 years had the same rate as
White persons aged ≥ 13 years (3.2), 23 cases per 100,000 population would have been prevented.
‣ Relative disparity (rate ratio)—Multiracial persons aged ≥ 13 years had a rate that was 8.0 times as
high as White persons aged ≥ 13 years.


HIV Surveillance Report

18

Vol. 33

• Rates (U.S. only) (Figure 9):
○ Highest: Northeast (9.3)
○ Lowest: Midwest (3.9)
▪ Disparities by region:
‣ Absolute disparities (rate difference): if the Northeast had the same rate as the Midwest, 5 cases per
100,000 population would have been prevented.
‣ Relative disparities (rate ratio): the Northeast had a rate that was 2.4 times as high as the Midwest.
Figure 9. Rates and disparities of deaths of persons aged ≥ 13 years with diagnosed HIV infection, by selected
characteristics, 2020 (COVID-19 pandemic)—United States

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary
and based on deaths reported to CDC as of December 2021. Asterisk (*) indicates incomplete reporting. Data for 2020 should
be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and
case surveillance activities in state/local jurisdictions. Absolute disparity measures the difference between rates in groups with
the highest rates and a reference group (Ratehighest group − Ratereference group). Relative disparity (rate ratio) measures the rates
in groups with the highest rates divided by a reference group (Ratehighest group ÷ Ratereference group).
a Hispanic/Latino persons can be of any race.

• Sex assigned at birth and transmission category—highest percentages (Table 11b):
○ Overall: infections attributed to MMSC (43%)
○ Among male sex at birth: MMSC (56%)
○ Among female sex at birth: heterosexual contact (66%)
• Gender and exposure category—highest percentages (Table 14b):
○ Among transgender women: sexual contact (68%)
○ Among transgender men: sexual contact (67%)
○ Among AGI: no deaths


HIV Surveillance Report

19

Vol. 33

• Region of residence, all persons (Table 11b):
○ Northeast: 24%
○ Midwest: 12%
○ South: 47%
○ West: 16%
○ U.S. dependent areas: 2%

PREVALENCE
Persons living with diagnosed HIV infection
At year-end 2020 in the United States and 6 dependent areas, 1,072,051 persons were living with diagnosed
HIV infection (persons aged ≥ 13 years: 1,070,604) (Table 15b, 17b). The overall rate of persons living with
diagnosed HIV infection was 321.9 (persons aged ≥ 13 years: 381.4) (Figure 10).
Figure 10. Rates of persons aged ≥ 13 years living with diagnosed HIV infection, year-end 2020 (COVID-19
pandemic)—United States and 6 dependent areas

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data are based on
address of residence as of December 31, 2020 (i.e., most recent known address). Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance
activities in state/local jurisdictions. Asterisk (*) indicates incomplete reporting.

Persons living with diagnosed HIV infection percentages and/or rates were as follows:
• Gender (Table 15b):
○ Male: 76%
○ Female: 23%
○ Transgender woman/girl: 1%
○ Transgender man/boy: <1%
○ AGI: <1%

HIV Surveillance Report

20

Vol. 33

• Age group (Table 15b):
○ 13–24 years: 3%
○ 25–34 years: 15%
○ 35–44 years: 19%
○ 45–54 years: 24%
○ ≥ 55 years: 39%
For additional data by 5-year age groups, see Table 15b.
• Race/ethnicity (Figure 11):
○ American Indian/Alaska Native: <1%
○ Asian: 2%
○ Black/African American: 40%
○ Hispanic/Latino: 24%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 29%
○ Multiracial: 5%
• Sex assigned at birth and race/ethnicity, persons aged ≥ 13 years (Figure 11):
○ Highest among male sex at birth: Black/African American (35%)
○ Highest among female sex at birth: Black/African American (57%)
Figure 11. Percentages of persons aged ≥ 13 years living with diagnosed HIV infection, by sex assigned at birth
and race/ethnicity, year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a
Includes Asian/Pacific Islander legacy cases.
b
Hispanic/Latino persons can be of any race.


HIV Surveillance Report

21

Vol. 33

• Rates (U.S. only) (Table 15a):
○ American Indian/Alaska Native: 133.5
○ Asian: 83.6
○ Black/African American: 1,038.0
○ Hispanic/Latino: 401.4
○ Native Hawaiian/other Pacific Islander: 152.6
○ White: 155.5
○ Multiracial: 693.7
• Sex assigned at birth and transmission category, persons aged ≥ 13 years—highest percentages
(Table 17b):
○ Overall: infections attributed to MMSC (56%)
○ Among male sex at birth: MMSC (74%)
○ Among female sex at birth: heterosexual contact (77%)
• Gender and exposure category, persons aged ≥ 13 years—highest percentages (Table 18b):
○ Among transgender women: sexual contact (85%)
○ Among transgender men: sexual contact (75%)
○ Among AGI: sexual contact (87%)
• Region of residence (Table 15b):
○ Northeast: 22%
○ Midwest: 12%
○ South: 45%
○ West: 20%
○ U.S. dependent areas: 2%
• Rates (U.S. only) (Table 15b):
○ Highest: Northeast (421.4)
○ Lowest: Midwest (185.8)


HIV Surveillance Report

22

Vol. 33

Note. This is not a stock image. The persons in this image are living with HIV or are advocates for those living with HIV.

The Special Focus Profiles highlight the distribution of HIV in 6 populations of particular interest to HIV prevention programs in state and local health departments: (1) Gay, Bisexual, and Other Men Who Have Sex With
Men, (2) Persons Who Inject Drugs, (3) Transgender Persons, (4) Women, and (5) Persons Aged 13–24 Years,
and (6) Children Aged < 13 Years. See suggested readings for references and additional information including
HIV risk behaviors, barriers to care, and prevention challenges for each population of particular interest.

GAY, BISEXUAL, AND OTHER MEN WHO HAVE SEX WITH MEN
Gay, bisexual, and other men who have sex with men (MSM) are the population most affected by HIV in the
United States. Stigma, homophobia, and discrimination make MSM of all races/ethnicities susceptible to multiple physical and mental health problems and can affect whether they seek and receive high-quality health services, including HIV testing, treatment, and other prevention services.
In 2020, MSM accounted for 71% (20,758 MMSC and 1,109 MMSC and IDU) of the 30,692 new HIV diagnoses in the United States and 6 dependent areas (Table 1b). Many Black/African American and Hispanic/Latino
MSM with HIV, particularly young MSM, are unaware of their HIV infection. Lack of awareness of HIV status
among young MSM may be due to recent infection, not getting tested due to underestimation of personal risk,
or fewer opportunities to get tested. Persons who do not know they have HIV do not get medical care or receive
treatment and can unknowingly infect others.

HIV Surveillance Report

23

Vol. 33

Diagnoses of HIV infection among MSM
HIV diagnosis percentages for 2020 were as follows:
• Age group (Figure 12):
○ 13–24 years: 24%
○ 25–34 years: 40%
○ 35–44 years: 17%
○ 45–54 years: 11%
○ ≥ 55 years: 8%
• Race/ethnicity (Figure 12):
○ American Indian/Alaska Native: 1%
○ Asian: 2%
○ Black/African American: 39%
○ Hispanic/Latino: 31%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 25%
○ Multiracial: 3%
• Region of residence (Figure 12):
○ Northeast: 13%
○ Midwest: 14%
○ South: 50%
○ West: 23%
○ U.S. dependent areas: 1%


HIV Surveillance Report

24

Vol. 33

Figure 12. Percentages of diagnoses of HIV infection among men who have sex with men, by selected
characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. Data for 2020 should be interpreted
with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Age group and race/ethnicity—highest percentages by age group (Figure 13):
○ Aged 13–24 years: Black/African American (54%)
○ Aged >24 years: Black/African American (34%)
Figure 13. Percentages of diagnoses of HIV infection among men who have sex with men, by age group and
race/ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. Data for 2020 should be interpreted
with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a
Hispanic/Latino persons can be of any race.

HIV Surveillance Report

25

Vol. 33

• Region of residence and race/ethnicity—highest numbers and percentages by region (Figure 14):
○ Northeast: Black/African American (941; 36%)
○ Midwest: Black/African American (1,323; 47%)
○ South: Black/African American (5,079; 49%)
○ West: Hispanic/Latino (2,199; 47%)
○ U.S. dependent areas: Hispanic/Latino (183; 99%)
Figure 14. Diagnoses of HIV infection among men who have sex with men, by region of residence and race/
ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. Data for 2020 should be interpreted
with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Prevalence and race/ethnicity (Table 16b):
At year-end 2020 in the United States and 6 dependent areas, 604,590 MSM were living with diagnosed
HIV infection attributed to MMSC.
Prevalence by race/ethnicity was as follows:
○ American Indian/Alaska Native: <1%
○ Asian: 2%
○ Black/African American: 31%
○ Hispanic/Latino: 26%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 36%
○ Multiracial: 5%

PERSONS WHO INJECT DRUGS
Persons who inject drugs (PWID) can get HIV if they use and share needles, syringes, or other drug injection
equipment (e.g., cookers) that someone with HIV has used. In 2020, persons who inject drugs account for about
1 in 15 HIV diagnoses in the United States. In recent years, the opioid (including prescription and synthetic
opioids) and heroin crisis has led to increased numbers of PWID. HIV diagnoses among PWID have increased

HIV Surveillance Report

26

Vol. 33

in the 50 states and District of Columbia. IDU in nonurban areas has created prevention challenges and brought
attention to populations who would benefit from HIV prevention efforts.

Diagnoses of HIV infection among PWID
In 2020, in the United States and 6 dependent areas, 2,055 diagnoses of HIV infection were attributed to IDU
(1,198 among male and 857 among female PWID) (Table 6b).
HIV diagnosis percentages among PWID for 2020 were as follows:
• Age group (Figure 15):
○ 13–24 years: 6%
○ 25–34 years: 32%
○ 35–44 years: 27%
○ 45–54 years: 18%
○ ≥ 55 years: 17%
For additional data by 5-year age groups, see Table 6b.
• Race/ethnicity (Figure 15):
○ American Indian/Alaska Native: 1%
○ Asian: 1%
○ Black/African American: 27%
○ Hispanic/Latino: 20%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 47%
○ Multiracial: 3%
• Region of residence (Figure 15):
○ Northeast: 21%
○ Midwest: 14%
○ South: 44%
○ West: 21%
○ U.S. dependent areas: 1%


HIV Surveillance Report

27

Vol. 33

Figure 15. Percentages of diagnoses of HIV infection among persons who inject drugs, by selected
characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. Data for 2020 should be interpreted
with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Sex assigned at birth and race/ethnicity—highest percentages (Figure 16):
○ White female: 49%
○ White male: 45%
○ Black/African American female: 29%
○ Black/African American male: 26%


HIV Surveillance Report

28

Vol. 33

Figure 16. Percentages of diagnoses of HIV infection among persons who inject drugs, by sex assigned at birth
and race/ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. Data for 2020 should be interpreted
with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Region of residence and race/ethnicity—highest numbers and percentages by region (Figure 17):
○ Northeast: White (157; 37%)
○ Midwest: White (152; 53%)
○ South: White (464; 52%)
○ West: White (188; 44%)
○ U.S. dependent areas: Hispanic/Latino (22; 100%)


HIV Surveillance Report

29

Vol. 33

Figure 17. Diagnoses of HIV infection among persons who inject drugs, by region and race/ethnicity, 2020
(COVID-19 pandemic)—United States and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. Data for 2020 should be interpreted
with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Prevalence and race/ethnicity (Table 16b):
○ At year-end 2020 in the United States and 6 dependent areas, 118,213 PWID were living with diagnosed
HIV infection. Prevalence by race/ethnicity was as follows:
○ American Indian/Alaska Native: <1%
○ Asian: 1%
○ Black/African American: 45%
○ Hispanic/Latino: 27%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 22%
○ Multiracial: 5%

TRANSGENDER PERSONS
Transgender is an umbrella term that is used to identify persons whose sex assigned at birth does not match
current gender identity or expression. Gender identity refers to one’s internal understanding of one’s own gender, or the gender with which a person identifies. Gender expression is a term used to describe people’s outward
presentation of their gender. Gender identity and sexual orientation are different facets of identity. Everyone
has a gender identity and a sexual orientation, but a person’s gender does not determine a person’s sexual orientation. Transgender persons may identify as heterosexual, homosexual, bisexual, or none of the above. Transgender persons are understudied in HIV prevention (e.g., preexposure prophylaxis [PrEP]) and treatment
interventions and face numerous prevention challenges, including social rejection and exclusion and lack of
public/provider knowledge about transgender issues.


HIV Surveillance Report

30

Vol. 33

Diagnoses of HIV infection
In 2020, in the United States and 6 dependent areas, 697 diagnoses of HIV infection were among transgender
and AGI persons (Table 4b). Diagnoses of HIV infection among transgender persons accounted for approximately 2% of diagnoses. Transgender women accounted for the highest percentage of diagnoses of HIV infections (92%).
HIV diagnosis percentages among transgender and AGI persons for 2020 were as follows:
• Age group (Figure 18):
○ 13–24 years: 28%
○ 25–34 years: 49%
○ 35–44 years: 13%
○ 45–54 years: 7%
○ ≥ 55 years: 2%
For additional data by 5-year age groups, see Table 4b.
• Race/ethnicity (Figure 18):
○ American Indian/Alaska Native: 1%
○ Asian: 2%
○ Black/African American: 47%
○ Hispanic/Latino: 31%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 13%
○ Multiracial: 5%
• Exposure category (Figure 18):
○ Sexual contact: 89%
○ IDU: <1%
○ Sexual contact and IDU: 6%
○ Other: 5%
• Region of residence (Figure 18):
○ Northeast: 16%
○ Midwest: 15%
○ South: 44%
○ West: 24%
○ U.S. dependent areas: <1%


HIV Surveillance Report

31

Vol. 33

Figure 18. Percentages of diagnoses of HIV infection among transgender and additional gender identity
persons aged ≥ 13 years, by selected characteristics, 2020 (COVID-19 pandemic)—United States and
6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.
b For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual
contact with a person assigned “male” sex at birth.
c Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data
were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.

• Gender and race/ethnicity—highest percentages (Figure 19):
○ Transgender woman: Black/African American (48%)
○ Transgender man: White (38%)
○ AGI: Black/African American (47%)


HIV Surveillance Report

32

Vol. 33

Figure 19. Percentages of diagnoses of HIV infection among transgender and additional gender identity
persons aged ≥ 13 years, by gender and race/ethnicity, 2020 (COVID-19 pandemic)—United States and
6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Gender and exposure category—highest percentages (Figure 20):
○ Transgender woman: sexual contact (90%)
○ Transgender man: sexual contact (73%)
○ AGI: sexual contact (82%)


HIV Surveillance Report

33

Vol. 33

Figure 20. Percentages of diagnoses of HIV infection among transgender and additional gender identity
persons aged ≥ 13 years, by gender and exposure category, 2020 (COVID-19 pandemic)—United
States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual
contact with a person assigned “male” sex at birth.
b Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data
were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.

WOMEN
More than 5,000 women received an HIV diagnosis in the United States and 6 dependent areas in 2020. One in
nine women with HIV are unaware they have it. Because some women may be unaware of their male partner’s
risk factors for HIV (such as injection drug use or having sex with men), they may not use condoms or medicines to prevent HIV. Additionally, HIV testing rates within the past year were low among women with sexual
behaviors that increase their risk of acquiring HIV and especially low among those who reported anal sex.


HIV Surveillance Report

34

Vol. 33

Diagnoses of HIV infection
In 2020 in the United States and 6 dependent areas, the rate of diagnoses of HIV infection among females aged
≥ 13 years was 3.8 (Figure 21).
Figure 21. Rates of diagnoses of HIV infection among females aged ≥ 13 years, 2020 (COVID-19 pandemic)—
United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates incomplete reporting.

In 2020 in the United States (Figure 22):
• Black/African American females aged ≥ 13 years made up 13% of the female population but accounted for
54% of diagnoses of HIV infection among females.
• White females aged ≥ 13 years made up 62% of the female population and accounted for 24% of diagnoses
of HIV infection.
• Hispanic/Latino females aged ≥ 13 years made up 17% of the female population and accounted for 17% of
diagnoses of HIV infection.


HIV Surveillance Report

35

Vol. 33

Figure 22. Percentages of diagnoses of HIV infection and population among females aged ≥ 13 years, by race/
ethnicity, 2020 (COVID-19 pandemic)—United States

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

HIV diagnosis rates among females aged ≥ 13 years were as follows:
• Age group (U.S. only) (Figure 23):
○ 13–24 years: 2.9
○ 25–34 years: 7.0
○ 35–44 years: 6.0
○ 45–54 years: 4.9
○ ≥ 55 years: 1.6
For additional data by 5-year age groups, see Table 3a.
▪ Disparities by age group:
‣ Absolute disparity (rate difference)—If persons aged 25–34 years had the same rate as persons aged
≥ 55 years, 5 cases per 100,000 population would have been prevented.
‣ Relative disparity (rate ratio)—Persons aged 25–34 years had a rate that was 4.4 times as high as
persons aged ≥ 55 years.
• Race/ethnicity (U.S. only) (Figure 23):
‣ American Indian/Alaska Native: 4.2
‣ Asian: 1.0
‣ Black/African American: 16.4
‣ Hispanic/Latino: 3.8
‣ Native Hawaiian/other Pacific Islander: 6.0
‣ White: 1.5
‣ Multiracial: 5.3


HIV Surveillance Report

36

Vol. 33

▪ Disparities by race/ethnicity:
‣ Absolute disparity (rate difference)—If Black/African American persons aged ≥ 13 years had the
same rate as White persons aged ≥ 13 years (1.5), 15 cases per 100,000 population would have been
prevented.
‣ Relative disparity (rate ratio)—Black/African American persons aged ≥ 13 years had a rate that was
10.9 times as high as White persons aged ≥ 13 years.
• Region of residence (U.S. only) (Figure 23):
○ Northeast: 3.6
○ Midwest: 2.5
○ South: 5.5
○ West: 2.4
▪ Disparities by region:
‣ Absolute disparities (rate difference): if the South had the same rate as the West, 3 cases per 100,000
population would have been prevented.
‣ Relative disparities (rate ratio): the South had a rate that was 2.3 times as high as the West.
Figure 23. Rates and disparities of diagnoses of HIV infection among females aged ≥ 13 years, by selected
characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions. Absolute disparity measures the difference
between rates in groups with the highest rates and a reference group (Ratehighest group − Ratereference group). Relative disparity
(rate ratio) measures the rates in groups with the highest rates divided by a reference group (Ratehighest group ÷
Ratereference group).
a
Hispanic/Latino persons can be of any race.

• Transmission category and race/ethnicity—highest percentages (Figure 24):
○ PWID: American Indian/Alaska Native (47%)
○ Heterosexual contact: Asian (92%)


HIV Surveillance Report

37

Vol. 33

Figure 24. Percentages of diagnoses of HIV infection among females aged ≥ 13 years, by transmission category
and race/ethnicity, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data have been statistically adjusted to account for missing transmission category. Data for 2020 should be interpreted
with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Region of residence and race/ethnicity—highest rates (U.S. only) (Figure 25):
○ Northeast: Black/African American (16.3)
○ Midwest: Black/African American (13.8)
○ South: Black/African American (17.2)
○ West: Black/African American (15.9)


HIV Surveillance Report

38

Vol. 33

Figure 25. Rates of diagnoses of HIV infection among females aged ≥ 13 years, by race/ethnicity and region,
2020 (COVID-19 pandemic)—United States

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Prevalence and race/ethnicity (Table 16b):
○ At year-end 2020 in the United States and 6 dependent areas, 248,819 females aged ≥ 13 years were living with diagnosed HIV infection. Prevalence by race/ethnicity was as follows:
○ American Indian/Alaska Native: <1%
○ Asian: 1%
○ Black/African American: 57%
○ Hispanic/Latino: 20%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 16%
○ Multiracial: 5%

PERSONS AGED 13–24 YEARS
Persons aged 13–24 years accounted for 20% of the 30,692 diagnoses of HIV infection in 2020 in the United
States and 6 dependent areas. They are the least likely of any age group to be aware of their HIV infection,
retained in care, or have a suppressed viral load. Lack of awareness of HIV status may be due to recent infection
or low rates of HIV testing. Persons who do not know that they have HIV do not get medical care or receive
treatment and can unknowingly infect others. In addition, persons aged 13–24 years have high rates of STDs
and low rates of condom use, greatly increasing the chance of getting or transmitting HIV. Addressing HIV
among persons aged 13–24 years requires that they have access to the information and tools they need to make
healthy decisions, reduce their risk factors, get treatment, and stay in care.


HIV Surveillance Report

39

Vol. 33

Diagnoses of HIV infection
In 2020 in the United States and 6 dependent areas, there were 6,135 diagnoses of HIV infection among persons
aged 13–24 years (Figure 26, Table 8b).
The percentage and/or rates of diagnoses of HIV infection among persons aged 13–24 years were as follows:
• Gender (Figure 26):
○ Male: 85%
○ Female: 12%
○ Transgender woman: 3%
○ Transgender man: <1%
○ AGI: <1%
• Age group (Figure 26):
○ 13–14 years: <1%
○ 15–17 years: 5%
○ 18–19 years: 16%
○ 20–21 years: 45%
○ 23–24 years: 35%%
• Race/ethnicity (Figure 26):
○ American Indian/Alaska Native: 1%
○ Asian: 1%
○ Black/African American: 54%
○ Hispanic/Latino: 26%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 15%
○ Multiracial: 3%
• Region of residence (Figure 26):
○ Northeast: 12%
○ Midwest: 15%
○ South: 55%
○ West: 17%
○ U.S. dependent areas: 1%


HIV Surveillance Report

40

Vol. 33

Figure 26. Percentages of diagnoses of HIV infection among persons aged 13–24 years, by selected
characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Sex assigned at birth and transmission category—highest percentages (Figure 27):
○ Male sex at birth: MMSC (82%)
○ Female sex at birth: heterosexual contact (10%)
Figure 27. Percentages of diagnoses of HIV infection among persons aged 13–24 years, by sex assigned at birth
and transmission category, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.

HIV Surveillance Report

41

Vol. 33

• Rates (U.S. only) (Figure 28):
○ Highest: persons aged 23–24 years (24.2)
○ Lowest: persons aged 13–14 years (0.1)
▪ Disparities by age group:
‣ Absolute disparity (rate difference)—If persons aged 23–24 years had the same rate as persons aged
18–19 years (11.4), 13 cases per 100,000 population would have been prevented.
‣ Relative disparity (rate ratio)—Persons aged 23–34 years had a rate that was 2.1 times as high as
persons aged 18–19 years.
• Rates (U.S. only) (Figure 28):
○ Highest: Black/African American (46.6)
○ Lowest: Asian (3.1)
▪ Disparities by race/ethnicity:
‣ Absolute disparity (rate difference)—If Black/African American persons aged 13–24 years had the
same rate as White persons aged 13–24 years (3.5), 43 cases per 100,000 population would have
been prevented.
‣ Relative disparity (rate ratio)—Black/African American persons aged 13–24 years had a rate that
was 13.3 times as high as White persons aged 13–24 years.
• Rates (U.S. only) (Figure 28):
○ Highest: South (17.3)
○ Lowest: Midwest (8.3)
▪ Disparities by region:
‣ Absolute disparity (rate difference): if the South had the same rate as the Midwest, 9 cases per
100,000 population would have been prevented.
‣ Relative disparity (rate ratio): the South had a rate that was 2.1 times as high as the Midwest.
Figure 28. Rates and disparities of diagnoses of HIV infection among persons aged 13–24 years, by selected
characteristics, 2020 (COVID-19 pandemic)—United States

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions. Absolute disparity measures the difference

HIV Surveillance Report

42

Vol. 33

between rates in groups with the highest rates and a reference group (Ratehighest group − Ratereference group). Relative disparity
(rate ratio) measures the rates in groups with the highest rates divided by a reference group (Ratehighest group ÷
Ratereference group).
a Hispanic/Latino persons can be of any race.

CHILDREN AGED <13 YEARS
To make informed decisions about antiretroviral therapy to reduce perinatal transmission of HIV to infants,
pregnant women should know their HIV infection status. In 1995, the first recommendations for HIV counseling and voluntary testing for pregnant women were published. In 2006, CDC released revised recommendations
for HIV testing which specified that opt-out HIV screening should be included in the routine panel of prenatal
screening tests for all pregnant women.
In 2019, 37 areas reported no perinatally acquired infections among infants born. Because of delays in the
reporting of births and diagnoses of HIV infection attributed to perinatal exposure, the exclusion of data for the
most recent 2 years allowed at least 24 months for data from 2019 to be reported to CDC. Data reflect all infants
with diagnosed, perinatally acquired HIV infection who were born in the United States and 6 dependent areas
during 2019, regardless of year of diagnosis.

Diagnoses of HIV infection
In the United States and 6 dependent areas, a total of 32 children born during 2019 received a diagnosis of HIV
infection attributed to perinatal transmission (Figure 29).
Figure 29. Diagnoses of perinatally acquired HIV infection among children born during 2019—United States and
6 dependent areas

Infected infants (Figure 30): From 2016 through 2019 in the United States and Puerto Rico, among the 193
children born with diagnosed, perinatally acquired HIV infection, time of maternal HIV testing was as follows:
• 45% were born to mothers who were tested before pregnancy
• 19% were born to mothers who were tested during pregnancy

HIV Surveillance Report

43

Vol. 33

• 8% to mothers tested at the time of birth
• 21% of children with diagnosed, perinatally acquired HIV infection were born to mothers who were tested
after the child's birth
• 7% were born to mothers whose time of maternal HIV testing was unknown
Exposed but not infected (Figure 30): From 2016 through 2019 in the United States and Puerto Rico, among
the 11,757 children born who were exposed but not perinatally infected with HIV, time of maternal HIV testing was as follows:
• 82% were born to mothers who were tested before pregnancy
• 15% were born to mothers who were tested during pregnancy
• 1% to mothers tested at the time of birth
• 1% to mothers tested after birth
• 1% were born to mothers whose time of maternal HIV testing was unknown
Note. The number of areas contributing exposure data varied by year. Because not all jurisdictions have exposure reporting in place, the number presented is likely a minimum count of the number of exposed infants in
the United States and Puerto Rico.
Figure 30. Time of maternal HIV testing among children with diagnosed perinatally acquired HV infection and
children exposed to HIV, birth years 2016–2019—United States and Puerto Rico

Diagnoses (Figure 31): In 2020, among children in the United States,
• Black/African American children made up approximately 14% of the population of children but accounted
for 56% of diagnoses of HIV infection.
• Hispanic/Latino children made up 26% of the population of children but accounted for 16% of diagnoses.
• White children made up 49% of the population of children but accounted for 21% of diagnoses.


HIV Surveillance Report

44

Vol. 33

Figure 31. Percentages of diagnoses of HIV infection among children, by race/ethnicity, 2020 (COVID-19
pandemic)—United States and 6 dependent areas

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,
care-related services, and case surveillance activities in state/local jurisdictions.
a Hispanic/Latino persons can be of any race.

• Prevalence, children (Figure 32):
○ At year-end 2020 in the United States and 6 dependent areas, approximately 1,447 children were living
with diagnosed HIV infection.
○ The overall rate of persons living with diagnosed HIV infection was 2.8.


HIV Surveillance Report

45

Vol. 33

Figure 32. Rates of children living with diagnosed HIV infection, year-end 2020 (COVID-19 pandemic)—United
States and 6 dependent areas

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data are based on
address of residence as of December 31, 2020 (i.e., most recent known address). Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance
activities in state/local jurisdictions. Asterisk (*) indicates incomplete reporting.

• Prevalence and race/ethnicity, children (Table 16b):
○ American Indian/Alaska Native: <1%
○ Asian: 7%
○ Black/African American: 58%
○ Hispanic/Latino: 13%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 13%
○ Multiracial: 8%
• Prevalence, perinatally acquired HIV infection (Figure 33):
○ At year-end 2020 in the United States and 6 dependent areas, there were 12,588 persons living with
diagnosed, perinatally acquired HIV infection.
○ Data reflect all persons (i.e., children, adolescents, and adults) with diagnosed, perinatally acquired HIV
infection who were alive at year-end 2020, regardless of their age at year-end 2020.


HIV Surveillance Report

46

Vol. 33

Figure 33. Persons living with diagnosed, perinatally acquired HIV infection, year-end 2020 (COVID-19
pandemic)—United States and 6 dependent areas

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data are based on
address of residence as of December 31, 2020 (i.e., most recent known address). Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance
activities in state/local jurisdictions. Asterisk (*) indicates incomplete reporting.

• Prevalence and race/ethnicity, perinatally acquired HIV infection (Table 16b):
○ American Indian/Alaska Native: <1%
○ Asian: 1%
○ Black/African American: 57%
○ Hispanic/Latino: 24%
○ Native Hawaiian/other Pacific Islander: <1%
○ White: 11%
○ Multiracial: 7%


HIV Surveillance Report

47

Vol. 33

A. SURVEILLANCE OF HIV INFECTION OVERVIEW
This report includes HIV surveillance data through 2020 and reported to CDC’s National HIV Surveillance
System (NHSS) through December 31, 2021. The data are from 50 states, the District of Columbia, and 6 U.S.
dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau,
and the U.S. Virgin Islands) in which laws or regulations require confidential reporting to the jurisdiction (not
to CDC), by name, for all persons (adults, adolescents, and children) with confirmed diagnoses of HIV
infection. After the removal of personally identifiable information, data from these reports were submitted to
CDC. Although AIDS cases have been reported to CDC since 1981, the date of implementation of HIV
infection reporting has differed from jurisdiction to jurisdiction. All states, the District of Columbia, and 6 U.S.
dependent areas had fully implemented name-based HIV infection reporting by April 2008.
All data presented in this reported are considered provisional (based on a ≥ 12-month reporting delay) and subject to change as additional reports are submitted for HIV cases and HIV surveillance data quality improves with
further evaluation of the surveillance system and data repository. Data are based on a 12-month reporting delay
to allow sufficient time for HIV-related laboratory results and deaths to be reported to CDC. Because reporting
delays can impact the reliability of data presented in this report, caution should be applied when interpreting the
results. Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may
not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested
at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing,
and some persons complete self-testing at home or in a private location; the results of anonymous tests and of
self-tests are not reported to the confidential, name-based HIV registries of state and local health departments
[8, 9]. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV
infection. In addition, testing patterns are influenced by many factors, including the extent to which testing is
routinely offered to specific groups and the availability of, and access to, medical care and testing services. The
data presented in this report provide minimum counts of persons for whom HIV infection has been diagnosed
and reported to the surveillance system. Although all jurisdictions use a uniform case report form, surveillance
practices in data collection and updating of case records may differ among jurisdictions.
Based on annual standard evaluation results [10], the completeness of reporting of HIV infection, as of December 2019, is estimated to be at least 85% in all but 1 jurisdiction. Data re-release agreements between CDC and
HIV Surveillance Report

48

Vol. 33

state/local HIV surveillance programs require specific levels of cell suppression at the state and county level in
order to ensure confidentiality of personally identifiable information.
Caution: Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

B. STAGES OF HIV INFECTION—CASE DEFINITIONS
Both the 2008 and 2014 HIV case definitions were used to classify HIV infection among persons aged ≥ 13
years and among children [11, 12]. In the following lists, some bulleted items are paraphrases, not quotations,
from the published surveillance case definitions. The intention is to emphasize the differences between the
2008 and 2014 case definitions.

B1. 2008 Case Definition
The 2008 case definition was used to classify cases diagnosed through 2013. For persons aged ≥ 13 years, this
definition incorporates an HIV infection staging system that includes AIDS (HIV infection, stage 3). The 2008
stages of HIV infection are defined as follows:
• HIV infection, stage 1: No AIDS-defining opportunistic illness (OI) and either CD4+ T-lymphocyte
(CD4 lymphocyte) count of ≥ 500 cells/L or CD4 percentage of total lymphocytes of ≥ 29.
• HIV infection, stage 2: No AIDS-defining OI and either CD4 lymphocyte count of 200–499 cells/L or
CD4 percentage of total lymphocytes of 14–28.
• HIV infection, stage 3 (AIDS): Documentation of an AIDS-defining OI or either a CD4 lymphocyte
count of < 200 cells/L or CD4 percentage of total lymphocytes of < 14. Documentation of an AIDSdefining OI supersedes a CD4 lymphocyte count or percentage that would not, by itself, be the basis for a
stage 3 (AIDS) classification.
• HIV infection, stage unknown: No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

B2. 2014 Case Definition
The 2014 case definition was used to classify cases diagnosed in 2014 and later. It is similar to the 2008 case
definition except for the following:
1. inclusion of criteria for stage 0
2. inclusion of CD4 lymphocyte testing criteria for stage 3 in children
3. changes in the cutoffs for CD4 percentage of total lymphocytes used for classification of stages 1 and 2 in
persons aged 6 years and older [3]
The stages of HIV infection in the 2014 case definition are based on age-specific CD4 lymphocyte counts or
percentages of total lymphocytes and are defined as follows:
• HIV infection, stage 0: First positive HIV test result within 6 months after a negative HIV test result. The
stage remains stage 0 until 6 months after the first positive test result. After 6 months, the stage may be
classified as 1, 2, 3, or unknown if based on a CD4 test result or the diagnosis of an OI. The diagnosis of an
AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the
stage from stage 0 to stage 3.
• HIV infection, stages 1, 2, and 3: Documentation of an AIDS-defining OI (excluding stage 0 as described
above) is stage 3. Otherwise, the stage is determined by the lowest CD4 lymphocyte test result:
○ Stage 1—CD4 lymphocyte count of ≥ 500 or a CD4 percentage of total lymphocytes of ≥ 26
○ Stage 2—CD4 lymphocyte count of 200–499 or a CD4 percentage of total lymphocytes of 14–25

HIV Surveillance Report

49

Vol. 33

○ Stage 3—CD4 lymphocyte count of < 200 or a CD4 percentage of total lymphocytes of < 14 or documentation of an AIDS-defining condition.
• HIV infection, stage unknown: No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

C. TABULATION AND PRESENTATION OF DATA
The data in this report include information received by CDC through December 31, 2021. The data are organized into 2 sections: National Profile and Special Focus Profiles. Tables are presented in 2 formats: (1) the
first format—labeled “a”—exclude data from the dependent areas (American Samoa, Guam, the Northern
Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands), and (2) the second format—
labeled “b”—include data from the dependent areas.
Please use caution when interpreting numbers less than 12, and rates and trends based on these numbers.

C1. Definitions and Data Specifications
C1.1 Diagnoses
In this report, the term diagnosis of HIV infection is defined as a diagnosis of HIV infection regardless of the
stage of disease (stage 0, 1, 2, 3 [AIDS], or unknown) and refers to all persons with a diagnosis of HIV infection.
The data on diagnoses of HIV infection reflect the date of diagnosis (diagnosed by December 31, 2020; reported
to NHSS as of December 31, 2021), not the date of report to NHSS. In addition,
• data from all areas are included in figures and tables displaying numbers and rates of diagnoses of HIV
infection, by selected characteristics, area of residence, and metropolitan statistical area (MSA) (Figures
A, 1–6, 12–31; Tables 1a/b–10a/b, 20, 22, and A1).
• data for Maryland should be interpreted with caution due to incomplete reporting of case information to
CDC during December 2021.
• tables presenting diagnosis data, region or area of residence reflects the address at the time of HIV
diagnosis.
• tables presenting exposure data, only include transgender and AGI persons aged ≥ 13 years at time of diagnosis of HIV infection.
Note. Because of reporting delays, the number of cases diagnosed in a given year may be lower than the numbers presented in later reports; however, fluctuations in the number of diagnoses for a calendar year typically
subside after 2 to 3 years of reporting. An evaluation of surveillance data (2015–2019 diagnoses) found that, on
average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnoses and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year.
C1.2 Deaths
Persons reported to NHSS are assumed alive unless their deaths have been reported to CDC. In addition,
• data for the year 2020 are preliminary and based on death data received by CDC as of December 31, 2021.
• deaths of persons with diagnosed HIV infection (Figures 7–9; Tables 11a/b–14a/b) are included regardless
of the cause of death, which may not be due to HIV.
• death data are based on a 12-month reporting delay to allow data to be reported to CDC.
• death data by region or area of residence is based on residence at death; when information on residence at
death is not available, the state where a person’s death occurred is used.
• due to incomplete reporting of deaths for the year 2020, death data for Guam, Kansas, North Carolina,
Puerto Rico, South Carolina, and Vermont should be interpreted with caution.

HIV Surveillance Report

50

Vol. 33

C1.3 Prevalence
Prevalence data reflect persons living with diagnosed HIV infection, regardless of stage of disease, at year-end
2020 (Figures 10, 11, 32, and 33; Tables 15a/b–22 and A2). In addition,
• data for the year 2020 are preliminary and based on death data received by CDC as of December 31, 2021.
• for tables presenting prevalence data, region or area of residence is based on most recent known address as
of the end of the specified year.
• due to incomplete reporting of deaths for the year 2020, prevalence data for Guam, Kansas, North Carolina, Puerto Rico, South Carolina, and Vermont should be interpreted with caution.

C2. Rates
Rates per 100,000 population were calculated for (1) the numbers of diagnoses of HIV infection, (2) the numbers of deaths of persons with diagnosed HIV infection, and (3) the numbers of persons living with diagnosed
HIV infection.
Rates were computed as follows:
For the 50 states, the District of Columbia, and Puerto Rico, the population denominators used to compute rates
were based on the Vintage 2020 postcensal estimates file from the U.S. Census Bureau [13].
• For American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin
Islands, the population denominators were based on estimates and projections from the U.S. Census
Bureau’s International Data Base [14].
• Each rate was calculated by dividing the total number of diagnoses (or deaths or prevalence) for the calendar year by the population for that calendar year and then multiplying the result by 100,000.
• The denominators used for calculating the rates specific to age, sex at birth, and race/ethnicity were computed by applying the appropriate vintage estimates for age, sex at birth, and race/ethnicity for the 50
states and the District of Columbia [13]. The same method was used to calculate the denominators for
Puerto Rico, with the exception of race/ethnicity estimates; these data are not available for Puerto Rico
(see Note below).
• For the other 5 U.S. dependent areas, estimates from the U.S. Census Bureau’s International Data Base
were used for age- and sex-specific population denominators [14].
Note. CDC currently does not provide subpopulation rates for the following:
• Race/ethnicity for the 6 U.S. dependent areas because the U.S. Census Bureau does not collect information
from all dependent areas.
• Gender, transmission categories, and exposure categories because of the absence of denominator data
from the U.S. Census Bureau, the source of denominator data used for calculating all rates in this report.
C2.1 Disparity Measures
This report includes absolute and relative measures of disparities. The literature recommends use of at least one
absolute and one relative disparity measure to monitor the magnitude and direction of disparities [15]. The absolute rate difference and the relative rate ratio disparity measures were chosen because they are used by federal
initiatives—Healthy People 2030, NHAS, and EHE—to measure progress in HIV indicators. In addition,
• absolute disparity measures the simple difference between two rates (i.e., Rate1 − Rate2). The absolute difference measures the magnitude of the difference, which provides some indication of how many lives
could be improved if the difference between the two rates were eliminated or reduced (i.e., preventable
cases) [16].


HIV Surveillance Report

51

Vol. 33

• relative disparity measure is the rate ratio between two rates (i.e., Rate1 ÷ Rate2). The relative disparity
measures the relative magnitude of the disparity.
• for this report, Rate2 is the reference group and is based on the lowest group rate with more than 5% of
cases.

D. DEMOGRAPHIC INFORMATION
D1. Age
For this report, age assignments are based on the following:
• For prevalence data, based on the person’s age as of December 31, 2020.
• For death data, determined by the person’s age at time of death.
• For all other tables, based on the person’s age at the time of HIV diagnosis.

D2. Sex/Gender
D2.1 Sex at birth
Sex designations in this report are based on a person’s sex assigned at birth.
D2.2 Gender
Gender identity refers to a person’s internal understanding of their own gender, or gender with which a person
identifies. HIV surveillance personnel collect data on gender identity, when available, from sources such as
case report forms submitted by health care or HIV testing providers and medical records, or by matching with
other health department databases (e.g., Ryan White program data). In May 2013, CDC issued guidance to
state and local programs on methods for collecting data on transgender persons and working with transgenderspecific data. However, characterization of HIV infection among transgender persons may require supplemental data from special studies. A person’s transgender status in NHSS is determined based on two variables: sex
assigned at birth and current gender identity. Both variables are examined, using a two-step approach, to
assess transgender status. Cisgender is a term used to indicate that a person’s sex assigned at birth and current
gender identity are the same (i.e., a person assigned male at birth and who currently identifies as a man is a cisgender male).
Categories
• Male: a person assigned “male” sex at birth who identifies as male.
• Female: a person assigned “female” sex at birth who identifies as female.
• Transgender woman: a person assigned “male” sex at birth who identifies as female.
• Transgender man: a person assigned “female” sex at birth who identifies as male.
• Additional gender identity (AGI): a person assigned “male” or “female” sex at birth who does not identify as male, female, transgender woman, or transgender man. AGI includes “bigender,” “gender queer,”
and “two-spirit.”

D3. Race and Ethnicity
In the Federal Register [17] for October 30, 1997, the Office of Management and Budget (OMB) announced
the Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity. Implementation by
January 1, 2003, was mandated. At a minimum, data on the following race categories should be collected:
• American Indian or Alaska Native
• Asian
• Black or African American

HIV Surveillance Report

52

Vol. 33

• Native Hawaiian or other Pacific Islander
• White
Additionally, systems must be able to retain information when multiple race categories are reported. In addition to data on race, data on 2 categories of ethnicity should be collected:
• Hispanic or Latino
• not Hispanic or Latino
The Asian or Pacific Islander category displayed in annual surveillance reports published prior to the 2007 surveillance report was split into 2 categories: (1) Asian and (2) Native Hawaiian or other Pacific Islander. The
Asian category (in tables where footnoted) includes the cases in Asian/Pacific Islander persons (referred to as
legacy cases) that were reported before the implementation of the new race categories in 2003 (e.g., cases of
HIV infection that were diagnosed and reported to CDC before 2003 but that were classified as stage 3 [AIDS]
after 2003) and a small percentage of cases that were reported after 2003 but that were reported according to
the old race category (Asian/Pacific Islander). In tables of diagnoses of HIV infection during 2016–2020, the
Asian category does not include Asian/Pacific Islander cases because these cases were diagnosed after 2003
and were reported to CDC in accordance with OMB’s Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity [17].
This report also presents data for persons for whom multiple race categories are reported (i.e., multiracial). In
this report, persons categorized by race were not Hispanic or Latino. The number of persons reported in each
race category may, however, include persons whose ethnicity was not reported.
Race and ethnicity are not risk factors but are instead markers for many underlying problems of greater
relevance to health, including socioeconomic status and cultural behavior-characteristics, which are social
and not biological [18, 19]. Racial and ethnic differences in health are more likely to reflect profound differences in people’s experience based on the relatively advantaged or disadvantaged position in society into which
they are born [19, 20]. Social determinant of health factors, shaped by income, education, wealth, and socioeconomic conditions, vary systematically by race and ethnicity and are important in explaining differences in
health outcomes [20].

D4. Transmission Categories
Transmission category is the term for the classification of cases that summarizes an adult’s or adolescent’s
possible HIV risk factors; the summary classification results from selecting, from the presumed hierarchical
order of probability, the 1 (single) risk factor most likely to have been responsible for transmission. For surveillance purposes, a diagnosis of HIV infection is counted only once in the hierarchy of transmission categories [21]. Adults or adolescents with more than 1 reported risk factor for HIV infection are classified in the
transmission category listed first in the hierarchy. The exception is men who had sexual contact with other
men and injected drugs; this group makes up a separate transmission category.
Hierarchical Categories
• Male-to-male sexual contact (MMSC): includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at
birth who have had sexual contact with both males and females (i.e., bisexual contact).
• Injection drug use (IDU): includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes.
• Male-to-male sexual contact and injection drug use (MMSC/IDU): includes individuals assigned male
sex at birth, regardless of current gender identity, who have had sexual contact with other males (or with
both males and females [i.e., bisexual contact]) and injected nonprescription drugs or injected prescription
drugs for nonmedical purposes.

HIV Surveillance Report

53

Vol. 33

• Heterosexual contact: includes persons who have ever had sexual contact with a person known to have,
or with a risk factor for, HIV infection.
• Perinatal: includes persons who acquired HIV through mother-to-child transmission.
• Other: includes persons with other risk factors (e.g., blood transfusion, hemophilia) or whose risk factor
was not reported or not identified.
Cases of HIV infection reported without a risk factor listed in the hierarchy of transmission categories are classified as “no identified risk (NIR).” Cases classified as NIR include cases that are being followed up by local
health department staff; cases in persons whose risk-factor information is missing because they died, declined
to be interviewed, or were lost to follow-up; and cases in persons who were interviewed or for whom other
follow-up information was available but for whom no risk factor was identified.
Because a substantial proportion of cases of HIV infection are reported to CDC without an identified risk factor,
multiple imputation is used to assign a transmission category to these cases [21]. Multiple imputation is a statistical approach in which each missing transmission category is replaced with a set of plausible values that represent the uncertainty about the true, but missing, value [22]. Each resulting data set containing the plausible values
is analyzed by using standard procedures, and the results from these analyses are then combined to produce the
final results. In tables displaying transmission categories, multiple imputation was used for adults and adolescents, but not for children (because the number of cases in children is small, missing transmission categories
were not imputed).
D4.2 Exposure category
Exposure category is the term for classifying patient history data (individual risk behaviors or events) by assigning individual risk behaviors or events into mutually exclusive categories. They are meant to convey all the
known ways a person could have been exposed to HIV. The exposure category classification was developed as
an alternative to the hierarchical transmission category classification. For the presentation of data in this report,
exposure category is used for the classification of transgender and AGI persons based on the risk factors that may
have been responsible for HIV transmission; classification has no presumed hierarchical order of probability,
except for rare circumstances where route of transmission has been confirmed through investigation. The categories are mutually exclusive. Data were not statistically adjusted to account for missing exposure category.
Categories
• Sexual contact: includes persons assigned “male” sex at birth, who reported sexual contact with any person. For persons assigned “female” sex at birth, they reported sexual contact with a person assigned
“male” sex at birth.
• Injection drug use (IDU): includes persons who inject nonprescription drugs or who injected prescription
drugs for nonmedical purposes.
• Sexual contact and IDU: includes persons assigned “male” sex at birth, who reported sexual contact with
any person and injected nonprescription drugs or injected prescription drugs for nonmedical purposes. For
persons assigned “female” sex at birth, they reported sexual contact with a person assigned “male” sex at
birth and injected nonprescription drugs or injected prescription drugs for nonmedical purposes.
• Perinatal: includes persons who acquired HIV through mother-to-child transmission.
• Other: includes persons with other risk factors (e.g., blood transfusion, hemophilia) or whose risk factor
was not reported or not identified.
Cases of HIV infection reported without a risk factor listed for exposure categories are classified as “no identified
risk (NIR).” Cases classified as NIR include cases that are being followed up by local health department staff;
cases in persons whose risk factor information is missing because they declined to be interviewed, were lost to
follow-up, or died; and cases in persons who were interviewed or for whom other follow-up information was
available but for whom no risk factor was identified.

HIV Surveillance Report

54

Vol. 33

E. GEOGRAPHIC DESIGNATION
E1. U.S. Census Regions
Data by region reflect the following:
• For diagnoses, region is based on address at the time of diagnosis of HIV infection (Figures 4, 12, 14, 15,
17, 18, 23, 25, 26, 28; Tables 1a/b–8a/b).
• For prevalence, region is based on most recent known address as of the end of the specified year (Tables
15a/b–19a/b).
• For deaths, region is based on residence at death. When information on residence at death is not available,
the state where a person’s death occurred is used (Figure 8; Tables 11a/b–14a/b).
The 4 regions of residence and 6 dependent areas used in this report are defined by the U.S. Census Bureau
as follows:
Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania,
Rhode Island, and Vermont
Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio,
South Dakota, and Wisconsin
South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia
West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah,
Washington, and Wyoming
U.S. dependent areas: American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of
Palau, and the U.S. Virgin Islands

E2. Metropolitan Statistical Areas
In the Federal Register for July 16, 2021, OMB published revised standards for defining MSAs in federal
statistical activities [23]. These standards, which provided for the identification of MSAs in the United States
and Puerto Rico, replaced the 2010 standards. The adoption of the new standards was effective as of July 16,
2021. On March 6, 2020, OMB announced new MSA delineations based on the new standards and Census
2010 data [24]. Table 22 (data on diagnosed HIV infection and prevalence of diagnosed HIV infection)
present numbers and rates of diagnoses and prevalence, by MSA, for areas with populations of 500,000 or
more. The MSAs listed in these tables were defined according to OMB’s most recent update (March 2020) of
statistical areas [24].


HIV Surveillance Report

55

Vol. 33

REFERENCES
1. The White House. National HIV/AIDS strategy for the United States 2022–2025. https://www.hiv.gov/federalresponse/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025. Published 2021. Accessed May 2, 2022.
2. Healthy People 2030. https://health.gov/healthypeople/objectives-and-data/browse-objectives. Updated January 15,
2021. Accessed May 2, 2022.
3. HHS. What is Ending the HIV Epidemic in the U.S.? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/
overview. Updated June 2, 2021. Accessed May 2, 2022.
4. Delaney KP, Jayanthi P, Emerson B, et al. Impact of COVID-19 on commercial laboratory testing for HIV in the United
States. 2021 CROI, March 6–10, 2021. Abstract 739.
5. Moitra E, Tao J, Olsen J, et al. Impact of the COVID-19 pandemic on HIV testing rates across four geographically
diverse urban centres in the United States: an observational study. Lancet Reg Health Am 2022;7:100159. doi:10.1016/
j.lana.2021.100159
6. Chang JJ, Chen Q, Hechter RC, Dionne-Odom J, Bruxvoort K. Changes in HIV and STI testing and diagnoses during
the COVID-19 pandemic. 2022 CROI, February 12–16 and 22–24, 2022. Oral Abstract 142.
7. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic
COVID-19 in the United States, February 24–April 21, 2020. MMWR 2020;69(18):551–556. doi:10.15585/
mmwr.mm6918e2
8. CDC. Sharing your test result. https://www.cdc.gov/hiv/basics/hiv-testing/sharing-test-results.html. Updated May
2021. Accessed May 2, 2022.
9. CDC. Self-Testing. https://www.cdc.gov/hiv/testing/self-testing.html. Updated July 2021. Accessed May 2, 2022.
10. Karch DL, Chen M, Tang T. Evaluation of the National Human Immunodeficiency Virus Surveillance System for the
2011 diagnosis year. J Public Health Manag Pract 2014;20(6):598–607. doi:10.1097/PHH.0000000000000033
11. CDC [Schneider E, Whitmore S, Glynn MK, Dominguez K, Mitsch A, McKenna MT]. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS
among children aged 18 months to <13 years—United States, 2008. MMWR 2008;57(RR-10):1–12.
12. CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for
HIV infection—United States, 2014. MMWR 2014;63(RR-03):1–10.
13. U.S. Census Bureau. Population and housing unit estimates datasets. https://go.usa.gov/xn4cc. Accessed May 2, 2022.
14. U.S. Census Bureau. International database. https://www.census.gov/programs-surveys/international-programs/about/
idb.html. Updated October 2020. Accessed May 2, 2022.
15. Moonesinghe R, Beckles GLA. Measuring health disparities: a comparison of absolute and relative disparities. PeerJ
2015;3:e1438. doi:10.7717/peerj.1438
16. Pearcy JN, Keppel KG. A summary measure of health disparity. Public Health Rep 2002;117(3):273–280.
doi:10.1093/phr/117.3.273
17. Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. Federal Register 1997;62:58782–58790. http://go.usa.gov/xPg4F. Accessed May 2, 2022.
18. CDC. Use of race and ethnicity in public health surveillance. Summary of the CDC/ATSDR workshop. MMWR
1993;42(RR-10):1–28.
19. Doubeni CA, Simon M, Krist AH. Addressing systemic racism through clinical preventive service recommendations
from the US Preventive Services Task Force. JAMA 2021;325(7):627–628. doi:10.1001/jama.2020.26188
20. Braveman PA, Egerter SA, Mockenhaupt RE. Broadening the focus: the need to address the social determinants of
health. Am J Prev Med 2011;40(1):S4–S18. doi.org/10.1016/j.amepre.2010.10.002
21. Harrison KM, Kajese T, Hall HI, Song R. Risk factor redistribution of the national HIV/AIDS surveillance data: an
alternative approach. Public Health Rep 2008;123(5):618–627.
22. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons Inc; 1987.
23. Office of Management and Budget. 2020 Standards for delineating core based statistical areas. Federal Register
2021;86(134):37770–37778. https://www.federalregister.gov/documents/2021/07/16/2021-15159/2020-standardsfor-delineating-core-based-statistical-areas. Accessed May 2, 2022.
24. Office of Management and Budget. Revised delineations of metropolitan statistical areas, micropolitan statistical
areas, and combined statistical areas, and guidance on uses of the delineations of these areas. OMB Bulletin 20-01.
https://www.whitehouse.gov/wp-content/uploads/2020/03/Bulletin-20-01.pdf. Published March 6, 2020. Accessed
May 2, 2022.

HIV Surveillance Report

56

Vol. 33

ADDITIONAL RESOURCES
The following were prepared by using HIV surveillance data:
• MMWR articles (selected): http://www.cdc.gov/hiv/library/reports/mmwr.html
• Other surveillance reports: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
• Public-use slides updated annually: http://www.cdc.gov/hiv/library/slidesets/
• NCHHSTP AtlasPlus [interactive tool for accessing HIV, STD, TB, and hepatitis data]: 
http://www.cdc.gov/nchhstp/atlas/

SUGGESTED READINGS
CDC. Establishing a holistic framework to reduce inequities in HIV, viral hepatitis, STDs, and tuberculosis in the United
States. http://stacks.cdc.gov/view/cdc/11585. Published October 2010. Accessed May 2, 2022.
CDC. Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveillance Supplemental
Report 2021;26(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2021.
Accessed May 2, 2022.
CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States
and 6 dependent areas, 2020. HIV Surveillance Supplemental Report 2022;27(No. 3). http://www.cdc.gov/hiv/library/
reports/hiv-surveillance.html. Published May 2022. Accessed May 2022.
CDC. HIV and gay and bisexual men. https://www.cdc.gov/hiv/group/gay-bisexual-men/index.html. Updated October
15, 2021. Accessed May 2, 2022.
CDC. HIV and people who inject drugs. https://www.cdc.gov/hiv/group/hiv-idu.html. Updated March 16, 2022.
Accessed May 2, 2022.
CDC. HIV and women. https://www.cdc.gov/hiv/group/gender/women/index.html. Updated March 10, 2022. Accessed
May 2, 2022.
CDC. HIV and youth (HIV in the United States by age). https://www.cdc.gov/hiv/group/age/youth/index.html. Updated
January 12, 2022. Accessed May 2, 2022.
CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for
HIV infection—United States, 2014. MMWR 2014;63(RR-03):1–10. http://www.cdc.gov/mmwr/indrr_2014.html.
Accessed May 2, 2022.
CDC [Schneider E, Whitmore S, Glynn MK, Dominguez K, Mitsch A, McKenna MT]. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS
among children aged 18 months to <13 years—United States, 2008. MMWR 2008;57(RR-10):1–12. http://www.cdc
.gov/mmwr/indrr_2008.html. Accessed May 2, 2022.
CDC [Harris NS, Satcher Johnson A, Huang YA, et al]. Vital Signs: Status of human immunodeficiency virus testing,
viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018. MMWR 2019;68(48):1117–1123.
https://www.cdc.gov/mmwr/volumes/68/wr/mm6848e1.htm. Accessed May 2, 2022.
CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—
United States, 2014–2016. MMWR 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
Cohen SM, Gray KM, Ocfemia MC, Johnson AS, Hall HI. The status of the National HIV Surveillance System, United
States, 2013. Public Health Rep 2014;129(4):335–341. doi:10.1177/003335491412900408
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: a plan for the United States.
JAMA 2019;321(9):844–845. doi:10.1001/jama.2019.1343
Frieden TR, Foti KE, Mermin J. Applying public health principles to the HIV epidemic—how are we doing? N Engl J
Med 2015;373:2281–2287. doi:10.1056/NEJMms1513641


HIV Surveillance Report

57

Vol. 33

COVID-19 SUGGESTED READINGS
CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR 2020;69(18):551–556. doi:10.15585/
mmwr.mm6918e2
Guidelines Working Groups of the NIH Office of AIDS Research Advisory Council. Guidance for COVID-19 and
people with HIV. https://clinicalinfo.hiv.gov/en/guidelines/guidance-covid-19-and-people-hiv/guidance-covid19-and-people-hiv. Updated February 22, 2022. Accessed March 22, 2022.
Hershow RB, Wilson S, Bonacci RA, et al. Notes from the Field: HIV outbreak during the COVID-19 pandemic
among persons who inject drugs—Kanawha County, West Virginia, 2019–2021. MMWR 2022;71(2):66–68.
doi:10.15585/mmwr.mm7102a4
CDC. HIV and COVID-19 basics. https://www.cdc.gov/hiv/basics/covid-19.html. Updated February 4, 2022.
Accessed March 21, 2022.
Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed
HIV infection in New York State. JAMA Netw Open 2021;4(2):e2037069. doi:10.1001/
jamanetworkopen.2020.37069
Weiser JK, Tie Y, Beer L, Neblett Fanfair R, Shouse RL. Racial/Ethnic and income disparities in the prevalence of
comorbidities that are associated with risk for severe COVID-19 among adults receiving HIV care, United States,
2014–2019; J Acquir Immune Defic Syndr 2020;86(3):297–304. doi:10.1097/QAI.0000000000002592
Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV 2021;8(11):e690–
700. doi:10.1016/S2352-3018(21)00239-3


HIV Surveillance Report

58

Vol. 33

Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States
2016
No.
Ratea
Gender
Male
Female
Transgender woman/girlb
Transgender man/boyb
Additional gender identityc
Age at diagnosis (yr)
< 13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categorye
Male sex at birth (≥ 13 yrs at diagnosis)f
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection drug use
Heterosexual contactg
Perinatalh
Otheri
Subtotal
Female sex at birth (≥ 13 yrs at diagnosis)f
Injection drug use
Heterosexual contactg
Perinatalh
Otheri
Subtotal
Child (< 13 yrs at diagnosis)
Perinatal
Otheri
Subtotal
Region of residencej
Northeast
Midwest
South
West
Total

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

2020 (COVID-19
pandemic)
No.
Ratea

31,332
7,512
675
22
11

—
—
—
—
—

30,461
7,300
612
33
15

—
—
—
—
—

29,730
7,084
627
48
15

—
—
—
—
—

28,948
6,917
652
45
23

—
—
—
—
—

24,269
5,439
638
40
17

—
—
—
—
—

130
26
1,715
6,915
7,947
5,641
4,210
3,245
3,046
2,856
1,882
1,080
859

0.2
0.3
8.1
30.9
34.6
25.8
20.3
16.5
14.6
13.1
8.6
5.6
1.7

105
25
1,786
6,466
7,723
5,672
4,260
2,980
2,930
2,637
1,872
1,083
882

0.2
0.3
8.5
29.3
33.1
25.8
20.1
15.2
14.0
12.4
8.5
5.4
1.7

87
20
1,719
6,109
7,711
5,673
4,209
2,971
2,780
2,455
1,843
1,046
881

0.2
0.2
8.2
28.0
32.7
25.6
19.5
15.1
13.4
11.8
8.4
5.2
1.7

57
21
1,648
5,969
7,402
5,673
4,140
2,974
2,575
2,312
1,832
1,107
875

0.1
0.3
7.8
27.6
31.4
25.3
19.0
14.9
12.6
11.3
8.4
5.4
1.6

57
12
1,248
4,822
6,061
5,197
3,409
2,515
2,072
1,857
1,575
885
693

0.1
0.1
6.0
22.3
26.1
22.8
15.6
12.4
10.4
9.1
7.3
4.3
1.2

216
931
16,799
10,101
38
9,885
1,582

9.1
5.2
41.7
17.6
6.7
5.0
23.2

200
930
16,279
9,941
51
9,643
1,377

8.3
5.1
40.1
17.0
8.8
4.9
19.7

173
868
15,786
9,956
61
9,448
1,212

7.2
4.6
38.6
16.7
10.3
4.8
16.9

205
739
15,503
9,896
66
9,070
1,106

8.5
3.9
37.6
16.4
10.9
4.6
15.0

201
637
12,856
8,008
66
7,843
792

8.3
3.3
31.0
13.1
10.8
4.0
10.5

25,948
1,189
1,539
3,251
10
15
31,952

—
—
—
—
—
—
24.2

25,346
1,292
1,470
2,902
14
17
31,041

—
—
—
—
—
—
23.3

24,545
1,407
1,465
2,877
16
21
30,331

—
—
—
—
—
—
22.6

23,975
1,381
1,524
2,669
20
19
29,589

—
—
—
—
—
—
21.9

20,572
1,178
1,105
2,012
9
20
24,897

—
—
—
—
—
—
18.3

1,034
6,380
48
8
7,470

—
—
—
—
5.4

1,086
6,131
51
7
7,275

—
—
—
—
5.2

1,105
5,928
46
7
7,086

—
—
—
—
5.1

1,154
5,730
47
7
6,939

—
—
—
—
4.9

855
4,536
51
7
5,449

—
—
—
—
3.8

107
23
130

—
—
0.2

88
17
105

—
—
0.2

68
19
87

—
—
0.2

46
11
57

—
—
0.1

44
13
57

—
—
0.1

6,211
5,172
20,274
7,895
39,552

11.1
7.6
16.6
10.3
12.2

5,987
5,115
19,725
7,594
38,421

10.7
7.5
16.0
9.8
11.8

5,565
4,940
19,412
7,587
37,504

9.9
7.2
15.6
9.7
11.5

5,312
4,748
19,181
7,344
36,585

9.5
6.9
15.3
9.4
11.1

4,271
4,127
15,689
6,316
30,403

7.6
6.0
12.4
8.0
9.2

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission or exposure category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender. Transgender men and women are adults or adolescents aged ≥ 13 years.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Data include transgender and additional gender identity persons.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
j Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

59

Vol. 33

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States and
6 dependent areas
2016
No.
Ratea
Gender
Male
Female
Transgender woman/girlb
Transgender man/boyb
Additional gender identityc
Age at diagnosis (yr)
< 13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categorye
Male sex at birth (≥ 13 yrs at diagnosis)f
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection drug use
Heterosexual contactg
Perinatalh
Otheri
Subtotal
Female sex at birth (≥ 13 yrs at diagnosis)f
Injection drug use
Heterosexual contactg
Perinatalh
Otheri
Subtotal
Child (< 13 yrs at diagnosis)
Perinatal
Otheri
Subtotal
Region of residencej
Northeast
Midwest
South
West
U.S. dependent areas
Total

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

2020 (COVID-19
pandemic)
No.
Ratea

31,774
7,617
678
22
11

—
—
—
—
—

30,825
7,394
614
33
15

—
—
—
—
—

30,098
7,164
629
49
15

—
—
—
—
—

29,277
6,998
654
45
23

—
—
—
—
—

24,515
5,480
640
40
17

—
—
—
—
—

130
26
1,725
6,988
8,018
5,706
4,280
3,302
3,105
2,901
1,930
1,107
884

0.2
0.3
8.1
30.9
34.6
25.9
20.4
16.6
14.7
13.2
8.7
5.6
1.8

105
25
1,798
6,532
7,786
5,734
4,312
3,015
2,971
2,687
1,907
1,106
903

0.2
0.3
8.4
29.3
33.0
25.9
20.1
15.2
14.1
12.5
8.6
5.5
1.8

87
20
1,736
6,171
7,788
5,731
4,243
3,012
2,824
2,504
1,871
1,066
902

0.2
0.2
8.1
28.0
32.7
25.7
19.5
15.1
13.5
11.9
8.4
5.2
1.7

57
21
1,654
6,026
7,461
5,730
4,179
3,013
2,612
2,342
1,869
1,131
902

0.1
0.2
7.8
27.5
31.4
25.3
19.0
15.0
12.7
11.3
8.5
5.4
1.6

57
12
1,256
4,867
6,103
5,233
3,445
2,540
2,094
1,883
1,599
901
702

0.1
0.1
5.9
22.3
26.0
22.7
15.6
12.4
10.4
9.1
7.3
4.3
1.2

216
932
16,805
10,636
43
9,887
1,583

—
—
—
—
—
—
—

200
933
16,283
10,387
52
9,648
1,378

—
—
—
—
—
—
—

173
872
15,794
10,388
63
9,451
1,214

—
—
—
—
—
—
—

205
746
15,508
10,287
70
9,075
1,106

—
—
—
—
—
—
—

201
637
12,859
8,294
66
7,843
792

—
—
—
—
—
—
—

26,244
1,225
1,551
3,353
10
15
32,397

—
—
—
—
—
—
24.2

25,580
1,326
1,483
2,987
14
17
31,407

—
—
—
—
—
—
23.3

24,810
1,431
1,477
2,947
16
21
30,701

—
—
—
—
—
—
22.6

24,204
1,406
1,536
2,734
20
19
29,920

—
—
—
—
—
—
21.9

20,758
1,198
1,109
2,051
9
20
25,145

—
—
—
—
—
—
18.3

1,046
6,473
48
8
7,575

—
—
—
—
5.4

1,095
6,216
51
7
7,369

—
—
—
—
5.2

1,107
6,008
46
7
7,167

—
—
—
—
5.1

1,160
5,805
47
7
7,020

—
—
—
—
4.9

857
4,575
51
7
5,490

—
—
—
—
3.8

107
23
130

—
—
0.2

88
17
105

—
—
0.2

68
19
87

—
—
0.2

46
11
57

—
—
0.1

44
13
57

—
—
0.1

6,211
5,172
20,274
7,895
550
40,102

11.1
7.6
16.6
10.3
14.4
12.3

5,987
5,115
19,725
7,594
460
38,881

10.7
7.5
16.0
9.8
12.4
11.8

5,565
4,940
19,412
7,587
451
37,955

9.9
7.2
15.6
9.7
12.6
11.5

5,312
4,748
19,181
7,344
412
36,997

9.5
6.9
15.3
9.4
11.5
11.1

4,271
4,127
15,689
6,316
289
30,692

7.6
6.0
12.4
8.0
8.1
9.2

Note. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution. Data for 2020 should be interpreted with caution due to the impact of
the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided
because U.S. census information is limited for U.S. dependent areas.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Data include transgender and additional gender identity persons.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
j Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

60

Vol. 33

Table 2a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—United States
American
Indian/
Alaska Native
No. Rateb
Gender
Male
Female
Transgender woman/girlc
Transgender man/boyc
Additional gender identityd
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Transmission categorye
Male sex at birth (≥ 13 yrs at
diagnosis)f
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactg
Perinatalh
Otheri
Subtotal
Female sex at birth (≥ 13 yrs at
diagnosis)f
Injection drug use
Heterosexual contactg
Perinatalh
Otheri
Subtotal
Child (<13 yrs at diagnosis)
Perinatal
Otheri
Subtotal
Region of residencej
Northeast
Midwest
South
West
Total

Asian
No. Rateb

Black/African
American
No. Rateb

Hispanic/
Latinoa
No. Rateb

Native
Hawaiian/
other Pacific
Islander
No. Rateb

White
No. Rateb

Multiracial
No. Rateb

Total
No. Rateb

149
44
8
0
0

—
—
—
—
—

532
88
16
0
1

—
—
—
—
—

9,558
2,970
309
11
8

—
—
—
—
—

6,885
907
202
10
4

—
—
—
—
—

48
15
3
0
0

—
—
—
—
—

6,471
1,281
72
15
4

—
—
—
—
—

626
134
28
4
0

—
—
—
—
—

24,269
5,439
638
40
17

—
—
—
—
—

1
0
5
28
36
35
30
25
11
16
7
4
3

0.2
0.0
2.8
15.4
18.2
19.3
18.7
17.2
7.8
11.2
4.5
2.8
0.9

2
0
19
68
144
111
72
55
58
41
24
22
21

0.1
0.0
1.7
5.5
9.4
6.6
4.4
3.8
4.1
3.3
2.1
2.2
0.8

32
8
735
2,544
2,646
2,159
1,232
882
737
640
602
363
276

0.4
0.7
25.7
83.7
77.0
68.3
44.1
33.9
29.2
25.4
23.2
15.2
5.3

9
4
294
1,231
1,707
1,447
996
745
524
466
298
173
114

0.1
0.2
5.8
25.1
34.4
31.0
22.1
17.6
13.6
13.8
10.2
7.4
2.3

1
0
4
8
15
10
10
6
4
3
3
2
0

0.9
0.0
9.6
18.6
30.2
18.7
20.0
14.0
10.6
8.4
8.6
6.6
0.0

12
0
149
792
1,336
1,323
976
734
682
656
615
301
267

0.0
0.0
1.4
6.9
10.7
10.5
7.9
6.4
5.8
5.1
4.2
2.1
0.6

0
0
42
151
177
112
93
68
56
35
26
20
12

0.0
0.0
5.4
21.8
29.1
23.9
24.1
21.0
20.2
14.3
11.1
9.5
2.6

57
12
1,248
4,822
6,061
5,197
3,409
2,515
2,072
1,857
1,575
885
693

0.1
0.1
6.0
22.3
26.1
22.8
15.6
12.4
10.4
9.1
7.3
4.3
1.2

126
8
20

—
—
—

491
14
12

—
—
—

8,062
313
230

—
—
—

6,176
261
256

—
—
—

42
3
3

—
—
—

5,126
539
545

—
—
—

550
42
38

—
—
—

20,572
1,178
1,105

—
—
—

3
0
0
157

—
—
—
16.0

30
0
2
549

—
—
—
7.1

1,240
—
8
—
8
—
9,859 60.9

390
0
3
7,086

—
—
—
29.4

2
0
0
50

—
—
—
19.9

325
1
6
6,542

—
—
—
7.8

24
0
0
654

—
—
—
26.8

20
23
0
0
43

—
—
—
—
4.2

6
79
1
1
86

—
—
—
—
1.0

250
—
2,674
—
40
—
1
—
2,965 16.4

134
773
5
1
913

—
—
—
—
3.8

2
12
0
0
15

—
—
—
—
6.0

422
858
5
4
1,289

—
—
—
—
1.5

21
116
1
0
138

—
—
—
—
5.3

855
4,536
51
7
5,449

—
—
—
—
3.8

0
1
1

—
—
0.2

0
2
2

—
—
0.1

26
6
32

—
—
0.4

8
1
9

—
—
0.1

1
0
1

—
—
0.9

9
3
12

—
—
0.0

0
0
0

—
—
0.0

44
13
57

—
—
0.1

7
32
49
113
201

5.4
7.7
6.0
10.5
8.3

93
75
151
318
637

2.4
3.1
3.2
3.8
3.3

1,721
1,980
8,081
1,074
12,856

27.2
27.5
33.3
29.6
31.0

1,340
515
3,435
2,718
8,008

16.0
9.1
14.6
11.4
13.1

4
5
13
44
66

17.7
12.9
12.9
9.8
10.8

972
1,396
3,566
1,909
7,843

2.7
2.7
5.0
4.9
4.0

134
124
394
140
792

13.2
8.6
15.6
5.5
10.5

2,012
—
9
—
20
—
24,897 18.3

4,271 7.6
4,127 6.0
15,689 12.4
6,316 8.0
30,403 9.2

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local
jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Hispanic/Latino persons can be of any race.
b Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex
at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data
have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Data presented include transgender and additional gender identity persons.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
j Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

61

Vol. 33

Table 2b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—United States and 6
dependent areas

Gender
Male
Female
Transgender woman/girlb
Transgender man/boyb
Additional gender identityc
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Transmission categoryd
Male sex at birth (≥ 13 yrs at
diagnosis)e
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactf
Perinatalg
Otherh
Subtotal
Female sex at birth (≥ 13 yrs at
diagnosis)e
Injection drug use
Heterosexual contactf
Perinatalg
Otherh
Subtotal
Child (< 13 yrs at diagnosis)
Perinatal
Otherh
Subtotal
Region of residencei
Northeast
Midwest
South
West
U.S. dependent areas
Total

Hispanic/
Latinoa
No.

Native
Hawaiian/
other Pacific
Islander
No.

White
No.

Multiracial
No.

Total
No.

9,561
2,970
309
11
8

7,128
948
204
10
4

48
15
3
0
0

6,471
1,281
72
15
4

626
134
28
4
0

24,515
5,480
640
40
17

2
0
19
68
144
111
72
55
58
41
24
22
21

32
8
737
2,544
2,646
2,160
1,232
882
737
640
602
363
276

9
4
300
1,276
1,749
1,482
1,032
770
546
492
322
189
123

1
0
4
8
15
10
10
6
4
3
3
2
0

12
0
149
792
1,336
1,323
976
734
682
656
615
301
267

0
0
42
151
177
112
93
68
56
35
26
20
12

57
12
1,256
4,867
6,103
5,233
3,445
2,540
2,094
1,883
1,599
901
702

126
8
20

491
14
12

8,064
313
230

6,359
280
261

42
3
3

5,126
539
545

550
42
38

20,758
1,198
1,109

3
0
0
157

30
0
2
549

1,241
8
8
9,862

427
0
3
7,331

2
0
0
50

325
1
6
6,542

24
0
0
654

2,051
9
20
25,145

20
23
0
0
43

6
79
1
1
86

250
2,674
40
1
2,965

136
812
5
1
954

2
12
0
0
15

422
858
5
4
1,289

21
116
1
0
138

857
4,575
51
7
5,490

0
1
1

0
2
2

26
6
32

8
1
9

1
0
1

9
3
12

0
0
0

44
13
57

7
32
49
113
0
201

93
75
151
318
0
637

1,721
1,980
8,081
1,074
3
12,859

1,340
515
3,435
2,718
286
8,294

4
5
13
44
0
66

972
1,396
3,566
1,909
0
7,843

134
124
394
140
0
792

4,271
4,127
15,689
6,316
289
30,692

American
Indian/
Alaska Native
No.

Asian
No.

Black/African
American
No.

149
44
8
0
0

532
88
16
0
1

1
0
5
28
36
35
30
25
11
16
7
4
3

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local
jurisdictions. Numbers less than 12 should be interpreted with caution.
a Hispanic/Latino persons can be of any race.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex
at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data
have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Data presented include transgender and additional gender identity persons.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

62

Vol. 33

Table 3a. Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, sex assigned at birth, and selected
characteristics, 2016–2020—United States

Male sex at birthb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Region of residenced
Northeast
Midwest
South
West
Subtotal
Female sex at birthb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Region of residenced
Northeast
Midwest
South
West
Subtotal
Total

2020 (COVID-19
pandemic)
No.
Ratea

2016
No.
Ratea

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

10
1,467
6,173
6,898
4,608
3,249
2,475
2,273
2,133
1,308
734
624

0.2
13.6
53.7
59.1
41.9
31.3
25.3
21.9
19.9
12.3
7.9
2.9

13
1,536
5,691
6,745
4,659
3,339
2,238
2,165
1,979
1,313
751
612

0.3
14.2
50.3
56.7
42.0
31.5
23.0
20.9
18.9
12.3
7.9
2.7

11
1,476
5,389
6,759
4,719
3,282
2,185
2,058
1,796
1,299
723
634

0.3
13.7
48.2
56.3
42.2
30.4
22.3
20.1
17.5
12.2
7.4
2.7

12
1,444
5,242
6,455
4,713
3,235
2,218
1,897
1,685
1,321
757
610

0.3
13.4
47.4
53.7
41.4
29.7
22.4
18.8
16.7
12.4
7.7
2.5

6
1,091
4,264
5,288
4,386
2,708
1,947
1,521
1,400
1,155
616
515

0.1
10.2
38.6
44.5
37.9
24.8
19.3
15.4
13.9
11.0
6.2
2.1

175
776
12,345
8,890
32
8,438
1,296

18.5
10.9
79.3
40.2
13.8
10.0
60.9

155
806
11,944
8,750
43
8,203
1,140

16.2
11.0
75.9
38.6
18.1
9.8
51.7

144
759
11,718
8,747
56
7,958
949

14.9
10.1
73.7
37.8
23.1
9.5
41.6

159
637
11,604
8,708
57
7,550
874

16.3
8.3
72.3
36.9
23.1
9.0
37.0

157
549
9,859
7,086
50
6,542
654

16.0
7.1
60.9
29.4
19.9
7.8
26.8

4,805
4,202
16,081
6,864
31,952

20.8
15.1
32.4
21.7
24.2

4,648
4,149
15,591
6,653
31,041

20.1
14.8
31.1
20.8
23.3

4,337
4,004
15,411
6,579
30,331

18.8
14.3
30.4
20.4
22.6

4,157
3,776
15,304
6,352
29,589

18.0
13.4
29.9
19.5
21.9

3,372
3,382
12,650
5,493
24,897

14.6
12.0
24.5
16.7
18.3

16
248
742
1,049
1,033
961
770
773
723
574
346
235

0.4
2.4
6.8
9.3
9.5
9.2
7.8
7.3
6.5
5.1
3.4
0.9

12
250
775
978
1,013
921
742
765
658
559
332
270

0.3
2.4
7.2
8.5
9.3
8.7
7.5
7.3
6.1
5.0
3.2
1.0

9
243
720
952
954
927
786
722
659
544
323
247

0.2
2.4
6.8
8.3
8.7
8.6
7.9
6.9
6.2
4.8
3.1
0.8

9
204
727
947
960
905
756
678
627
511
350
265

0.2
2.0
6.9
8.2
8.7
8.3
7.5
6.6
6.0
4.5
3.3
0.9

6
157
558
773
811
701
568
551
457
420
269
178

0.1
1.5
5.3
6.8
7.2
6.4
5.6
5.5
4.4
3.8
2.5
0.6

41
147
4,378
1,193
6
1,427
278

4.1
1.8
25.1
5.5
2.6
1.6
12.2

45
117
4,279
1,175
7
1,425
227

4.5
1.4
24.3
5.3
3.0
1.6
9.7

29
103
4,018
1,198
5
1,475
258

2.9
1.2
22.6
5.2
2.1
1.7
10.6

45
96
3,867
1,181
9
1,513
228

4.4
1.1
21.6
5.1
3.7
1.7
9.1

43
86
2,965
913
15
1,289
138

4.2
1.0
16.4
3.8
6.0
1.5
5.3

1,393
939
4,128
1,010
7,470
39,422

5.6
3.2
7.9
3.1
5.4
14.6

1,329
947
4,071
928
7,275
38,316

5.4
3.3
7.7
2.9
5.2
14.1

1,220
923
3,953
990
7,086
37,417

4.9
3.2
7.4
3.0
5.1
13.6

1,148
964
3,845
982
6,939
36,528

4.6
3.3
7.1
3.0
4.9
13.2

890
736
3,011
812
5,449
30,346

3.6
2.5
5.5
2.4
3.8
10.9

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population.
b Data include transgender and additional gender identity persons.
c Hispanic/Latino persons can be of any race.
d Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

63

Vol. 33

Table 3b. Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, sex assigned at birth, and selected
characteristics, 2016–2020—United States and 6 dependent areas

Male sex at birthb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Region of residenced
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Female sex at birthb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Region of residenced
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Total

2020 (COVID-19
pandemic)
No.
Ratea

2016
No.
Ratea

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

10
1,475
6,240
6,963
4,664
3,302
2,516
2,317
2,169
1,342
753
646

0.2
13.5
53.7
59.0
42.0
31.5
25.5
22.1
20.0
12.5
8.0
2.9

13
1,544
5,752
6,797
4,714
3,379
2,266
2,191
2,017
1,336
769
629

0.3
14.1
50.2
56.5
42.1
31.6
23.1
20.9
19.0
12.4
8.0
2.8

11
1,491
5,442
6,829
4,771
3,311
2,218
2,088
1,834
1,319
738
649

0.3
13.7
48.2
56.3
42.3
30.4
22.4
20.2
17.7
12.2
7.5
2.8

12
1,450
5,294
6,508
4,761
3,269
2,244
1,924
1,708
1,345
776
629

0.3
13.3
47.3
53.6
41.5
29.7
22.4
18.9
16.8
12.5
7.8
2.6

6
1,099
4,305
5,327
4,421
2,741
1,966
1,538
1,420
1,172
629
521

0.1
10.2
38.6
44.4
37.9
24.8
19.3
15.4
14.0
11.0
6.2
2.1

175
777
12,351
9,320
37
8,440
1,297

—
—
—
—
—
—
—

155
809
11,946
9,106
44
8,206
1,141

—
—
—
—
—
—
—

144
763
11,726
9,098
58
7,961
951

—
—
—
—
—
—
—

159
644
11,608
9,020
60
7,555
874

—
—
—
—
—
—
—

157
549
9,862
7,331
50
6,542
654

—
—
—
—
—
—
—

4,805
4,202
16,081
6,864
445
32,397

20.8
15.1
32.4
21.7
29.0
24.2

4,648
4,149
15,591
6,653
366
31,407

20.1
14.8
31.1
20.8
24.2
23.3

4,337
4,004
15,411
6,579
370
30,701

18.8
14.3
30.4
20.4
25.1
22.6

4,157
3,776
15,304
6,352
331
29,920

18.0
13.4
29.9
19.5
22.4
21.9

3,372
3,382
12,650
5,493
248
25,145

14.6
12.0
24.5
16.7
16.9
18.3

16
250
748
1,055
1,042
978
786
788
732
588
354
238

0.4
2.4
6.8
9.3
9.5
9.3
7.8
7.4
6.5
5.2
3.4
0.9

12
254
780
989
1,020
933
749
780
670
571
337
274

0.3
2.4
7.2
8.5
9.3
8.7
7.5
7.3
6.1
5.0
3.2
1.0

9
245
729
959
960
932
794
736
670
552
328
253

0.2
2.3
6.8
8.2
8.7
8.6
7.9
7.0
6.2
4.8
3.1
0.9

9
204
732
953
969
910
769
688
634
524
355
273

0.2
2.0
6.8
8.2
8.7
8.3
7.6
6.6
6.0
4.6
3.3
0.9

6
157
562
776
812
704
574
556
463
427
272
181

0.1
1.5
5.3
6.8
7.1
6.4
5.6
5.4
4.4
3.8
2.5
0.6

41
147
4,378
1,298
6
1,427
278

—
—
—
—
—
—
—

45
117
4,281
1,265
7
1,427
227

—
—
—
—
—
—
—

29
103
4,018
1,279
5
1,475
258

—
—
—
—
—
—
—

45
96
3,868
1,260
10
1,513
228

—
—
—
—
—
—
—

43
86
2,965
954
15
1,289
138

—
—
—
—
—
—
—

1,393
939
4,128
1,010
105
7,575
39,972

5.6
3.2
7.9
3.1
6.1
5.4
14.6

1,329
947
4,071
928
94
7,369
38,776

5.4
3.3
7.7
2.9
5.6
5.2
14.1

1,220
923
3,953
990
81
7,167
37,868

4.9
3.2
7.4
3.0
5.0
5.1
13.7

1,148
964
3,845
982
81
7,020
36,940

4.6
3.3
7.1
3.0
4.9
4.9
13.2

890
736
3,011
812
41
5,490
30,635

3.6
2.5
5.5
2.4
2.5
3.8
10.9

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population.
b Data include transgender and additional gender identity persons.
c Hispanic/Latino persons can be of any race.
d Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

64

Vol. 33

Table 4a. Diagnoses of HIV infection among transgender and additional gender identity persons, by year of diagnosis and selected
characteristics, 2016–2020—United States

Transgender womana
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryc
Sexual contactd
Injection drug use
Sexual contactd and injection drug use
Othere
Region of residencef
Northeast
Midwest
South
West
Subtotal
Transgender mana
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryc
Sexual contactd
Injection drug use
Sexual contactd and injection drug use
Othere
Region of residencef
Northeast
Midwest
South
West
Subtotal


HIV Surveillance Report

2016
No.

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
61
201
185
90
69
27
17
9
9
3
3

0
57
149
171
109
55
30
21
8
7
5
0

0
41
163
185
95
72
32
22
7
6
2
2

0
40
166
165
130
62
40
21
16
7
4
1

0
31
145
193
125
47
37
31
16
7
5
1

4
8
343
212
2
61
44

2
18
306
184
3
76
23

9
9
302
211
3
63
30

5
11
315
215
5
80
21

8
16
309
202
3
72
28

620
0
40
14

555
3
38
16

563
4
50
10

580
2
54
16

576
1
35
26

144
99
302
129
674

102
99
278
133
612

114
98
272
143
627

104
85
287
176
652

105
98
279
156
638

0
1
5
5
4
3
1
2
1
0
0
0

0
3
7
16
1
3
0
2
0
1
0
0

0
2
9
18
9
4
4
1
1
0
0
0

0
0
11
18
12
2
0
2
0
0
0
0

0
1
12
10
8
5
2
1
1
0
0
0

0
1
5
7
0
6
3

0
2
11
6
0
11
3

0
0
18
10
0
18
2

0
1
18
12
0
10
4

0
0
11
10
0
15
4

20
0
1
1

28
1
1
3

40
2
2
4

36
1
2
6

29
1
5
5

2
5
6
9
22

5
8
12
8
33

7
7
16
18
48

6
6
17
16
45

8
2
24
6
40

65

Vol. 33

Table 4a. Diagnoses of HIV infection among transgender and additional gender identity persons, by year of diagnosis and selected
characteristics, 2016–2020—United States (cont)

Additional gender identityg
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryc
Sexual contactd
Injection drug use
Sexual contactd and injection drug use
Othere
Region of residencef
Northeast
Midwest
South
West
Subtotal
Total

2020 (COVID-19
pandemic)
No.

2016
No.

2017
No.

2018
No.

2019
No.

0
1
4
4
1
0
0
0
0
1
0
0

0
1
2
3
3
4
0
2
0
0
0
0

0
4
5
4
1
1
0
0
0
0
0
0

0
3
8
6
3
2
0
0
1
0
0
0

0
1
7
6
1
2
0
0
0
0
0
0

0
0
5
3
0
2
1

0
1
6
5
0
3
0

1
2
5
2
0
3
2

0
0
8
6
0
5
4

0
1
8
4
0
4
0

9
0
2
0

14
0
0
1

15
0
0
0

21
0
1
1

14
0
1
2

4
1
4
2
11
707

9
2
4
0
15
660

10
0
3
2
15
690

8
7
4
4
23
720

2
5
5
5
17
695

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender.
b Hispanic/Latino persons can be of any race.
c Risk factor data for transgender and additional gender identity persons are presented using the exposure category classification, which is meant to convey all the known ways the
person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where
route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
e Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure
category; therefore, case counts for “Other” might be high.
f Data are based on residence at time of diagnosis of HIV infection.
g Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”


HIV Surveillance Report

66

Vol. 33

Table 4b. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13 years, by year of diagnosis
and selected characteristics, 2016–2020—United States and 6 dependent areas

Transgender womana
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryc
Sexual contactd
Injection drug use
Sexual contactd and injection drug use
Othere
Region of residencef
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Transgender mana
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryc
Sexual contactd
Injection drug use
Sexual contactd and injection drug use
Othere
Region of residencef
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal


HIV Surveillance Report

2016
No.

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
61
202
186
91
69
27
17
9
9
3
3

0
57
150
172
109
55
30
21
8
7
5
0

0
41
164
186
95
72
32
22
7
6
2
2

0
40
167
166
130
62
40
21
16
7
4
1

0
31
146
193
126
47
37
31
16
7
5
1

4
8
343
215
2
61
44

2
18
306
186
3
76
23

9
9
302
213
3
63
30

5
11
315
217
5
80
21

8
16
309
204
3
72
28

623
0
40
14

557
3
38
16

565
4
50
10

582
2
54
16

578
1
35
26

144
99
302
129
3
677

102
99
278
133
2
614

114
98
272
143
2
629

104
85
287
176
2
654

105
98
279
156
2
640

0
1
5
5
4
3
1
2
1
0
0
0

0
3
7
16
1
3
0
2
0
1
0
0

0
2
9
18
9
5
4
1
1
0
0
0

0
0
11
18
12
2
0
2
0
0
0
0

0
1
12
10
8
5
2
1
1
0
0
0

0
1
5
7
0
6
3

0
2
11
6
0
11
3

0
0
18
11
0
18
2

0
1
18
12
0
10
4

0
0
11
10
0
15
4

20
0
1
1

28
1
1
3

41
2
2
4

36
1
2
6

29
1
5
5

2
5
6
9
0
22

5
8
12
8
0
33

7
7
16
18
1
49

6
6
17
16
0
45

8
2
24
6
0
40

67

Vol. 33

Table 4b. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13 years, by year of diagnosis
and selected characteristics, 2016–2020—United States and 6 dependent areas (cont)

Additional gender identityg
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryc
Sexual contactd
Injection drug use
Sexual contactd and injection drug use
Othere
Region of residencef
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Total

2020 (COVID-19
pandemic)
No.

2016
No.

2017
No.

2018
No.

2019
No.

0
1
4
4
1
0
0
0
0
1
0
0

0
1
2
3
3
4
0
2
0
0
0
0

0
4
5
4
1
1
0
0
0
0
0
0

0
3
8
6
3
2
0
0
1
0
0
0

0
1
7
6
1
2
0
0
0
0
0
0

0
0
5
3
0
2
1

0
1
6
5
0
3
0

1
2
5
2
0
3
2

0
0
8
6
0
5
4

0
1
8
4
0
4
0

9
0
2
0

14
0
0
1

15
0
0
0

21
0
1
1

14
0
1
2

4
1
4
2
0
11
710

9
2
4
0
0
15
662

10
0
3
2
0
15
693

8
7
4
4
0
23
722

2
5
5
5
0
17
697

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender.
b Hispanic/Latino persons can be of any race.
c Risk factor data for transgender and additional gender identity persons are presented using the exposure category classification, which is meant to convey all the known ways the
person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where
route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
e Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure
category; therefore, case counts for “Other” might be high.
f Data are based on residence at time of diagnosis of HIV infection.
g Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”


HIV Surveillance Report

68

Vol. 33

Table 5a. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States
Male-to-male sexual contact

Male-to-male sexual contact and injection drug use

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
2
24
36
28
12
14
6
5
3
3
1

0
2
18
31
18
14
11
6
8
2
2
1

0
7
25
21
18
9
7
7
7
3
0
3

0
7
25
28
16
19
6
7
9
3
2
0

0
5
23
25
20
14
14
7
10
5
2
1

0
0
4
5
3
2
0
0
1
0
0
0

0
0
3
5
6
1
2
1
0
0
1
1

0
0
2
7
6
2
1
2
0
0
0
0

0
0
3
6
1
3
0
1
1
0
0
0

0
0
4
4
3
5
3
1
1
0
0
0

Region of residencea
Northeast
Midwest
South
West

7
12
33
82

2
10
26
75

5
13
17
72

4
8
41
67

6
11
35
74

0
1
6
9

0
3
9
7

0
5
4
13

0
2
3
11

0
4
0
16

135

112

106

120

126

16

20

21

16

20

Total

Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
20
109
155
123
78
86
50
31
19
8
10

0
25
148
151
113
90
74
65
35
20
8
7

1
24
108
168
119
74
62
58
24
19
9
10

0
18
91
131
94
74
43
51
35
18
7
9

0
17
64
124
89
52
44
42
25
14
12
8

0
0
4
2
2
1
1
1
1
0
0
1

0
0
3
4
5
0
1
3
0
0
0
0

0
0
1
3
3
3
1
0
0
0
0
0

0
0
2
2
6
2
0
1
0
0
0
0

0
0
1
4
4
0
2
1
0
0
0
0

Region of residencea
Northeast
Midwest
South
West

134
59
147
348

129
76
153
379

130
66
173
306

105
53
145
268

73
57
110
251

3
4
1
6

3
0
1
12

2
0
1
10

2
1
4
7

0
1
1
10

Total

689

737

675

570

491

13

16

13

14

12


HIV Surveillance Report

69

Vol. 33

Table 5a. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States (cont)
Male-to-male sexual contact

Male-to-male sexual contact and injection drug use

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

4
802
2,815
2,544
1,210
721
447
377
346
202
98
64

4
855
2,530
2,492
1,330
761
442
356
321
206
111
67

7
811
2,425
2,513
1,274
744
448
354
309
200
101
79

7
802
2,399
2,353
1,425
744
469
339
281
212
114
80

2
608
2,076
1,982
1,466
670
397
269
244
203
92
55

0
16
65
78
50
32
16
20
13
9
7
4

0
13
43
71
49
37
17
12
24
12
5
5

0
10
51
78
49
27
20
10
18
10
5
4

0
10
39
88
66
40
23
18
17
8
6
2

0
10
42
56
55
22
15
11
9
6
2
2

Region of residencea
Northeast
Midwest
South
West

1,144
1,584
6,064
839

1,143
1,502
6,013
819

1,082
1,461
5,892
829

1,108
1,415
5,899
803

941
1,323
5,079
719

38
66
167
40

36
51
150
51

50
52
137
44

41
46
175
55

36
41
115
37

Total

9,630

9,476

9,264

9,226

8,062

311

288

282

318

230

Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

2
314
1,486
1,796
1,325
934
624
475
356
154
76
54

5
337
1,382
1,750
1,332
927
594
513
342
172
71
74

0
320
1,375
1,791
1,321
914
557
501
335
197
90
69

2
356
1,382
1,752
1,312
926
611
458
348
182
92
70

3
252
1,047
1,434
1,187
735
537
358
294
191
85
54

0
17
80
85
77
47
37
12
17
7
4
3

0
11
68
98
68
50
22
18
16
8
3
2

0
10
73
105
54
44
27
19
16
3
4
2

0
7
64
96
71
62
34
22
21
10
2
3

0
5
33
70
55
32
20
19
11
4
7
1

Region of residencea
Northeast
Midwest
South
West

1,247
494
3,253
2,602

1,285
517
3,199
2,498

1,172
521
3,220
2,557

1,163
521
3,247
2,562

924
412
2,642
2,199

56
30
146
155

40
30
132
164

54
27
112
166

60
35
142
156

26
17
90
123

Total

7,596

7,499

7,469

7,492

6,176

386

365

359

394

256


HIV Surveillance Report

70

Vol. 33

Table 5a. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States (cont)
Male-to-male sexual contact

Male-to-male sexual contact and injection drug use

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
1
1
7
3
7
3
0
2
0
0
1

0
1
9
9
9
2
5
1
1
0
0
0

0
3
7
9
11
8
2
2
1
4
1
1

0
1
6
19
10
7
4
0
4
1
1
0

0
3
6
11
7
7
5
1
2
1
0
0

0
0
0
2
2
0
0
0
0
0
0
1

0
0
0
0
0
1
0
0
0
0
0
0

0
0
2
2
1
0
0
0
0
0
0
0

0
0
0
0
1
1
0
0
0
0
0
0

0
0
0
1
1
0
0
1
0
0
0
0

Region of residencea
Northeast
Midwest
South
West

2
1
4
18

3
2
7
25

2
2
8
36

2
5
13
33

3
3
8
28

1
0
0
4

0
0
0
1

0
0
0
5

0
0
0
2

0
1
0
2

Total

24

37

48

52

42

5

1

5

3

3

White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
155
868
1,206
962
673
612
709
733
459
239
200

1
161
916
1,204
885
726
490
614
672
440
243
185

0
169
798
1,124
948
658
523
562
535
432
250
208

1
132
730
1,096
888
662
455
467
503
458
235
182

0
120
591
913
858
544
454
406
441
410
204
185

0
20
95
160
129
86
67
58
44
35
14
9

0
13
87
169
130
100
62
60
41
25
16
10

0
10
70
181
145
115
57
49
43
27
7
6

0
14
74
166
144
112
64
52
36
31
14
10

0
1
48
124
106
103
52
42
32
23
9
5

Region of residencea
Northeast
Midwest
South
West

953
1,183
2,968
1,712

831
1,216
2,837
1,655

749
1,086
2,794
1,580

693
968
2,657
1,490

583
937
2,282
1,325

66
141
280
229

81
107
310
213

76
133
285
217

61
145
294
215

73
99
206
166

Total

6,815

6,538

6,208

5,808

5,126

716

712

711

715

545


HIV Surveillance Report

71

Vol. 33

Table 5a. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States (cont)
Male-to-male sexual contact

Male-to-male sexual contact and injection drug use

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Multiracial
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
57
276
265
150
79
69
57
44
33
20
9

0
57
221
245
144
81
55
49
52
21
15
8

0
43
183
197
119
83
44
40
31
14
10
11

0
45
154
175
118
73
46
31
17
32
9
7

0
34
115
134
77
62
43
34
24
13
7
9

0
3
18
25
16
9
3
7
5
3
3
0

0
2
12
11
11
13
4
6
6
3
0
0

0
3
9
25
13
12
2
6
4
0
0
0

0
2
6
17
24
5
7
1
2
2
0
1

0
1
6
10
4
6
5
5
1
0
0
0

Region of residencea
Northeast
Midwest
South
West

205
142
497
216

167
151
451
178

136
112
370
157

138
77
363
127

94
83
266
106

16
18
36
22

10
10
35
14

7
14
29
23

7
13
31
15

5
7
16
11

1,059

947

775

706

550

92

69

73

66

38

Total

Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

5
1,351
5,579
6,010
3,801
2,504
1,854
1,674
1,517
870
444
339

10
1,439
5,224
5,881
3,831
2,600
1,670
1,605
1,432
862
451
342

8
1,376
4,920
5,823
3,810
2,490
1,643
1,522
1,242
869
460
380

10
1,359
4,787
5,553
3,863
2,505
1,634
1,353
1,196
905
460
349

5
1,038
3,921
4,622
3,704
2,083
1,494
1,116
1,040
836
401
312

0
55
265
357
279
177
125
99
82
54
29
18

0
39
215
359
269
201
108
100
87
49
25
18

0
32
208
402
271
204
108
87
82
41
18
13

0
33
189
375
312
224
128
96
77
50
23
17

0
17
134
269
227
169
96
79
54
33
19
8

Region of residencea
Northeast
Midwest
South
West

3,691
3,475
12,966
5,816

3,559
3,474
12,684
5,629

3,274
3,261
12,473
5,537

3,213
3,047
12,364
5,350

2,624
2,826
10,420
4,702

178
260
636
465

170
201
637
462

188
232
567
478

172
242
650
461

141
171
428
365

Total

25,948

25,346

24,545

23,974

20,572

1,539

1,470

1,465

1,524

1,105

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and
include transgender and additional gender identity persons.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanic/Latino persons can be of any race.


HIV Surveillance Report

72

Vol. 33

Table 5b. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States and
6 dependent areas
Male-to-male sexual contact

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Male-to-male sexual contact and injection drug use
2020
(COVID-19
2016
2017
2018
2019
pandemic)
No.

No.

No.

No.

No.

American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

0
2
24
36
28
12
14
6
5
3
3
1

0
2
18
31
18
14
11
6
8
2
2
1

0
7
25
21
18
9
7
7
7
3
0
3

0
7
25
28
16
19
6
7
9
3
2
0

0
5
23
25
20
14
14
7
10
5
2
1

0
0
4
5
3
2
0
0
1
0
0
0

0
0
3
5
6
1
2
1
0
0
1
1

0
0
2
7
6
2
1
2
0
0
0
0

0
0
3
6
1
3
0
1
1
0
0
0

0
0
4
4
3
5
3
1
1
0
0
0

7
12
33
82
0
135

2
10
26
75
0
112

5
13
17
72
0
106

4
8
41
67
0
120

6
11
35
74
0
126

0
1
6
9
0
16

0
3
9
7
0
20

0
5
4
13
0
21

0
2
3
11
0
16

0
4
0
16
0
20

Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

0
20
109
155
123
79
86
50
31
19
8
10

0
25
148
151
115
91
74
65
35
20
8
7

1
24
108
169
121
74
62
58
24
19
9
10

0
18
91
134
95
75
43
51
35
18
7
9

0
17
64
124
89
52
44
42
25
14
12
8

0
0
4
2
2
1
1
1
1
0
0
1

0
0
3
4
5
0
1
3
0
0
0
0

0
0
1
3
3
3
1
0
0
0
0
0

0
0
2
3
6
2
0
1
1
0
0
0

0
0
1
4
4
0
2
1
0
0
0
0

134
59
147
348
1
690

129
76
153
379
3
740

130
66
173
306
4
679

105
53
145
268
6
576

73
57
110
251
0
491

3
4
1
6
0
13

3
0
1
12
0
16

2
0
1
10
0
13

2
1
4
7
1
15

0
1
1
10
0
12


HIV Surveillance Report

73

Vol. 33

Table 5b. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States and
6 dependent areas (cont)
Male-to-male sexual contact

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Male-to-male sexual contact and injection drug use
2020
(COVID-19
2016
2017
2018
2019
pandemic)
No.

No.

No.

No.

No.

Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

4
802
2,816
2,544
1,211
721
448
377
346
202
98
64

4
855
2,530
2,492
1,330
761
443
356
321
206
111
67

7
811
2,425
2,515
1,275
744
449
354
309
200
101
79

7
802
2,400
2,353
1,425
744
469
339
281
212
114
80

2
610
2,076
1,982
1,466
670
397
269
244
203
92
55

0
16
65
78
50
32
16
20
13
9
7
4

0
13
43
71
49
37
17
12
24
12
5
5

0
10
51
78
49
27
20
10
18
10
5
4

0
10
39
88
66
40
23
18
17
8
6
2

0
10
42
56
55
22
15
11
9
6
2
2

1,144
1,584
6,064
839
3
9,633

1,143
1,502
6,013
819
1
9,478

1,082
1,461
5,892
829
4
9,268

1,108
1,415
5,899
803
1
9,227

941
1,323
5,079
719
2
8,064

38
66
167
40
0
311

36
51
150
51
0
288

50
52
137
44
0
282

41
46
175
55
0
318

36
41
115
37
0
230

Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

2
321
1,547
1,853
1,367
970
644
495
379
169
78
56

5
344
1,432
1,792
1,369
948
609
529
364
181
75
76

0
334
1,425
1,844
1,356
934
579
523
351
207
97
72

2
362
1,426
1,796
1,349
950
624
471
363
193
101
73

3
258
1,085
1,467
1,217
761
547
370
310
197
89
56

0
18
80
87
79
50
38
13
17
7
4
3

0
11
70
102
70
52
23
21
16
8
3
2

0
10
74
108
57
45
28
19
17
5
5
3

0
7
67
97
73
64
35
22
21
11
2
4

0
5
34
72
55
34
20
19
11
4
7
1

1,247
494
3,253
2,602
285
7,881

1,285
517
3,199
2,498
226
7,725

1,172
521
3,220
2,557
253
7,722

1,163
521
3,247
2,562
217
7,709

924
412
2,642
2,199
183
6,359

56
30
146
155
11
397

40
30
132
164
13
378

54
27
112
166
12
371

60
35
142
156
10
404

26
17
90
123
5
261


HIV Surveillance Report

74

Vol. 33

Table 5b. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States and
6 dependent areas (cont)
Male-to-male sexual contact

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Male-to-male sexual contact and injection drug use
2020
(COVID-19
2016
2017
2018
2019
pandemic)
No.

No.

No.

No.

No.

Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

0
1
2
7
5
7
3
0
2
0
0
1

0
1
9
9
9
2
5
1
1
0
0
0

0
3
7
9
11
9
2
2
1
4
1
1

0
1
6
19
10
7
5
0
5
1
1
0

0
3
6
11
7
7
5
1
2
1
0
0

0
0
0
3
2
0
0
0
0
0
0
1

0
0
0
0
0
1
0
0
0
0
0
0

0
0
2
2
1
0
0
0
0
0
0
0

0
0
0
1
1
1
0
0
0
0
0
0

0
0
0
1
1
0
0
1
0
0
0
0

2
1
4
18
3
28

3
2
7
25
0
37

2
2
8
36
1
49

2
5
13
33
2
54

3
3
8
28
0
42

1
0
0
4
1
6

0
0
0
1
0
1

0
0
0
5
0
5

0
0
0
2
1
4

0
1
0
2
0
3

White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

0
155
869
1,206
963
673
612
709
733
459
239
200

1
161
916
1,204
885
728
490
614
673
440
243
185

0
169
798
1,124
948
658
524
562
536
433
250
208

1
132
730
1,096
890
662
455
467
503
458
236
183

0
120
591
913
858
544
454
406
441
410
204
185

0
20
95
160
129
86
67
58
44
35
14
9

0
13
87
169
130
100
62
60
41
25
16
10

0
10
70
181
145
115
57
49
43
27
7
6

0
14
74
166
144
112
64
52
36
31
14
10

0
1
48
124
106
103
52
42
32
23
9
5

953
1,183
2,968
1,712
2
6,817

831
1,216
2,837
1,655
3
6,541

749
1,086
2,794
1,580
3
6,211

693
968
2,657
1,490
4
5,812

583
937
2,282
1,325
0
5,126

66
141
280
229
0
716

81
107
310
213
0
712

76
133
285
217
0
711

61
145
294
215
0
715

73
99
206
166
0
545


HIV Surveillance Report

75

Vol. 33

Table 5b. Diagnoses of HIV infection among males, based on sex at birth, attributed to male-to-male sexual contact and male-to-male
sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States and
6 dependent areas (cont)
Male-to-male sexual contact

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Male-to-male sexual contact and injection drug use
2020
(COVID-19
2016
2017
2018
2019
pandemic)
No.

No.

No.

No.

No.

Multiracial
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

0
57
276
265
150
79
69
57
44
33
21
9

0
57
221
245
144
81
55
49
52
21
15
8

0
43
183
197
119
83
44
40
31
14
10
11

0
45
154
175
118
73
46
31
17
32
9
7

0
34
115
134
77
62
43
34
24
13
7
9

0
3
18
25
16
9
3
7
5
3
3
0

0
2
12
11
11
13
4
6
6
3
0
0

0
3
9
25
13
12
2
6
4
0
0
0

0
2
6
17
24
5
7
1
2
2
0
1

0
1
6
10
4
6
5
5
1
0
0
0

205
142
497
216
1
1,060

167
151
451
178
1
948

136
112
370
157
0
775

138
77
363
127
0
706

94
83
266
106
0
550

16
18
36
22
0
92

10
10
35
14
0
69

7
14
29
23
0
73

7
13
31
15
0
66

5
7
16
11
0
38

Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
Total

5
1,358
5,642
6,067
3,847
2,540
1,876
1,694
1,540
885
448
342

10
1,446
5,274
5,923
3,870
2,626
1,686
1,621
1,455
871
455
344

8
1,390
4,970
5,879
3,848
2,510
1,668
1,544
1,260
881
468
383

10
1,365
4,832
5,600
3,902
2,530
1,648
1,366
1,213
917
469
352

5
1,046
3,958
4,655
3,734
2,109
1,505
1,128
1,056
842
406
314

0
56
265
361
281
180
126
100
82
54
29
18

0
39
217
363
272
204
108
102
87
49
25
18

0
32
209
405
274
205
108
87
82
42
19
14

0
33
192
378
315
226
128
96
77
51
23
18

0
17
135
272
227
170
96
79
54
33
19
8

3,691
3,475
12,966
5,816
295
26,244

3,559
3,474
12,684
5,629
234
25,580

3,274
3,261
12,473
5,537
264
24,810

3,213
3,047
12,364
5,350
230
24,204

2,624
2,826
10,420
4,702
185
20,758

178
260
636
465
12
1,551

170
201
637
462
13
1,483

188
232
567
478
12
1,477

172
242
650
461
12
1,536

141
171
428
365
5
1,109

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and
include transgender and additional gender identity persons.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanic/Latino persons can be of any race.


HIV Surveillance Report

76

Vol. 33

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
3
5
0
1
2
2
0
3
0
0

0
0
0
6
3
0
1
0
3
1
1
1

0
1
0
1
3
0
0
1
2
0
0
0

0
0
2
1
2
4
3
1
1
0
0
0

0
0
1
0
3
1
0
0
2
0
0
0

0
0
1
3
1
2
1
2
4
0
0
0

0
0
1
2
1
3
2
2
2
0
0
1

0
0
0
3
2
3
1
2
2
1
1
0

0
0
2
1
2
7
3
1
2
0
0
1

0
0
0
6
3
4
3
1
1
0
0
1

Region of residencea
Northeast
Midwest
South
West

0
0
3
14

1
2
2
11

0
2
1
5

0
4
2
8

0
3
3
2

1
1
1
12

1
1
4
9

0
2
5
6

0
5
7
8

0
10
2
8

Total

17

16

9

15

8

15

15

14

19

20

Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
2
1
3
1
3
1
1
0
1

0
0
1
1
0
2
3
2
1
1
0
0

0
0
1
0
2
0
2
2
1
0
1
1

0
0
0
2
0
3
1
3
3
1
0
1

0
0
0
1
2
1
2
3
2
1
2
1

0
0
1
1
1
1
1
2
0
0
0
0

0
0
0
2
0
1
0
0
1
0
1
0

0
0
0
0
2
1
0
0
0
0
0
0

0
0
0
0
2
1
1
1
0
0
0
0

0
0
0
0
2
1
0
1
1
0
0
1

Region of residencea
Northeast
Midwest
South
West

4
2
2
6

4
0
2
5

5
1
4
1

4
3
3
6

3
3
1
8

3
0
2
3

1
1
2
4

1
0
2
2

1
0
1
4

1
0
2
3

14

10

11

15

14

8

7

5

6

6

Total


HIV Surveillance Report

77

Vol. 33

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
4
20
29
33
44
44
41
57
43
36
29

0
6
16
35
49
41
31
46
47
53
35
31

0
4
21
46
51
59
35
43
50
51
36
35

0
4
22
51
57
45
44
31
40
39
42
33

0
3
20
35
41
37
26
29
30
39
23
30

1
7
22
39
42
36
29
33
53
42
28
18

0
8
30
38
40
39
40
41
40
31
25
19

0
7
24
29
40
35
30
36
41
39
26
16

1
7
29
44
43
44
34
40
30
31
29
21

0
7
20
34
36
30
18
25
24
31
16
10

Region of residencea
Northeast
Midwest
South
West

103
54
183
39

123
61
173
32

122
59
204
45

117
51
199
40

90
42
155
26

76
54
182
39

92
60
164
35

80
46
162
37

94
51
164
42

50
46
125
29

Total

379

389

430

407

313

350

351

324

351

250

Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
2
18
37
48
43
23
34
39
25
12
13

0
4
20
40
58
44
43
38
41
23
12
13

0
3
24
34
63
46
35
35
39
25
14
10

0
1
17
44
44
48
38
25
27
25
13
12

0
2
15
37
36
39
42
26
27
13
12
14

0
4
13
31
25
14
17
17
17
13
7
7

0
4
19
18
29
24
21
16
14
7
7
4

0
2
22
20
27
26
15
21
14
9
9
6

0
6
19
21
23
35
13
15
17
9
6
5

1
2
8
18
26
23
16
9
11
9
9
3

Region of residencea
Northeast
Midwest
South
West

97
14
85
98

115
16
93
114

109
14
95
110

85
10
88
111

74
13
76
98

52
11
54
48

47
11
53
52

55
9
49
58

51
12
55
52

38
6
34
56

295

338

329

295

261

165

163

170

170

134

Total


HIV Surveillance Report

78

Vol. 33

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
1
0
0
0

0
0
0
0
0
0
0
1
0
0
0
0

0
0
0
1
0
0
0
0
0
0
0
0

0
0
0
1
0
1
0
0
0
0
0
0

0
0
0
0
0
0
0
0
2
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
1
0
0
1
0

Region of residencea
Northeast
Midwest
South
West

0
0
0
0

0
0
0
1

0
0
0
1

0
1
0
0

0
1
0
1

0
0
0
2

0
0
0
0

0
0
0
0

0
0
0
0

0
0
1
2

Total

0

1

1

1

3

2

0

0

0

2

White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
3
30
77
61
65
44
49
53
25
17
17

0
3
35
86
89
74
49
57
36
36
18
17

0
4
36
99
107
113
63
51
50
35
22
10

0
0
44
103
112
102
71
69
43
43
17
9

0
4
21
81
113
116
61
52
32
36
13
8

0
5
44
93
70
59
45
45
38
20
16
10

0
9
51
91
99
79
52
40
41
34
9
6

0
8
46
87
99
96
71
46
41
27
10
6

0
6
44
89
106
97
75
55
38
35
12
5

0
2
17
74
84
69
46
38
37
32
16
7

Region of residencea
Northeast
Midwest
South
West

82
80
159
120

93
92
196
119

115
118
223
134

96
105
276
133

99
89
243
108

87
85
187
85

90
92
234
95

92
109
224
112

78
98
279
108

59
63
221
80

Total

440

501

589

611

539

445

510

537

563

422


HIV Surveillance Report

79

Vol. 33

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Multiracial
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
1
3
10
1
7
6
2
8
5
3
1

0
0
2
8
6
5
4
5
3
2
1
2

0
0
5
5
4
4
4
3
7
4
1
1

0
0
4
3
12
2
2
3
5
2
1
2

0
0
5
4
10
10
2
3
3
2
2
0

0
1
4
6
3
9
5
7
5
6
1
1

0
2
6
8
4
6
5
3
3
3
0
0

0
3
9
12
6
6
5
5
5
1
3
1

0
2
2
9
4
8
8
3
5
2
1
1

0
0
2
4
2
3
3
3
1
1
2
0

Region of residencea
Northeast
Midwest
South
West

8
3
16
18

10
9
11
8

6
8
13
11

15
7
10
6

7
7
22
5

12
6
20
11

13
4
15
7

10
9
24
12

10
11
19
6

2
4
11
4

Total

44

37

38

37

42

49

39

55

46

21

Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
11
73
158
144
163
120
131
158
101
68
62

0
13
73
176
205
166
130
149
133
116
67
64

0
13
87
186
230
223
140
134
149
116
74
57

0
5
88
207
228
204
159
132
119
110
74
57

0
9
62
160
204
205
133
112
95
92
53
53

1
17
86
174
143
122
98
104
120
81
52
36

1
23
107
159
174
152
120
102
101
75
42
30

0
19
101
150
176
166
123
110
103
77
49
30

1
21
96
164
179
192
133
115
93
78
48
34

1
11
48
137
153
128
86
78
75
73
44
21

Region of residencea
Northeast
Midwest
South
West

293
153
448
295

346
180
477
290

358
202
540
307

317
182
579
304

273
158
501
247

230
157
446
201

244
169
471
202

239
174
465
227

234
176
523
221

150
128
396
181

1,189

1,292

1,407

1,381

1,178

1,034

1,086

1,105

1,154

855

Total

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanic/Latino persons can be of any race.


HIV Surveillance Report

80

Vol. 33

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
3
5
0
1
2
2
0
3
0
0

0
0
0
6
3
0
1
0
3
1
1
1

0
1
0
1
3
0
0
1
2
0
0
0

0
0
2
1
2
4
3
1
1
0
0
0

0
0
1
0
3
1
0
0
2
0
0
0

0
0
1
3
1
2
1
2
4
0
0
0

0
0
1
2
1
3
2
2
2
0
0
1

0
0
0
3
2
3
1
2
2
1
1
0

0
0
2
1
2
7
3
1
2
0
0
1

0
0
0
6
3
4
3
1
1
0
0
1

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

0
0
3
14
0

1
2
2
11
0

0
2
1
5
0

0
4
2
8
0

0
3
3
2
0

1
1
1
12
0

1
1
4
9
0

0
2
5
6
0

0
5
7
8
0

0
10
2
8
0

Total

17

16

9

15

8

15

15

14

19

20

Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
2
1
3
1
3
1
1
0
1

0
0
1
1
0
2
3
2
1
1
0
0

0
0
1
0
2
0
2
2
1
0
1
1

0
0
0
2
0
3
1
3
3
1
0
1

0
0
0
1
2
1
2
3
2
1
2
1

0
0
1
1
1
1
1
2
0
0
0
0

0
0
0
2
0
1
0
0
1
0
1
0

0
0
0
0
2
1
0
0
0
0
0
0

0
0
0
0
2
1
1
1
0
0
0
0

0
0
0
0
2
1
0
1
1
0
0
1

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

4
2
2
6
0

4
0
2
5
0

5
1
4
1
0

4
3
3
6
0

3
3
1
8
0

3
0
2
3
0

1
1
2
4
0

1
0
2
2
0

1
0
1
4
0

1
0
2
3
0

14

10

11

16

14

8

7

5

6

6

Total


HIV Surveillance Report

81

Vol. 33

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
4
20
29
33
44
44
41
57
43
36
29

0
6
16
35
49
41
31
46
47
53
35
31

0
4
21
46
51
59
35
43
50
52
36
35

0
4
22
51
57
45
44
31
40
40
42
33

0
3
20
35
41
37
26
29
30
39
23
30

1
7
22
39
42
36
29
33
53
42
28
18

0
8
30
38
40
39
40
41
40
31
25
19

0
7
24
29
40
35
30
36
41
39
26
16

1
7
29
44
43
44
34
40
30
31
29
21

0
7
20
34
36
30
18
25
24
31
16
10

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

103
54
183
39
1

123
61
173
32
0

122
59
204
45
1

117
51
199
40
1

90
42
155
26
0

76
54
182
39
0

92
60
164
35
0

80
46
162
37
0

94
51
164
42
0

50
46
125
29
0

Total

380

389

431

409

313

350

351

324

351

250

Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
2
20
38
49
48
27
39
42
32
16
16

0
4
20
42
63
45
44
41
51
28
16
17

0
3
24
36
65
47
40
38
44
26
16
12

0
1
17
45
44
53
42
27
29
26
16
17

0
2
15
37
39
41
47
28
27
17
14
15

0
4
14
32
26
16
19
18
19
13
9
7

0
4
19
18
29
26
21
19
15
8
8
4

0
2
22
20
28
26
15
21
14
9
9
6

0
6
19
21
23
36
13
17
18
10
6
5

1
2
8
18
26
23
17
9
12
9
9
3

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

97
14
85
98
35

115
16
93
114
34

109
14
95
110
23

85
10
88
111
23

74
13
76
98
19

52
11
54
48
12

47
11
53
52
9

55
9
49
58
2

51
12
55
52
6

38
6
34
56
2

329

371

352

318

280

177

172

172

175

136

Total


HIV Surveillance Report

82

Vol. 33

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
1
0
0
0

0
0
0
0
0
0
0
1
0
0
0
0

0
0
0
1
0
0
0
0
0
0
0
0

0
0
0
1
0
1
0
0
0
0
0
0

0
0
0
0
0
0
0
0
2
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
1
0
0
1
0

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

0
0
0
0
0

0
0
0
1
0

0
0
0
1
0

0
1
0
0
0

0
1
0
1
0

0
0
0
2
0

0
0
0
0
0

0
0
0
0
0

0
0
0
0
0

0
0
1
2
0

Total

0

1

2

1

3

2

0

0

0

2

White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
3
30
77
61
65
44
49
53
25
17
17

0
3
35
86
89
74
49
57
36
36
18
17

0
4
36
99
107
113
63
51
50
35
22
10

0
0
44
103
112
102
71
69
43
43
17
9

0
4
21
81
113
116
61
52
32
36
13
8

0
5
44
93
70
59
45
45
38
20
16
10

0
9
51
91
99
79
52
40
41
34
9
6

0
8
46
87
99
96
71
46
41
27
10
6

0
6
44
89
106
97
75
55
38
35
12
5

0
2
17
74
84
69
46
38
37
32
16
7

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

82
80
159
120
0

93
92
196
119
0

115
118
223
134
0

96
105
276
133
0

99
89
243
108
0

87
85
187
85
0

90
92
234
95
0

92
109
224
112
0

78
98
279
108
0

59
63
221
80
0

Total

440

501

589

611

539

445

511

537

563

422


HIV Surveillance Report

83

Vol. 33

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Multiracial
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
1
3
10
1
7
6
2
8
5
3
1

0
0
2
8
6
5
4
5
3
2
1
2

0
0
5
5
4
4
4
3
7
4
1
1

0
0
4
3
12
2
2
3
5
2
1
2

0
0
5
4
10
10
2
3
3
2
2
0

0
1
4
6
3
9
5
7
5
6
1
1

0
2
6
8
4
6
5
3
3
3
0
0

0
3
9
12
6
6
5
5
5
1
3
1

0
2
2
9
4
8
8
3
5
2
1
1

0
0
2
4
2
3
3
3
1
1
2
0

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

8
3
16
18
0

10
9
11
8
0

6
8
13
11
0

15
7
10
6
0

7
7
22
5
0

12
6
20
11
0

13
4
15
7
0

10
9
24
12
0

10
11
19
6
0

2
4
11
4
0

Total

44

37

38

37

42

49

39

55

46

21

Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
11
75
160
145
168
124
136
161
109
71
64

0
13
73
178
210
167
131
152
142
120
71
68

0
13
87
188
232
224
145
137
154
118
76
59

0
5
89
208
228
208
163
134
121
113
76
61

0
9
62
160
207
208
138
115
95
95
55
54

1
17
87
175
144
124
100
105
122
81
54
36

1
24
107
159
174
154
120
105
102
76
43
31

0
19
101
150
177
166
123
111
103
77
49
30

1
21
96
164
179
193
133
117
94
79
48
34

1
11
48
137
153
128
87
78
76
73
44
21

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

293
153
448
295
36

346
180
477
290
34

358
202
540
307
24

317
182
579
304
25

273
158
501
247
19

230
157
446
201
12

244
169
471
202
9

239
174
465
227
2

234
176
523
221
6

150
128
396
181
2

1,225

1,326

1,431

1,406

1,198

1,046

1,095

1,106

1,160

857

Total

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanic/Latino persons can be of any race.


HIV Surveillance Report

84

Vol. 33

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
0
1
1
1
1
1
0
0
1

0
0
0
0
2
3
0
1
0
0
0
0

0
1
1
1
1
1
0
0
0
1
0
0

0
0
2
0
1
0
2
0
1
1
0
0

0
0
0
0
0
0
0
0
2
0
1
0

0
0
0
4
3
6
6
3
1
2
2
1

0
0
3
5
2
4
3
5
5
2
2
0

0
1
1
1
1
2
3
3
2
3
0
0

0
1
2
2
3
6
6
3
2
1
1
1

0
0
0
1
6
6
5
2
1
2
1
1

Region of residencea
Northeast
Midwest
South
West

0
1
2
5

0
0
3
4

1
1
2
3

0
2
6
1

0
0
2
1

1
1
9
15

0
3
5
22

0
1
8
7

0
9
4
12

1
4
7
11

Total

7

7

8

9

3

26

30

15

26

23

Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
3
2
11
13
4
8
4
3
4
6

0
0
2
4
4
10
3
6
3
3
4
3

0
0
5
1
8
8
11
6
6
2
5
6

0
1
1
2
3
2
5
4
6
5
4
3

0
1
1
3
2
3
2
4
4
4
2
5

1
0
9
20
33
24
14
11
10
8
4
5

0
2
5
18
8
24
11
12
12
7
6
5

0
0
6
15
16
11
12
8
9
9
6
7

0
1
6
8
16
16
6
14
4
8
7
4

0
1
2
11
12
15
4
8
9
6
7
4

Region of residencea
Northeast
Midwest
South
West

8
9
24
17

9
7
12
15

13
2
24
19

14
1
12
7

3
5
12
10

32
13
43
49

16
18
30
45

27
5
28
38

13
11
29
37

12
8
24
34

Total

58

42

58

35

30

137

109

97

90

79


HIV Surveillance Report

85

Vol. 33

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
39
161
248
230
234
224
221
229
182
121
122

0
23
125
197
207
221
185
185
201
190
127
112

0
32
115
226
232
210
163
171
201
168
102
106

0
26
119
178
189
181
162
196
175
154
131
123

0
17
93
153
158
145
140
126
110
122
90
87

5
137
396
552
525
540
419
423
378
304
187
123

3
140
404
516
535
476
409
398
344
296
198
167

2
131
394
485
467
460
424
363
326
300
175
128

4
94
379
450
466
433
379
326
323
274
191
159

2
79
277
377
398
326
286
277
223
200
139
91

Region of residencea
Northeast
Midwest
South
West

349
192
1,379
93

315
190
1,205
64

256
199
1,196
75

244
186
1,138
66

184
137
867
51

652
488
2,556
292

638
504
2,507
236

554
484
2,343
275

521
476
2,222
259

403
365
1,703
203

Total

2,012

1,774

1,725

1,634

1,240

3,988

3,885

3,656

3,478

2,674

Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
4
50
72
89
88
83
77
56
38
29
24

0
8
28
68
75
77
79
57
53
38
31
29

0
7
29
60
88
87
72
77
62
48
20
31

0
7
27
76
67
69
72
54
55
38
33
21

0
3
31
48
44
61
44
41
53
26
23
17

1
31
100
137
159
126
122
102
99
68
40
40

1
39
118
139
134
125
100
120
83
70
40
37

4
33
95
132
128
146
106
107
111
71
44
46

3
34
111
145
144
114
112
96
94
63
50
38

0
30
96
99
98
104
87
71
72
55
37
25

Region of residencea
Northeast
Midwest
South
West

161
43
306
101

140
28
279
96

138
35
321
87

108
33
296
83

78
17
231
64

303
58
437
226

261
61
458
227

244
56
484
238

219
69
470
247

196
47
359
172

Total

611

543

581

520

390

1,024

1,007

1,022

1,004

773


HIV Surveillance Report

86

Vol. 33

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
0
0
1
0
1
0
0
0
0

0
0
0
1
1
0
0
1
0
0
0
1

0
0
0
0
1
0
0
0
0
0
0
0

0
0
0
1
0
0
0
0
0
0
0
0

0
0
0
0
1
1
0
0
0
0
0
0

0
0
1
0
1
1
0
0
1
0
0
0

0
0
0
2
3
2
0
0
0
0
0
0

0
1
0
0
2
0
0
0
1
1
0
0

0
1
1
2
1
2
1
0
1
0
0
0

0
1
2
2
1
1
1
1
1
2
1
0

Region of residencea
Northeast
Midwest
South
West

0
1
1
0

1
0
1
2

0
0
1
0

0
0
0
1

0
0
0
2

0
0
0
4

1
0
2
4

1
0
1
3

0
4
1
4

1
0
4
7

Total

2

4

2

1

2

4

7

5

9

12

White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
4
31
37
45
47
52
47
74
49
35
42

0
5
16
46
50
47
51
52
64
47
37
33

0
4
20
48
61
51
42
54
44
50
38
32

0
3
19
50
41
43
47
54
50
47
27
27

0
1
16
30
40
37
32
40
40
39
26
26

0
30
103
132
140
108
94
102
101
92
53
20

1
28
95
109
126
109
85
104
98
93
39
24

1
31
93
123
126
117
103
105
97
73
38
26

0
31
91
130
125
121
97
103
95
82
46
23

0
20
96
113
120
107
88
104
72
73
31
34

Region of residencea
Northeast
Midwest
South
West

93
48
255
64

81
51
237
77

81
57
242
63

66
59
215
67

62
56
163
44

121
161
502
190

116
150
489
154

105
166
497
164

112
174
487
172

95
147
435
181

Total

461

446

443

407

325

974

910

933

944

858


HIV Surveillance Report

87

Vol. 33

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Multiracial
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
8
13
7
20
11
13
10
8
3
5

0
1
4
11
14
10
12
9
6
7
6
5

0
1
3
9
15
6
4
7
9
1
4
4

0
1
3
8
8
5
9
7
5
8
3
7

0
0
3
0
4
2
5
2
2
2
1
2

0
12
39
26
28
33
17
27
13
18
6
9

0
6
26
22
26
27
14
24
15
15
4
5

0
13
19
35
34
23
14
26
10
9
10
8

0
10
22
35
22
19
21
20
15
5
7
6

0
7
20
23
15
10
10
9
4
8
9
1

Region of residencea
Northeast
Midwest
South
West

28
12
52
6

23
11
46
7

22
6
32
2

19
13
27
4

4
3
14
3

45
45
117
20

42
27
89
27

42
27
106
26

39
31
91
21

22
20
65
10

Total

99

86

62

64

24

227

184

200

181

116

Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
48
254
371
384
404
375
368
374
281
191
200

0
37
175
327
352
369
330
311
327
285
206
183

1
44
173
346
406
364
292
315
322
270
168
177

0
39
171
315
309
301
296
315
292
253
198
181

0
22
143
234
249
249
223
212
209
193
142
136

7
210
647
869
888
838
671
668
601
492
292
198

6
214
651
811
833
767
622
663
556
483
289
237

7
210
608
790
774
759
662
611
555
466
273
214

8
173
612
772
777
710
622
562
533
431
301
229

2
136
492
626
651
570
481
472
382
346
224
155

Region of residencea
Northeast
Midwest
South
West

639
306
2,019
286

568
286
1,782
265

511
300
1,818
248

451
294
1,696
229

331
218
1,289
175

1,155
765
3,664
796

1,074
763
3,580
715

972
739
3,467
751

903
774
3,303
751

730
591
2,596
619

Total

3,251

2,902

2,877

2,669

2,012

6,380

6,131

5,928

5,730

4,536

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as heterosexual contact include transgender and additional gender identity persons.
Includes persons who have ever had sexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs).
Excludes men who have ever had sexual contact with both men and women.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanic/Latino persons can be of any race.


HIV Surveillance Report

88

Vol. 33

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
0
1
1
1
1
1
0
0
1

0
0
0
0
2
3
0
1
0
0
0
0

0
1
1
1
1
1
0
0
0
1
0
0

0
0
2
0
1
0
2
0
1
1
0
0

0
0
0
0
0
0
0
0
2
0
1
0

0
0
0
4
3
6
6
3
1
2
2
1

0
0
3
5
2
4
3
5
5
2
2
0

0
1
1
1
1
2
3
3
2
3
0
0

0
1
2
2
3
6
6
3
2
1
1
1

0
0
0
1
6
6
5
2
1
2
1
1

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

0
1
2
5
0

0
0
3
4
0

1
1
2
3
0

0
2
6
1
0

0
0
2
1
0

1
1
9
15
0

0
3
5
22
0

0
1
8
7
0

0
9
4
12
0

1
4
7
11
0

Total

7

7

8

9

3

26

30

15

26

23

Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
3
2
11
13
4
8
4
3
4
6

0
0
2
4
4
10
3
6
3
3
4
3

0
0
5
1
8
8
11
6
6
2
5
6

0
1
1
2
3
2
5
4
6
5
4
3

0
1
1
3
2
3
2
4
4
4
2
5

1
0
9
20
33
24
14
11
10
8
4
5

0
2
5
18
8
24
11
12
12
7
6
5

0
0
6
15
16
11
12
8
9
9
6
7

0
1
6
8
16
16
6
14
4
8
7
4

0
1
2
11
12
15
4
8
9
6
7
4

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

8
9
24
17
0

9
7
12
15
0

13
2
24
19
0

14
1
12
7
0

3
5
12
10
0

32
13
43
49
0

16
18
30
45
0

27
5
28
38
0

13
11
29
37
0

12
8
24
34
0

Total

58

42

58

35

30

137

109

97

90

79


HIV Surveillance Report

89

Vol. 33

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
39
161
248
230
234
224
222
229
182
122
122

0
23
125
197
207
221
185
185
201
190
127
112

0
32
115
227
232
210
163
172
201
169
102
106

0
26
119
178
189
181
162
196
175
154
131
124

0
17
93
153
159
145
140
126
110
122
90
87

5
137
396
552
525
540
419
423
378
304
187
123

3
140
404
516
536
476
409
399
344
296
198
167

2
131
394
485
467
460
424
363
326
300
175
128

4
94
379
450
466
433
379
326
323
274
191
159

2
79
277
377
398
326
286
277
223
200
139
91

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

349
192
1,379
93
2

315
190
1,205
64
0

256
199
1,196
75
3

244
186
1,138
66
2

184
137
867
51
1

652
488
2,556
292
0

638
504
2,507
236
2

554
484
2,343
275
0

521
476
2,222
259
1

403
365
1,703
203
0

Total

2,014

1,774

1,728

1,636

1,241

3,988

3,887

3,656

3,479

2,674

Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
4
51
76
95
97
98
95
67
49
39
41

0
9
36
72
83
88
89
61
59
47
41
40

0
8
31
68
97
92
75
81
77
51
24
40

0
7
30
79
73
73
78
65
59
47
40
31

0
3
33
52
45
65
47
43
57
34
30
20

1
33
105
142
167
141
136
116
106
82
46
42

1
42
123
150
140
135
107
131
93
81
44
41

4
35
104
139
133
151
114
121
122
79
49
52

3
34
115
151
153
118
125
104
99
75
55
46

0
30
100
102
99
107
92
76
77
62
40
28

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

161
43
306
101
100

140
28
279
96
83

138
35
321
87
64

108
33
296
83
62

78
17
231
64
38

303
58
437
226
93

261
61
458
227
81

244
56
484
238
80

219
69
470
247
73

196
47
359
172
39

Total

711

627

644

581

427

1,117

1,088

1,101

1,077

812


HIV Surveillance Report

90

Vol. 33

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
0
0
1
0
1
0
0
0
0

0
0
1
1
1
0
0
1
0
0
0
1

0
0
0
0
1
0
0
0
0
1
0
0

0
0
0
1
0
0
0
0
0
0
0
0

0
0
0
0
1
1
0
0
0
0
0
0

0
0
1
0
1
1
0
0
1
0
0
0

0
0
0
2
3
2
0
0
0
0
0
0

0
1
0
0
2
0
0
0
1
1
0
0

0
1
2
2
1
2
1
0
1
0
0
0

0
1
2
2
1
1
1
1
1
2
1
0

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

0
1
1
0
0

1
0
1
2
1

0
0
1
0
1

0
0
0
1
0

0
0
0
2
0

0
0
0
4
0

1
0
2
4
0

1
0
1
3
0

0
4
1
4
1

1
0
4
7
0

Total

3

5

2

1

2

4

7

5

10

12

White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
4
31
37
45
47
52
47
74
49
35
42

0
5
16
46
50
47
51
52
64
47
37
33

0
4
20
48
61
51
42
54
44
50
38
32

0
3
19
50
41
43
47
55
50
47
27
27

0
1
16
30
40
37
32
40
40
39
26
26

0
30
103
132
140
108
94
102
101
92
53
20

1
28
95
109
126
109
85
104
99
93
39
24

1
31
93
123
126
117
103
105
97
73
38
26

0
31
91
130
125
121
97
103
95
82
46
23

0
20
96
113
120
107
88
104
72
73
31
34

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

93
48
255
64
0

81
51
237
77
0

81
57
242
63
0

66
59
215
67
1

62
56
163
44
0

121
161
502
190
0

116
150
489
154
2

105
166
497
164
0

112
174
487
172
0

95
147
435
181
0

Total

461

446

443

408

325

974

911

933

944

858


HIV Surveillance Report

91

Vol. 33

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and
selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
Male sex at birth

Female sex at birth

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

2016

2017

2018

2019

2020
(COVID-19
pandemic)

No.

No.

No.

No.

No.

Multiracial
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
8
13
7
20
11
13
10
8
3
5

0
1
4
11
14
11
12
9
6
7
6
5

0
1
3
9
15
7
4
7
9
1
4
4

0
1
3
8
8
5
9
7
5
8
3
7

0
0
3
0
4
2
5
2
2
2
1
2

0
12
39
26
28
33
17
27
13
18
6
9

0
6
26
22
26
27
14
24
15
15
4
5

0
13
19
35
34
23
14
26
10
9
10
8

0
10
22
35
22
19
21
20
15
5
7
6

0
7
20
23
15
10
10
9
4
8
9
1

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

28
12
52
6
0

23
11
46
7
0

22
6
32
2
2

19
13
27
4
0

4
3
14
3
0

45
45
117
20
0

42
27
89
27
0

42
27
106
26
0

39
31
91
21
0

22
20
65
10
0

Total

99

86

64

64

24

227

184

200

181

116

Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
48
255
375
390
413
390
387
385
292
203
217

0
38
184
331
361
380
340
315
333
294
216
194

1
45
175
355
415
370
295
320
337
275
173
187

0
39
174
318
315
305
303
327
296
262
205
192

0
22
145
238
251
252
226
214
214
201
149
139

7
212
652
874
896
853
685
682
608
506
298
200

6
218
656
822
840
777
629
675
567
494
293
241

7
212
617
797
779
764
670
625
566
474
277
220

8
173
617
778
786
714
635
570
539
443
306
237

2
136
496
629
652
573
486
477
387
353
227
158

Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas

639
306
2,019
286
102

568
286
1,782
265
85

511
300
1,818
248
70

451
294
1,696
229
65

331
218
1,289
175
39

1,155
765
3,664
796
93

1,074
763
3,580
715
85

972
739
3,467
751
80

903
774
3,303
751
75

730
591
2,596
619
39

Total

3,353

2,987

2,947

2,734

2,051

6,473

6,216

6,008

5,805

4,575

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local
jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as heterosexual contact include transgender and additional gender identity persons.
Includes persons who have ever had sexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs).
Excludes men who have ever had sexual contact with both men and women.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanic/Latino persons can be of any race.


HIV Surveillance Report

92

Vol. 33

Table 8a. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, sex assigned at birth, and selected characteristics,
2020 (COVID-19 pandemic)—United States
13–14 years
No.
Ratea
Sex at birth
Male
Female
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categoryc
Male sex at birthd
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contacte
Perinatalf
Otherg
Subtotal
Female sex at birthd
Injection drug use
Heterosexual contacte
Perinatalf
Otherg
Subtotal
Region of residenceh
Northeast
Midwest
South
West
Total

15–17 years
No.
Ratea

18–19 years
No.
Ratea

20–22 years
No.
Ratea

23–24 years
No.
Ratea

No.

Total
Ratea

6
6

0.1
0.1

240
49

3.8
0.8

851
108

19.8
2.6

2,436
289

36.9
4.6

1,828
269

41.3
6.3

5,361
721

20.6
2.9

0
0
8
4
0
0
0

0.0
0.0
0.7
0.2
0.0
0.0
0.0

2
1
170
71
0
34
11

1.9
0.2
10.1
2.3
0.0
0.5
2.3

3
18
565
223
4
115
31

4.2
4.0
48.4
11.1
24.3
2.6
10.5

14
37
1,506
678
4
400
86

12.8
5.2
82.7
22.8
15.7
5.8
20.1

14
31
1,038
553
4
392
65

19.5
5.9
85.3
28.6
22.9
8.4
24.5

33
87
3,287
1,529
12
941
193

7.7
3.1
46.6
12.6
11.8
3.5
10.6

5
0
0

—
—
—

227
1
4

—
—
—

811
9
14

—
—
—

2,268
30
61

—
—
—

1,653
31
73

—
—
—

4,964
71
151

—
—
—

0
1
0
6

—
—
—
0.1

7
1
0
240

—
—
—
3.8

15
2
0
851

—
—
—
19.8

74
2
0
2,436

—
—
—
36.9

69
1
1
1,828

—
—
—
41.3

165
8
1
5,361

—
—
—
20.6

1
2
3
0
6

—
—
—
—
0.1

2
41
6
0
49

—
—
—
—
0.8

8
96
4
0
108

—
—
—
—
2.6

25
253
12
0
289

—
—
—
—
4.6

23
239
6
0
269

—
—
—
—
6.3

59
631
31
0
721

—
—
—
—
2.9

2
3
5
2
12

0.2
0.2
0.2
0.1
0.1

41
43
163
42
289

2.0
1.6
3.3
1.4
2.3

111
121
590
137
959

7.7
6.8
18.2
6.9
11.4

297
420
1,550
458
2,725

13.8
15.2
31.2
15.0
21.1

281
305
1,096
415
2,097

19.9
17.0
33.1
19.3
24.2

732
892
3,404
1,054
6,082

8.8
8.3
17.3
8.6
11.9

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local
jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Hispanic/Latino persons can be of any race.
c Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data
have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
d Data include transgender and additional gender identity persons.
e Sexual contact with a person known to have, or with a risk factor for, HIV infection.
f Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
h Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

93

Vol. 33

Table 8b. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, sex assigned at birth, and selected characteristics,
2020 (COVID-19 pandemic)—United States and 6 dependent areas
13–14 years
No.
Sex at birth
Male
Female
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinoa
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categoryb
Male sex at birthc
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactd
Perinatale
Otherf
Subtotal
Female sex at birthc
Injection drug use
Heterosexual contacte
Perinatale
Otherf
Subtotal
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
Total

15–17 years
No.

18–19 years
No.

20–22 years
No.

23–24 years
No.

Total
No.

6
6

242
49

857
108

2,448
291

1,857
271

5,410
725

0
0
8
4
0
0
0

2
1
170
73
0
34
11

3
18
567
227
4
115
31

14
37
1,506
692
4
400
86

14
31
1,038
584
4
392
65

33
87
3,289
1,580
12
941
193

5
0
0

229
1
4

817
9
14

2,279
30
62

1,679
32
73

5,009
72
152

0
1
0
6

7
1
0
242

15
2
0
857

74
2
0
2,448

71
1
1
1,857

167
8
1
5,410

1
2
3
0
6

2
41
6
0
49

8
96
4
0
108

25
255
12
0
291

23
241
6
0
271

59
635
31
0
725

2
3
5
2
0
12

41
43
163
42
2
291

111
121
590
137
6
965

297
420
1,550
458
14
2,739

281
305
1,096
415
31
2,128

732
892
3,404
1,054
53
6,135

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local
jurisdictions. Numbers less than 12 should be interpreted with caution.
a Hispanic/Latino persons can be of any race.
b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data
have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
c Data include transgender and additional gender identity persons.
d Sexual contact with a person known to have, or with a risk factor for, HIV infection.
e Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
g Data are based on residence at time of diagnosis of HIV infection.


HIV Surveillance Report

94

Vol. 33

Table 9a. Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–2020—United States

Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/other Pacific Islander
White
Multiracial
Total

2016
No.
Ratea

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

2020 (COVID-19
pandemic)
No.
Ratea

0
8
76
18
0
20
8

0.0
0.3
1.1
0.1
0.0
0.1
0.3

0
7
56
16
1
15
10

0.0
0.3
0.8
0.1
0.9
0.1
0.4

0
6
50
11
0
15
5

0.0
0.2
0.7
0.1
0.0
0.1
0.2

1
6
32
7
0
7
4

0.2
0.2
0.4
0.1
0.0
0.0
0.2

1
2
32
9
1
12
0

0.2
0.1
0.4
0.1
0.9
0.0
0.0

130

0.2

105

0.2

87

0.2

57

0.1

57

0.1

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local
jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
Rates are per 100,000 population.
b
Hispanic/Latino persons can be of any race.

Table 9b. Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–
2020—United States and 6 dependent areas

Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinoa
Native Hawaiian/other Pacific Islander
White
Multiracial
Total

2016
No.

2017
No.

2018
No.

2019
No.

2020
(COVID-19
pandemic)
No.

0
8
76
18
0
20
8

0
7
56
16
1
15
10

0
6
50
11
0
15
5

1
6
32
7
0
7
4

1
2
32
9
1
12
0

130

105

87

57

57

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and
case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
a Hispanic/Latino persons can be of any race.


HIV Surveillance Report

95

Vol. 33


HIV Surveillance Report

Table 10a. Diagnoses of HIV infection among Hispanic/Latino persons aged ≥ 13 years, by place of birth and transmission category, 2020 (COVID-19 pandemic)—United States and
6 dependent areas
Caribbeana
United States
Transmission categoryd

South Americab

Central Americac

Mexico

Puerto Rico

Cuba

Other

Total

96

%

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

No.e

Male sex at birthf
Male-to-male sexual contact
2,140
Injection drug use
107
Male-to-male sexual contact and injection drug use
112
Heterosexual contactg
104
Perinatalh
0
Otheri
1
Subtotal
2,465

86.8
4.4
4.6
4.2
0.0
0.0
100

459
3
7
29
0
0
498

92.2
0.7
1.4
5.8
0.0
0.0
100

325
9
9
47
0
0
391

83.2
2.3
2.3
12.1
0.0
0.0
100

574
13
15
57
0
0
660

87.0
2.0
2.3
8.7
0.0
0.0
100

268
32
9
50
0
0
359

74.6
8.9
2.6
13.9
0.0
0.0
100

199
3
1
28
0
0
230

86.5
1.3
0.3
12.0
0.0
0.0
100

80
4
2
23
0
0
109

73.8
3.4
1.6
21.2
0.0
0.0
100

6,359
280
261
427
0
3
7,331

86.7
3.8
3.6
5.8
0.0
0.0
100

Female sex at birthf
Injection drug use
Heterosexual contactg
Perinatalh
Otheri
Subtotal

19.6
80.2
0.2
0.0
100

1
35
0
0
37

3.5
95.7
0.0
0.0
100

3
71
0
0
74

3.4
96.2
0.0
0.0
100

4
48
2
0
54

8.1
88.7
3.0
0.0
100

8
56
0
0
64

11.9
88.0
0.0
0.0
100

0
18
0
0
18

1.1
97.8
0.0
0.0
100

3
44
1
0
48

6.0
92.3
1.7
0.0
100

136
812
5
1
954

14.3
85.1
0.5
0.1
100

Total

No.

63
257
1
0
320
2,785

100

535

100

465

100

714

100

423

100

248

100

157

100

8,285

%

100

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and percentages
based on these numbers, should be interpreted with caution.
Hispanic/Latino persons can be of any race.
a Countries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint
Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S).Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission;
classification is determined based on the person’s sex assigned at birth. Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
b Countries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
c Countries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for
missing transmission category; therefore, values may not sum to column subtotals and total.
e Total includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
f Data include transgender and additional gender identity persons.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Vol. 33


HIV Surveillance Report

Table 10b. Diagnoses of HIV infection among Hispanic/Latino transgender and additional gender identity persons aged ≥ 13 years, by place of birth and exposure category,
2020 (COVID 19 pandemic)—United States and 6 dependent areas
Caribbeana
United States

South Americab

Central Americac

Mexico

Puerto Rico

Cuba

Other

97

Exposure categoryd

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

No.

Transgender womanf
Sexual contactg
Injection drug use
Sexual contactg and injection drug use
Otherh
Subtotal

64
0
7
2
73

87.7
0.0
9.6
2.7
100

7
0
0
0
7

100
0.0
0.0
0.0
100

23
0
0
1
24

95.8
0.0
0.0
4.2
100

25
0
2
1
28

89.3
0.0
7.1
3.6
100

6
0
0
1
7

85.7
0.0
0.0
14.3
100

5
0
0
0
5

100
0.0
0.0
0.0
100

Transgender manf
Sexual contactg
Injection drug use
Sexual contactg and injection drug use
Otherh
Subtotal

5
0
4
0
9

55.6
0.0
44.4
0.0
100

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

Additional gender identityi
Sexual contactg
Injection drug use
Sexual contactg and injection drug use
Otherh
Subtotal

3
0
0
0
3

100
0.0
0.0
0.0
100

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

100

7

Total

85

100

24

100

28

100

7

100

5

Total
%

No.e

%

5
0
0
0
5

100
0.0
0.0
0.0
100

179
1
13
11
204

87.7
0.5
6.4
5.4
100

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

6
0
4
0
10

60.0
0.0
40.0
0.0
100

0.0
0.0
0.0
0.0
0.0

0
0
0
0
0

0.0
0.0
0.0
0.0
0.0

3
0
0
1
4

75.0
0.0
0.0
25.0
100

100

5

100

218

100

Vol. 33

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and percentages
based on these numbers, should be interpreted with caution.
Hispanic/Latino persons can be of any race.
a Countries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint
Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S).Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission;
classification is determined based on the person’s sex assigned at birth. Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
b Countries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
c Countries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
d Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure
categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on
exposure categories.
e
Total includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
f
“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
g
For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
h
Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i
Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”


HIV Surveillance Report

Table 11a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States
2016
No.

98

Gender
Male
Female
Transgender woman/girlb
Transgender man/boyb
Additional gender identityc
Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asiand
Black/African American
Hispanic/Latinoe
Native Hawaiian/other Pacific Islander
White
Multiracial

2017
Ratea

No.

2018
Ratea

No.

2019
Ratea

No.

2020 (COVID-19 pandemic)
Ratea

No.

Ratea

12,224
4,025
120
2
1

—
—
—
—
—

12,244
3,995
106
5
2

—
—
—
—
—

12,103
3,984
117
5
1

—
—
—
—
—

12,252
3,830
144
5
1

—
—
—
—
—

13,530
4,437
188
9
0

—
—
—
—
—

1
1
10
155
444
656
838
1,130
1,812
2,838
2,985
2,413
3,089

0.0
0.0
0.0
0.7
1.9
3.0
4.0
5.7
8.7
13.0
13.6
12.4
6.3

2
0
7
144
445
601
864
970
1,743
2,726
2,971
2,489
3,390

0.0
0.0
0.0
0.7
1.9
2.7
4.1
5.0
8.3
12.8
13.5
12.5
6.7

1
0
9
121
419
614
813
958
1,599
2,583
2,930
2,526
3,637

0.0
0.0
0.0
0.6
1.8
2.8
3.8
4.9
7.7
12.4
13.4
12.4
6.9

2
1
10
122
433
662
855
932
1,394
2,231
2,909
2,664
4,017

0.0
0.0
0.0
0.6
1.8
2.9
3.9
4.7
6.8
10.9
13.3
13.0
7.4

4
0
14
131
428
754
889
1,078
1,410
2,225
3,166
3,029
5,036

0.0
0.0
0.1
0.6
1.8
3.3
4.1
5.3
7.1
10.9
14.7
14.6
9.0

47
100
7,233
2,632
14
5,310
1,033

2.0
0.6
18.0
4.6
2.5
2.7
15.2

47
88
7,199
2,694
9
5,239
1,074

2.0
0.5
17.7
4.6
1.5
2.6
15.3

48
84
6,984
2,840
13
5,151
1,090

2.0
0.4
17.1
4.8
2.2
2.6
15.2

58
101
6,993
2,741
14
5,234
1,087

2.4
0.5
17.0
4.5
2.3
2.7
14.7

78
97
7,930
3,245
10
5,514
1,290

3.2
0.5
19.1
5.3
1.6
2.8
17.1

Vol. 33


HIV Surveillance Report

Table 11a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States (cont)
2016
No.

2017
Rate

a

2018
Ratea

No.

2019
Ratea

No.

2020 (COVID-19 pandemic)
Ratea

No.

No.

Ratea

f

Transmission category
Male sex at birth (≥ 13 yrs at death)g
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Female sex at birth (≥ 13 yrs at death)g
Injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Child (< 13 yrs at death)
Perinatal
Otherj
Subtotal

99

Region of residencek
Northeast
Midwest
South
West
Totall

6,889
2,270
1,391
1,690
40
63
12,344

—
—
—
—
—
—
9.3

6,992
2,170
1,372
1,709
41
67
12,351

—
—
—
—
—
—
9.3

6,893
2,173
1,444
1,602
52
57
12,220

—
—
—
—
—
—
9.1

7,177
2,071
1,366
1,685
42
55
12,395

—
—
—
—
—
—
9.2

7,801
2,327
1,595
1,873
56
64
13,716

—
—
—
—
—
—
10.1

1,390
2,562
49
26
4,027

—
—
—
—
2.9

1,381
2,547
43
28
3,999

—
—
—
—
2.9

1,323
2,603
36
27
3,989

—
—
—
—
2.8

1,304
2,469
37
26
3,835

—
—
—
—
2.7

1,425
2,939
44
37
4,444

—
—
—
—
3.1

1
0
1

—
—
0.0

2
0
2

—
—
0.0

1
0
1

—
—
0.0

1
1
2

—
—
0.0

3
1
4

—
—
0.0

3,709
1,858
8,049
2,756

6.6
2.7
6.6
3.6

3,699
1,916
7,997
2,740

6.6
2.8
6.5
3.5

3,529
2,004
7,870
2,807

6.3
2.9
6.3
3.6

3,632
1,939
7,894
2,767

6.5
2.8
6.3
3.5

4,426
2,230
8,608
2,900

7.9
3.3
6.8
3.7

16,372

5.1

16,352

5.0

16,210

5.0

16,232

4.9

18,164

5.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention through December 2021. Data for 2020 should
be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers,
should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for
missing transmission category; therefore, values may not sum to column subtotals and total.
g Data presented include transgender and additional gender identity persons.
h Sexual contact with a person known to have, or with a risk factor for, HIV infection.
i Include individuals aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
l Includes persons whose race/ethnicity is unknown.

Vol. 33


HIV Surveillance Report

Table 11b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States and 6 dependent areas
2016
No.

100

Gender
Male
Female
Transgender woman/girlb
Transgender man/boyb
Additional gender identityc
Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asiand
Black/African American
Hispanic/Latinoe
Native Hawaiian/other Pacific Islander
White
Multiracial

2017
a

Rate

No.

2018
a

Rate

No.

2019
Rate

a

No.

2020 (COVID-19 pandemic)
a

Rate

No.

Ratea

12,549
4,121
120
2
1

—
—
—
—
—

12,545
4,103
108
5
2

—
—
—
—
—

12,395
4,060
118
5
1

—
—
—
—
—

12,526
3,913
146
5
1

—
—
—
—
—

13,776
4,519
189
9
0

—
—
—
—
—

1
1
11
159
451
664
870
1,161
1,864
2,910
3,060
2,468
3,173

0.0
0.0
0.1
0.7
1.9
3.0
4.1
5.8
8.8
13.2
13.8
12.5
6.4

2
0
7
146
451
616
879
1,005
1,795
2,803
3,053
2,531
3,475

0.0
0.0
0.0
0.7
1.9
2.8
4.1
5.1
8.5
13.0
13.8
12.6
6.8

1
0
9
125
427
626
832
988
1,637
2,634
3,001
2,575
3,724

0.0
0.0
0.0
0.6
1.8
2.8
3.8
5.0
7.8
12.5
13.5
12.5
7.0

2
1
10
124
439
674
872
970
1,431
2,305
2,961
2,716
4,086

0.0
0.0
0.0
0.6
1.8
3.0
4.0
4.8
6.9
11.1
13.4
13.1
7.5

4
0
14
131
430
758
908
1,107
1,441
2,265
3,235
3,076
5,124

0.0
0.0
0.1
0.6
1.8
3.3
4.1
5.4
7.1
11.0
14.8
14.6
9.1

47
100
7,243
3,039
16
5,311
1,034

—
—
—
—
—
—
—

47
88
7,204
3,099
9
5,240
1,074

—
—
—
—
—
—
—

48
84
6,984
3,203
16
5,152
1,092

—
—
—
—
—
—
—

58
101
6,994
3,092
16
5,236
1,090

—
—
—
—
—
—
—

78
97
7,932
3,570
10
5,516
1,290

—
—
—
—
—
—
—

Vol. 33


HIV Surveillance Report

Table 11b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
2016

2017
Ratea

No.

2018
Ratea

No.

2019
Ratea

No.

2020 (COVID-19 pandemic)
Ratea

No.

No.

Ratea

Transmission categoryf

101

Male sex at birth (≥ 13 yrs at death)g
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Female sex at birth (≥ 13 yrs at death)g
Injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Child (< 13 yrs at death)
Perinatal
Otherj
Subtotal
Region of residencek
Northeast
Midwest
South
West
U.S. dependent areas
Totall

6,968
2,403
1,423
1,766
46
63
12,669

—
—
—
—
—
—
9.5

7,063
2,302
1,396
1,783
42
67
12,654

—
—
—
—
—
—
9.4

6,972
2,295
1,467
1,664
58
58
12,513

—
—
—
—
—
—
9.2

7,250
2,191
1,390
1,742
44
55
12,671

—
—
—
—
—
—
9.3

7,874
2,424
1,621
1,923
57
64
13,963

—
—
—
—
—
—
10.2

1,425
2,620
51
27
4,123

—
—
—
—
2.9

1,416
2,619
44
29
4,107

—
—
—
—
2.9

1,356
2,644
38
27
4,065

—
—
—
—
2.9

1,335
2,519
38
27
3,918

—
—
—
—
2.7

1,450
2,995
44
37
4,526

—
—
—
—
3.2

1
0
1

—
—
0.0

2
0
2

—
—
0.0

1
0
1

—
—
0.0

1
1
2

—
—
0.0

3
1
4

—
—
0.0

3,709
1,858
8,049
2,756
421

6.6
2.7
6.6
3.6
11.1

3,699
1,916
7,997
2,740
411

6.6
2.8
6.5
3.5
11.0

3,529
2,004
7,870
2,807
369

6.3
2.9
6.3
3.6
10.3

3,632
1,939
7,894
2,767
359

6.5
2.8
6.3
3.5
10.0

4,426
2,230
8,608
2,900
329

7.9
3.3
6.8
3.7
9.3

16,793

5.1

16,763

5.1

16,579

5.0

16,591

5.0

18,493

5.6

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention through December 2021. Data for 2020 should
be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers,
should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for
missing transmission category; therefore, values may not sum to column subtotals and total.
g Data presented include transgender and additional gender identity persons.
h Sexual contact with a person known to have, or with a risk factor for, HIV infection.
i Include individuals aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k
Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
l
Includes persons whose race/ethnicity is unknown.

Vol. 33


HIV Surveillance Report

Table 12a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—United States
American Indian/
Alaska Native
No.
Rated

Asiana
No.
Rated

Black/African
American
No.
Rated

Hispanic/Latinob
No.
Rated

Native Hawaiian/
other Pacific
Islander
No.
Rated

White
No.
Rated

Multiracial
No.
Rated

Totalc
No.
Rated

102
Vol. 33

Gender
Male
Female
Transgender woman/girle
Transgender man/boye
Additional gender identityf

41
33
4
0
0

—
—
—
—
—

79
15
3
0
0

—
—
—
—
—

5,331
2,502
94
3
0

—
—
—
—
—

2,497
697
49
2
0

—
—
—
—
—

8
1
1
0
0

—
—
—
—
—

4,672
820
20
2
0

—
—
—
—
—

902
369
17
2
0

—
—
—
—
—

13,530
4,437
188
9
0

—
—
—
—
—

Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

0
0
0
0
2
8
7
4
9
11
11
9
17

0.0
0.0
0.0
0.0
1.0
4.4
4.4
2.7
6.4
7.7
7.1
6.2
5.4

0
0
0
3
5
2
9
8
7
14
12
16
21

0.0
0.0
0.0
0.2
0.3
0.1
0.6
0.5
0.5
1.1
1.1
1.6
0.8

2
0
7
76
210
367
407
515
642
886
1,280
1,370
2,168

0.0
0.0
0.2
2.5
6.1
11.6
14.6
19.8
25.5
35.2
49.3
57.3
41.8

0
0
2
27
92
142
167
216
280
443
548
486
842

0.0
0.0
0.0
0.6
1.9
3.0
3.7
5.1
7.2
13.1
18.7
20.9
17.2

0
0
0
0
0
2
1
2
0
2
1
1
1

0.0
0.0
0.0
0.0
0.0
3.7
2.0
4.7
0.0
5.6
2.9
3.3
1.6

2
0
4
18
89
182
238
257
365
717
1,053
927
1,662

0.0
0.0
0.0
0.2
0.7
1.4
1.9
2.2
3.1
5.6
7.2
6.3
3.9

0
0
1
7
30
51
60
76
107
152
261
220
325

0.0
0.0
0.1
1.0
4.9
10.9
15.6
23.4
38.6
62.2
111.1
104.4
71.6

4
0
14
131
428
754
889
1,078
1,410
2,225
3,166
3,029
5,036

0.0
0.0
0.1
0.6
1.8
3.3
4.1
5.3
7.1
10.9
14.7
14.6
9.0

—
—
—

60
4
6

—
—
—

2,516
1,154
448

—
—
—

1,404
525
315

—
—
—

6
0
1

—
—
—

3,289
472
660

—
—
—

498
164
160

—
—
—

7,801
2,327
1,595

—
—
—

—
—
—
4.6

12
0
1
82

—
—
—
1.1

1,256
33
18
5,424

—
—
—
33.5

281
13
9
2,546

—
—
—
10.6

2
0
0
9

—
—
—
3.6

232
4
34
4,691

—
—
—
5.6

88
6
3
919

—
—
—
37.6

1,873
56
64
13,716

—
—
—
10.1

—
—
—
—
3.2

3
12
0
1
15

—
—
—
—
0.2

643
1,820
29
13
2,504

—
—
—
—
13.8

263
423
8
6
699

—
—
—
—
2.9

0
1
0
0
1

—
—
—
—
0.4

379
427
1
14
821

—
—
—
—
0.9

123
238
6
4
371

—
—
—
—
14.4

1,425
2,939
44
37
4,444

—
—
—
—
3.1

—
—
0.0

0
0
0

—
—
0.0

2
0
2

—
—
0.0

0
0
0

—
—
0.0

0
0
0

—
—
0.0

1
1
2

—
—
0.0

0
0
0

—
—
0.0

3
1
4

—
—
0.0

Transmission categoryg
Male sex at birth (≥ 13 yrs at death)h
Male-to-male sexual contact
30
Injection drug use
7
Male-to-male sexual contact and
5
injection drug use
Heterosexual contacti
3
Perinatalj
0
Otherk
0
Subtotal
45
Female sex at birth (≥ 13 yrs at death)h
Injection drug use
14
Heterosexual contacti
19
Perinatalj
0
Otherk
0
Subtotal
33
Child (< 13 yrs at death)
Perinatal
0
Otherk
0
Subtotal
0


HIV Surveillance Report

Table 12a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—United States (cont)
American Indian/
Alaska Native
No.
Rated

Asiana
No.
Rated

Black/African
American
No.
Rated

Hispanic/Latinob
No.
Rated

Native Hawaiian/
other Pacific
Islander
No.
Rated

White
No.
Rated

Multiracial
No.
Rated

Totalc
No.
Rated

Region of residencel
Northeast
Midwest
South
West

0
8
27
43

0.0
1.9
3.3
4.0

21
11
17
48

0.5
0.5
0.4
0.6

1,763
969
4,699
499

27.8
13.4
19.4
13.7

1,313
182
1,007
743

15.6
3.2
4.3
3.1

0
0
2
8

0.0
0.0
2.0
1.8

909
890
2,351
1,364

2.5
1.7
3.3
3.5

420
170
505
195

41.5
11.8
19.9
7.6

4,426
2,230
8,608
2,900

7.9
3.3
6.8
3.7

Total

78

3.2

97

0.5

7,930

19.1

3,245

5.3

10

1.6

5,514

2.8

1,290

17.1

18,164

5.5

103

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention through December 2021. Data for 2020 should
be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be
interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanic/Latino persons can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
e “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for
missing transmission category; therefore, values may not sum to column subtotals and total.
h Data include transgender and additional gender identity persons.
i Sexual contact with a person known to have, or with a risk factor for, HIV infection.
j Includes individuals aged ≥ 13 years at time of diagnosis of HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
l Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Vol. 33


HIV Surveillance Report

Table 12b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas

104
Vol. 33

Hispanic/Latinob
No.

Native Hawaiian/
other Pacific
Islander
No.

White
No.

5,332
2,503
94
3
0

2,740
778
50
2
0

8
1
1
0
0

4,674
820
20
2
0

902
369
17
2
0

13,776
4,519
189
9
0

0
0
0
3
5
2
9
8
7
14
12
16
21

2
0
7
76
210
367
407
515
642
886
1,281
1,370
2,169

0
0
2
27
94
146
186
245
311
482
616
533
928

0
0
0
0
0
2
1
2
0
2
1
1
1

2
0
4
18
89
182
238
257
365
718
1,053
927
1,663

0
0
1
7
30
51
60
76
107
152
261
220
325

4
0
14
131
430
758
908
1,107
1,441
2,265
3,235
3,076
5,124

30
7
5
3
0
0
45

60
4
6
12
0
1
82

2,516
1,154
448
1,257
33
18
5,425

1,475
622
341
329
14
9
2,790

6
0
1
2
0
0
9

3,290
472
661
232
4
34
4,693

498
164
160
88
6
3
919

7,874
2,424
1,621
1,922
57
64
13,963

14
19
0
0
33

3
12
0
1
15

643
1,821
29
13
2,505

288
478
8
6
780

0
1
0
0
1

379
427
1
14
821

123
238
6
4
371

1,450
2,995
44
37
4,526

0
0
0

0
0
0

2
0
2

0
0
0

0
0
0

1
1
2

0
0
0

3
1
4

American Indian/
Alaska Native
No.
Gender
Male
Female
Transgender woman/girld
Transgender man/boyd
Additional gender identitye
Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Transmission categoryf
Male sex at birth (≥ 13 yrs at death)g
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Female sex at birth (≥ 13 yrs at death)g
Injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Child (< 13 yrs at death)
Perinatal
Otherj
Subtotal

Asiana
No.

Black/African
American
No.

41
33
4
0
0

79
15
3
0
0

0
0
0
0
2
8
7
4
9
11
11
9
17

Multiracial
No.

Totalc
No.


HIV Surveillance Report

Table 12b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 pandemic)—United States and 6 dependent areas (cont)
American Indian/
Alaska Native
No.
Region of residencek
Northeast
Midwest
South
West
U.S. dependent areas
Total

Hispanic/Latinob
No.

Native Hawaiian/
other Pacific
Islander
No.

White
No.

1,763
969
4,699
499
2

1,313
182
1,007
743
325

0
0
2
8
0

909
890
2,351
1,364
2

420
170
505
195
0

4,426
2,230
8,608
2,900
329

7,932

3,570

10

5,516

1,290

18,493

Asiana
No.

Black/African
American
No.

0
8
27
43
0

21
11
17
48
0

78

97

Multiracial
No.

Totalc
No.

105

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention through December 2021. Data for 2020 should
be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution.
a
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b
Hispanic/Latino persons can be of any race.
c
Includes persons whose race/ethnicity is unknown.
d “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
e Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for
missing transmission category; therefore, values may not sum to column subtotals and total.
g Data include transgender and additional gender identity persons.
h Sexual contact with a person known to have, or with a risk factor for, HIV infection.
i Includes individuals aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Vol. 33

Table 13a. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected
characteristics, 2016–2020—United States
2016

2017

2018

2020 (COVID-19
pandemic)

2019

No.

Ratea

No.

Ratea

No.

Ratea

No.

Ratea

No.

Ratea

Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

1
5
111
350
474
584
743
1,303
2,125
2,327
1,844
2,477

0.0
0.0
1.0
3.0
4.3
5.6
7.6
12.6
19.8
21.8
19.8
11.4

0
5
112
347
446
625
659
1,226
2,035
2,249
1,933
2,714

0.0
0.0
1.0
2.9
4.0
5.9
6.8
11.8
19.4
21.1
20.3
12.1

0
5
95
346
464
576
631
1,127
1,904
2,255
1,909
2,908

0.0
0.0
0.9
2.9
4.1
5.3
6.5
11.0
18.6
21.2
19.6
12.5

1
8
94
368
510
617
642
976
1,651
2,266
2,056
3,206

0.0
0.1
0.8
3.1
4.5
5.7
6.5
9.7
16.4
21.3
20.9
13.3

0
10
101
334
571
654
762
971
1,651
2,444
2,322
3,896

0.0
0.1
0.9
2.8
4.9
6.0
7.5
9.8
16.4
23.2
23.3
15.7

Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial

38
87
4,855
2,033
10
4,552
766

4.0
1.2
31.2
9.2
4.3
5.4
36.0

33
73
4,909
2,109
5
4,413
808

3.4
1.0
31.2
9.3
2.1
5.2
36.7

33
73
4,708
2,257
12
4,320
817

3.4
1.0
29.6
9.7
5.0
5.1
35.8

39
93
4,791
2,174
9
4,464
822

4.0
1.2
29.9
9.2
3.6
5.3
34.8

45
82
5,424
2,546
9
4,691
919

4.6
1.1
33.5
10.6
3.6
5.6
37.6

6,889
2,270
1,391

—
—
—

6,992
2,170
1,372

—
—
—

6,893
2,173
1,444

—
—
—

7,177
2,071
1,366

—
—
—

7,801
2,327
1,595

—
—
—

1,690
40
63

—
—
—

1,709
41
67

—
—
—

1,602
52
57

—
—
—

1,685
42
55

—
—
—

1,873
56
64

—
—
—

2,628
1,475
5,838
2,403
12,344

11.4
5.3
11.8
7.6
9.3

2,623
1,513
5,820
2,395
12,351

11.4
5.4
11.6
7.5
9.3

2,490
1,598
5,707
2,425
12,220

10.8
5.7
11.3
7.5
9.1

2,586
1,554
5,861
2,394
12,395

11.2
5.5
11.5
7.4
9.2

3,151
1,795
6,252
2,518
13,716

13.6
6.4
12.1
7.7
10.1

Male sex at birth

b

Transmission categorye
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection
drug use
Heterosexual contactf
Perinatalg
Otherh
Region of residencei
Northeast
Midwest
South
West
Subtotal


HIV Surveillance Report

106

Vol. 33

Table 13a. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected
characteristics, 2016–2020—United States (cont)
2016
No.

2017

Ratea

No.

2018

Ratea

No.

2020 (COVID-19
pandemic)

2019

Ratea

No.

Ratea

No.

Ratea

Female sex at birthb
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categorye
Injection drug use
Heterosexual contactf
Perinatalg
Otherh
Region of residencei
Northeast
Midwest
South
West
Subtotal
Total

0
5
44
94
182
254
387
509
713
658
569
612

0.0
0.0
0.4
0.8
1.7
2.4
3.9
4.8
6.4
5.8
5.6
2.2

0
2
32
98
155
239
311
517
691
722
556
676

0.0
0.0
0.3
0.9
1.4
2.3
3.2
4.9
6.4
6.4
5.3
2.4

0
4
26
73
150
237
327
472
679
675
617
729

0.0
0.0
0.2
0.6
1.4
2.2
3.3
4.5
6.4
6.0
5.8
2.5

0
2
28
65
152
238
290
418
580
643
608
811

0.0
0.0
0.3
0.6
1.4
2.2
2.9
4.1
5.6
5.7
5.7
2.7

0
4
30
94
183
235
316
439
574
722
707
1,140

0.0
0.0
0.3
0.8
1.6
2.2
3.1
4.3
5.5
6.5
6.5
3.7

9
13
2,377
599
4
758
267

0.9
0.2
13.6
2.7
1.7
0.9
11.8

14
15
2,289
585
4
825
266

1.4
0.2
13.0
2.6
1.7
0.9
11.3

15
11
2,275
583
1
831
273

1.5
0.1
12.8
2.6
0.4
1.0
11.3

19
8
2,201
566
5
770
265

1.9
0.1
12.3
2.4
2.0
0.9
10.6

33
15
2,504
699
1
821
371

3.2
0.2
13.8
2.9
0.4
0.9
14.4

1,390
2,562
49
26

—
—
—
—

1,381
2,547
43
28

—
—
—
—

1,323
2,603
36
27

—
—
—
—

1,304
2,469
37
26

—
—
—
—

1,425
2,939
44
37

—
—
—
—

1,081
382
2,211
353
4,027
16,371

4.4
1.3
4.2
1.1
2.9
6.1

1,076
402
2,176
345
3,999
16,350

4.4
1.4
4.1
1.1
2.9
6.0

1,038
406
2,163
382
3,989
16,209

4.2
1.4
4.0
1.2
2.8
5.9

1,046
384
2,032
373
3,835
16,230

4.2
1.3
3.8
1.1
2.7
5.9

1,273
435
2,355
381
4,444
18,160

5.2
1.5
4.3
1.1
3.1
6.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease
Control and Prevention through December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related
services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated for transmission category because of the lack of denominator data.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Includes individuals aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.


HIV Surveillance Report

107

Vol. 33

Table 13b. Death of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected
characteristics, 2016–2020—United States and 6 dependent areas

Male sex at birthb
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categorye
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactf
Perinatalg
Otherh
Region of residencei
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal


HIV Surveillance Report

2020 (COVID-19
pandemic)
No.
Ratea

2016
No.
Ratea

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

1
6
114
356
479
609
763
1,346
2,181
2,384
1,889
2,541

0.0
0.1
1.0
3.0
4.3
5.8
7.7
12.9
20.1
22.1
20.1
11.5

0
5
113
351
456
636
687
1,267
2,094
2,307
1,962
2,776

0.0
0.0
1.0
2.9
4.1
5.9
7.0
12.1
19.7
21.4
20.4
12.2

0
5
99
353
472
589
655
1,154
1,942
2,311
1,951
2,982

0.0
0.0
0.9
2.9
4.2
5.4
6.6
11.1
18.7
21.5
19.9
12.6

1
8
96
372
516
628
669
1,003
1,711
2,306
2,097
3,264

0.0
0.1
0.9
3.1
4.5
5.7
6.7
9.8
16.8
21.4
21.1
13.4

0
10
101
336
573
669
786
989
1,681
2,495
2,356
3,967

0.0
0.1
0.9
2.8
4.9
6.1
7.7
9.9
16.5
23.5
23.4
15.8

38
87
4,862
2,349
11
4,552
767

—
—
—
—
—
—
—

33
73
4,913
2,407
5
4,414
808

—
—
—
—
—
—
—

33
73
4,708
2,546
13
4,321
819

—
—
—
—
—
—
—

39
93
4,792
2,443
11
4,466
824

—
—
—
—
—
—
—

45
82
5,425
2,790
9
4,693
919

—
—
—
—
—
—
—

6,968
2,403
1,423

—
—
—

7,063
2,302
1,396

—
—
—

6,972
2,295
1,467

—
—
—

7,249
2,191
1,390

—
—
—

7,874
2,424
1,621

—
—
—

1,766
46
63

—
—
—

1,783
42
67

—
—
—

1,664
58
58

—
—
—

1,742
44
55

—
—
—

1,923
57
64

—
—
—

2,628
1,475
5,838
2,403
325
12,669

11.4
5.3
11.8
7.6
21.2
9.5

2,623
1,513
5,820
2,395
303
12,654

11.4
5.4
11.6
7.5
20.0
9.4

2,490
1,598
5,707
2,425
293
12,513

10.8
5.7
11.3
7.5
19.9
9.2

2,586
1,554
5,861
2,394
276
12,671

11.2
5.5
11.5
7.4
18.7
9.3

3,151
1,795
6,252
2,518
247
13,963

13.6
6.4
12.1
7.7
16.8
10.2

108

Vol. 33

Table 13b. Death of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected
characteristics, 2016–2020—United States and 6 dependent areas (cont)
2016
No.
Ratea
Female sex at birthb
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categorye
Injection drug use
Heterosexual contactf
Perinatalg
Otherh
Region of residencei
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Total

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

2020 (COVID-19
pandemic)
No.
Ratea

0
5
45
95
185
261
398
518
729
676
579
632

0.0
0.0
0.4
0.8
1.7
2.5
4.0
4.9
6.5
5.9
5.6
2.3

0
2
33
100
160
243
318
528
709
746
569
699

0.0
0.0
0.3
0.9
1.5
2.3
3.2
4.9
6.5
6.5
5.4
2.4

0
4
26
74
154
243
333
483
692
690
624
742

0.0
0.0
0.2
0.6
1.4
2.2
3.3
4.6
6.5
6.1
5.8
2.5

0
2
28
67
158
244
301
428
594
655
619
822

0.0
0.0
0.3
0.6
1.4
2.2
3.0
4.1
5.6
5.8
5.7
2.7

0
4
30
94
185
239
321
452
584
740
720
1,157

0.0
0.0
0.3
0.8
1.6
2.2
3.1
4.4
5.6
6.6
6.6
3.7

9
13
2,380
690
5
759
267

—
—
—
—
—
—
—

14
15
2,290
692
4
825
266

—
—
—
—
—
—
—

15
11
2,275
657
3
831
273

—
—
—
—
—
—
—

19
8
2,201
648
5
770
266

—
—
—
—
—
—
—

33
15
2,505
780
1
821
371

—
—
—
—
—
—
—

1,425
2,620
51
27

—
—
—
—

1,416
2,619
44
29

—
—
—
—

1,356
2,644
38
27

—
—
—
—

1,335
2,519
38
27

—
—
—
—

1,450
2,995
44
37

—
—
—
—

1,081
382
2,211
353
96
4,123
16,792

4.4
1.3
4.2
1.1
5.6
2.9
6.1

1,076
402
2,176
345
108
4,107
16,761

4.4
1.4
4.1
1.1
6.4
2.9
6.1

1,038
406
2,163
382
76
4,065
16,578

4.2
1.4
4.0
1.2
4.6
2.9
6.0

1,046
384
2,032
373
83
3,918
16,589

4.2
1.3
3.8
1.1
5.0
2.7
5.9

1,273
435
2,355
381
82
4,526
18,489

5.2
1.5
4.3
1.1
5.0
3.2
6.6

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease
Control and Prevention through December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related
services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated for transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S.
census information is limited for U.S. dependent areas.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Includes individuals aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.


HIV Surveillance Report

109

Vol. 33

Table 14a. Deaths of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year
of death and selected characteristics, 2016–2020—United States

Transgender womana
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Otherf
Region of residenceg
Northeast
Midwest
South
West
Subtotal
Transgender mana
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Otherf
Region of residenceg
Northeast
Midwest
South
West
Subtotal


HIV Surveillance Report

2016
No.

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
0
1
10
10
13
12
21
13
17
11
12

0
0
2
8
9
15
13
18
10
18
7
6

0
0
1
12
9
13
12
12
19
17
11
11

0
0
5
17
19
16
17
17
17
17
12
7

0
0
7
15
26
26
21
25
19
24
12
13

0
3
55
27
1
22
12

0
0
43
36
1
18
8

2
2
45
34
0
21
13

1
1
69
33
0
23
17

4
3
94
49
1
20
17

83
0
33
4

77
0
26
3

77
0
38
2

98
1
39
6

128
2
53
5

27
12
41
40
120

25
11
39
31
106

32
11
42
32
117

39
22
54
29
144

58
22
63
45
188

0
0
0
0
0
2
0
0
0
0
0
0

0
0
0
0
1
0
0
1
0
2
0
1

0
0
0
0
0
0
0
2
1
1
0
1

0
0
0
1
0
0
0
0
1
1
2
0

0
0
1
0
1
1
2
1
0
1
1
1

0
0
1
0
0
1
0

0
0
3
1
0
0
1

0
0
0
2
0
2
1

0
0
1
2
0
1
1

0
0
3
2
0
2
2

2
0
0
0

3
0
2
0

0
0
5
0

3
0
1
1

6
0
3
0

0
0
2
0
2

1
0
3
1
5

0
1
3
1
5

1
1
3
0
5

2
2
3
2
9

110

Vol. 33

Table 14a. Deaths of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year
of death and selected characteristics, 2016–2020—United States (cont)
2016
No.
Additional gender identityh
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Otherf
Region of residenceg
Northeast
Midwest
South
West
Subtotal
Total

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
0
0
0
1
0
0
0
0
0
0
0

0
0
0
0
1
0
0
0
0
1
0
0

0
0
0
0
0
0
0
0
0
1
0
0

0
0
0
0
0
0
1
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
1
0
0
0
0

0
0
0
1
0
1
0

0
0
0
1
0
0
0

0
0
1
0
0
0
0

0
0
0
0
0
0
0

1
0
0
0

1
0
1
0

0
0
1
0

1
0
0
0

0
0
0
0

0
0
0
1
1
123

1
1
0
0
2
113

0
0
0
1
1
123

1
0
0
0
1
150

0
0
0
0
0
197

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease
Control and Prevention through December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related
services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Classification of persons aged ≥ 13 years based on their risk factors that may have been responsible for HIV transmission; classification has no presume hierarchical order of
probability, except for rare circumstances where route of transmission has been confirmed through investigation. The categories are mutually exclusive. Data were not statistically
adjusted to account for missing exposure category.
e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f Other risk factors, including perinatal transmission, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for
missing exposure category; therefore, case counts for “Other” might be high.
g Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
h Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”


HIV Surveillance Report

111

Vol. 33

Table 14b. Deaths of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year
of death and selected characteristics, 2016–2020—United States and 6 dependent areas

Transgender womana
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Otherf
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Transgender mana
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Otherf
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal


HIV Surveillance Report

2016
No.

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
0
1
10
10
13
12
21
13
17
11
12

0
0
2
8
9
16
13
18
11
18
7
6

0
0
1
12
9
13
12
12
19
17
11
12

0
0
5
17
19
16
17
18
17
17
12
8

0
0
7
15
26
26
21
25
20
24
12
13

0
3
55
27
1
22
12

0
0
43
38
1
18
8

2
2
45
35
0
21
13

1
1
69
35
0
23
17

4
3
94
50
1
20
17

83
0
33
4

77
0
28
3

78
0
38
2

98
1
41
6

129
2
53
5

27
12
41
40
0
120

25
11
39
31
2
108

32
11
42
32
1
118

39
22
54
29
2
146

58
22
63
45
1
189

0
0
0
0
0
2
0
0
0
0
0
0

0
0
0
0
1
0
0
1
0
2
0
1

0
0
0
0
0
0
0
2
1
1
0
1

0
0
0
1
0
0
0
0
1
1
2
0

0
0
1
0
1
1
2
1
0
1
1
1

0
0
1
0
0
1
0

0
0
3
1
0
0
1

0
0
0
2
0
2
1

0
0
1
2
0
1
1

0
0
3
2
0
2
2

2
0
0
0

3
0
2
0

0
0
5
0

3
0
1
1

6
0
3
0

0
0
2
0
0
2

1
0
3
1
0
5

0
1
3
1
0
5

1
1
3
0
0
5

2
2
3
2
0
9

112

Vol. 33

Table 14b. Deaths of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year
of death and selected characteristics, 2016–2020—United States and 6 dependent areas (cont)

Additional gender identityh
Age at death (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Otherf
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Total

2016
No.

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
0
0
0
1
0
0
0
0
0
0
0

0
0
0
0
1
0
0
0
0
1
0
0

0
0
0
0
0
0
0
0
0
1
0
0

0
0
0
0
0
0
1
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
1
0
0
0
0

0
0
0
1
0
1
0

0
0
0
1
0
0
0

0
0
1
0
0
0
0

0
0
0
0
0
0
0

1
0
0
0

1
0
1
0

0
0
1
0

1
0
0
0

0
0
0
0

0
0
0
1
0
1
123

1
1
0
0
0
2
115

0
0
0
1
0
1
124

1
0
0
0
0
1
152

0
0
0
0
0
0
198

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to the Centers for Disease
Control and Prevention through December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related
services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Classification of persons aged ≥ 13 years based on their risk factors that may have been responsible for HIV transmission; classification has no presume hierarchical order of
probability, except for rare circumstances where route of transmission has been confirmed through investigation. The categories are mutually exclusive. Data were not statistically
adjusted to account for missing exposure category.
e
For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f
Other risk factors, including perinatal transmission, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for
missing exposure category; therefore, case counts for “Other” might be high.
g Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
h Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”


HIV Surveillance Report

113

Vol. 33


HIV Surveillance Report

Table 15a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States
2016
No.

2017
Ratea

No.

2018
Ratea

No.

2019
Ratea

No.

2020 (COVID-19 pandemic)
Ratea

No.

Ratea

114

Gender
Male
Female
Transgender woman/girlb
Transgender man/boyb
Additional gender identityc

731,528
231,679
9,855
362
166

—
—
—
—
—

750,778
235,624
10,378
390
184

—
—
—
—
—

769,364
239,274
10,918
437
202

—
—
—
—
—

787,151
242,869
11,466
479
226

—
—
—
—
—

798,697
244,205
11,949
509
243

—
—
—
—
—

Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

2,210
679
4,639
29,783
68,250
78,999
89,346
97,070
135,715
165,941
135,369
87,269
78,320

4.2
8.3
21.9
133.2
297.5
361.8
429.9
493.3
649.1
761.3
617.0
448.7
159.2

2,057
669
4,536
28,381
70,339
82,684
91,617
95,806
129,676
162,434
143,953
95,802
89,400

3.9
8.1
21.5
128.6
301.1
376.5
432.3
489.4
620.5
761.5
656.0
480.7
176.1

1,894
666
4,358
26,949
70,809
87,608
93,487
96,455
123,026
157,168
152,372
103,919
101,484

3.6
8.0
20.7
123.5
300.7
395.8
433.8
490.0
593.9
753.6
695.3
511.8
193.8

1,669
650
4,238
25,982
69,281
93,030
95,411
97,980
116,855
150,353
159,672
111,790
115,280

3.2
7.8
20.1
120.0
294.3
414.1
438.6
491.9
573.1
734.5
730.1
543.7
213.3

1,444
640
3,778
24,186
65,455
97,029
96,659
100,348
109,234
145,107
162,542
120,013
129,168

2.8
7.6
18.0
112.0
281.8
424.9
442.8
494.1
547.0
711.5
752.4
577.0
232.1

Race/ethnicity
American Indian/Alaska Native
Asiand
Black/African American
Hispanic/Latinoe
Native Hawaiian/other Pacific Islander
White
Multiracial

2,690
12,948
396,530
217,205
738
290,404
52,339

112.9
72.5
985.3
379.2
129.5
146.7
768.6

2,848
13,908
406,215
225,188
777
294,999
52,685

118.8
75.8
1,000.8
385.6
133.4
149.1
752.2

2,976
14,795
415,577
233,010
827
299,442
52,834

123.5
79.0
1,016.1
391.8
139.3
151.6
734.6

3,124
15,558
424,689
240,872
880
303,443
52,895

129.0
81.6
1,031.0
398.8
145.7
153.8
717.1

3,248
16,198
430,015
246,097
936
305,956
52,423

133.5
83.6
1,038.0
401.4
152.6
155.5
693.7

Vol. 33


HIV Surveillance Report

Table 15a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States (cont)
2016

2017

2018
a

2019

115

No.

No.

Male sex at birth (≥ 13 yrs at end of year)g
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal

531,004
68,935
56,977
76,039
4,732
2,799
740,486

—
—
—
—
—
—
560.5

550,084
68,166
57,124
77,339
4,832
2,800
760,344

—
—
—
—
—
—
570.9

568,405
67,525
57,180
78,725
4,928
2,791
779,554

—
—
—
—
—
—
581.3

586,044
66,954
57,361
79,821
5,051
2,794
798,026

—
—
—
—
—
—
591.2

599,433
65,912
56,882
80,035
5,135
2,783
810,180

—
—
—
—
—
—
596.8

Female sex at birth (≥ 13 yrs at end of year)g
Injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal

49,201
174,674
5,351
1,668
230,894

—
—
—
—
167.1

48,995
178,746
5,532
1,680
234,953

—
—
—
—
168.8

48,837
182,501
5,713
1,697
238,747

—
—
—
—
170.3

48,727
186,172
5,876
1,722
242,496

—
—
—
—
171.9

48,195
188,033
6,015
1,736
243,979

—
—
—
—
172.0

1,827
383
2,210

—
—
4.2

1,701
356
2,057

—
—
3.9

1,548
346
1,894

—
—
3.6

1,372
297
1,669

—
—
3.2

1,194
250
1,444

—
—
2.8

Region of residencek
Northeast
Midwest
South
West

230,044
115,828
436,538
191,180

410.3
170.3
356.6
249.7

232,022
118,984
449,534
196,814

413.7
174.6
363.7
254.7

234,097
122,094
461,779
202,225

417.4
178.9
370.5
259.8

235,593
124,872
474,316
207,410

420.7
182.7
377.4
264.9

235,337
126,929
482,479
210,858

421.4
185.8
380.9
268.1

Totall

973,590

301.4

997,354

306.8

1,020,195

312.1

1,042,191

317.4

1,055,603

320.4

Rate

No.

a

2020 (COVID-19 pandemic)

Ratea

Rate

No.

a

Rate

No.

Ratea

Transmission categoryf

Child (< 13 yrs at end of year)
Perinatal
Otherj
Subtotal

Vol. 33

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services,
and case surveillance activities in state/local jurisdictions.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Transmission category is classified based on a hierarchy
of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not
sum to column subtotals and total.
g
Data include transgender and additional gender identity persons.
h
Sexual contact with a person known to have, or with a risk factor for, HIV infection.
i
Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j
Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k
Data are based on residence at the end of the specified year (i.e., most recent known address).
l Includes persons whose race/ethnicity is unknown.


HIV Surveillance Report

Table 15b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States and 6 dependent areas
2016
No.

2017
a

Rate

No.

2018
a

Rate

No.

2019
a

Rate

No.

2020 (COVID-19 pandemic)
Rate

a

No.

Ratea

116

Gender
Male
Female
Transgender woman/girlb
Transgender man/boyb
Additional gender identityc

743,223
236,769
9,890
363
167

—
—
—
—
—

762,324
240,574
10,413
391
184

—
—
—
—
—

780,831
244,164
10,949
439
203

—
—
—
—
—

798,709
247,754
11,499
481
226

—
—
—
—
—

810,267
249,044
11,985
512
243

—
—
—
—
—

Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

2,224
682
4,686
30,131
69,013
79,964
90,749
98,741
138,131
168,965
137,939
89,003
80,184

4.2
8.2
21.9
133.1
297.6
362.5
431.7
495.8
653.0
766.2
621.7
452.3
160.7

2,066
675
4,581
28,677
71,045
83,595
92,903
97,393
131,864
165,360
146,606
97,654
91,467

3.9
8.1
21.4
128.5
300.9
377.0
433.7
491.7
623.8
766.2
660.7
484.4
177.8

1,900
674
4,400
27,216
71,504
88,485
94,664
97,974
125,006
159,981
155,114
105,941
103,727

3.6
8.0
20.6
123.3
300.6
396.2
434.9
492.2
596.7
758.2
700.0
516.0
195.5

1,674
654
4,264
26,232
69,966
93,936
96,491
99,438
118,722
152,961
162,572
113,927
117,832

3.2
7.8
20.0
119.8
294.1
414.3
439.3
493.7
575.7
738.6
735.1
548.0
215.2

1,447
643
3,800
24,403
66,068
97,943
97,688
101,775
110,929
147,624
165,411
122,308
132,012

2.8
7.6
17.9
111.8
281.4
424.8
443.4
495.8
549.3
715.6
757.1
581.5
234.1

Race/ethnicity
American Indian/Alaska Native
Asiand
Black/African American
Hispanic/Latinoe
Native Hawaiian/other Pacific Islander
White
Multiracial

2,692
13,000
396,835
233,531
767
290,485
52,363

—
—
—
—
—
—
—

2,850
13,964
406,513
241,218
809
295,085
52,710

—
—
—
—
—
—
—

2,978
14,856
415,886
248,889
858
299,526
52,856

—
—
—
—
—
—
—

3,126
15,626
425,003
256,817
912
303,536
52,916

—
—
—
—
—
—
—

3,250
16,266
430,332
262,007
968
306,048
52,447

—
—
—
—
—
—
—

Vol. 33


HIV Surveillance Report

Table 15b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States and 6 dependent areas (cont)
2016

2017

2018

2019

2020 (COVID-19 pandemic)

117

No.

Ratea

No.

Ratea

No.

Ratea

No.

Ratea

No.

535,741
72,548
57,809
78,423
4,864
2,826
752,210

—
—
—
—
—
—
562.9

554,845
71,657
57,919
79,709
4,963
2,827
771,920

—
—
—
—
—
—
573.1

573,263
70,889
57,945
81,079
5,058
2,817
791,050

—
—
—
—
—
—
583.5

591,073
70,228
58,120
82,192
5,183
2,820
809,615

—
—
—
—
—
—
593.3

604,590
69,099
57,629
82,394
5,265
2,808
821,785

—
—
—
—
—
—
598.9

50,248
178,573
5,477
1,680
235,978

—
—
—
—
168.7

49,985
182,568
5,655
1,692
239,900

—
—
—
—
170.3

49,792
186,307
5,829
1,708
243,636

—
—
—
—
171.8

49,670
189,994
5,984
1,732
247,380

—
—
—
—
173.3

49,114
191,832
6,126
1,747
248,819

—
—
—
—
173.4

1,841
383
2,224

—
—
4.2

1,710
356
2,066

—
—
3.9

1,554
346
1,900

—
—
3.6

1,377
297
1,674

—
—
3.2

1,197
250
1,447

—
—
2.8

Region of residencek
Northeast
Midwest
South
West
U.S. dependent areas

230,044
115,828
436,538
191,180
16,822

410.3
170.3
356.6
249.7
441.9

232,022
118,984
449,534
196,814
16,532

413.7
174.6
363.7
254.7
443.9

234,097
122,094
461,779
202,225
16,391

417.4
178.9
370.5
259.8
456.4

235,593
124,872
474,316
207,410
16,478

420.7
182.7
377.4
264.9
459.0

235,337
126,929
482,479
210,858
16,448

421.4
185.8
380.9
268.1
462.7

Totall

990,412

303.0

1,013,886

308.3

1,036,586

313.7

1,058,669

319.0

1,072,051

321.9

Transmission categoryf
Male sex at birth (≥ 13 yrs at diagnosis)g
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Female sex at birth (≥ 13 yrs at diagnosis)g
Injection drug use
Heterosexual contacth
Perinatali
Otherj
Subtotal
Child (<13 yrs at end of year)
Perinatal
Otherj
Subtotal

Ratea

Vol. 33

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services,
and case surveillance activities in state/local jurisdictions.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for
missing transmission category; therefore, values may not sum to column subtotals and total.
g
Data include transgender and additional gender identity persons.
h
Sexual contact with a person known to have, or with a risk factor for, HIV infection.
i
Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j
Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k
Data are based on residence at the end of the specified year (i.e., most recent known address).
l
Includes persons whose race/ethnicity is unknown.


HIV Surveillance Report

Table 16a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 pandemic)—United States
American Indian/
Alaska Native
No.
Rated
Gender
Male
Female
Transgender woman/girle
Transgender man/boye
Additional gender identityf

118

Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

Asiana
No.
Rated

Black/
African American
No.
Rated

Hispanic/Latinob
No.
Rated

Native Hawaiian/
other Pacific
Islander
No.
Rated

White
No.
Rated

Multiracial
No.
Rated

Totalc
No.
Rated

Vol. 33

2,390
796
57
4
1

—
—
—
—
—

13,156
2,830
197
9
6

—
—
—
—
—

281,564
142,547
5,592
219
93

—
—
—
—
—

196,810
45,181
3,931
108
67

—
—
—
—
—

750
151
35
0
0

—
—
—
—
—

264,233
40,316
1,235
124
48

—
—
—
—
—

39,268
12,180
902
45
28

—
—
—
—
—

798,697
244,205
11,949
509
243

—
—
—
—
—

7
1
11
98
268
374
392
377
345
452
401
264
258

1.7
1.4
6.3
54.0
135.4
206.0
244.3
258.8
246.0
317.0
258.4
182.6
81.2

100
33
96
387
1,185
1,792
1,877
2,019
2,392
2,191
1,629
1,115
1,382

3.5
7.8
8.7
31.3
77.4
106.4
115.2
137.9
168.1
176.7
144.7
109.2
52.8

843
374
2,311
13,509
33,053
46,183
40,805
40,593
43,155
54,228
59,336
46,380
49,245

11.8
32.4
81.0
444.5
961.4
1,460.4
1,461.0
1,559.5
1,711.2
2,151.4
2,284.4
1,938.4
949.8

192
85
763
5,835
16,688
24,545
26,543
28,166
29,123
34,943
33,620
22,479
23,115

1.4
3.9
14.9
118.9
336.3
526.1
588.1
665.9
754.1
1,031.4
1,148.7
965.1
473.5

3
0
7
26
80
122
118
130
99
103
103
72
73

2.6
0.0
16.7
60.6
160.9
228.7
235.9
303.8
263.1
288.6
295.8
238.9
113.5

182
88
421
3,323
10,895
18,879
21,692
23,833
28,557
45,675
59,200
43,863
49,348

0.7
2.1
3.9
28.9
87.6
149.6
176.4
207.3
243.9
356.2
407.5
299.0
117.1

117
59
169
1,003
3,279
5,127
5,227
5,210
5,522
7,415
8,092
5,684
5,519

4.6
16.8
21.8
144.9
538.9
1,094.9
1,356.2
1,606.7
1,994.0
3,034.4
3,444.3
2,696.4
1,215.6

1,444
640
3,778
24,186
65,455
97,029
96,659
100,348
109,234
145,107
162,542
120,013
129,168

2.8
7.6
18.0
112.0
281.8
424.9
442.8
494.1
547.0
711.5
752.4
577.0
232.1

11,252
452
417

—
—
—

187,976
30,306
15,327

—
—
—

150,900
18,742
13,224

—
—
—

672
23
48

—
—
—

217,022
13,429
23,153

—
—
—

29,508
2,662
4,363

—
—
—

599,433
65,912
56,882

—
—
—

1,068
60
66
13,315

—
—
—
171.1

49,490
2,930
803
286,831

—
—
—
1,772.7

16,185
1,223
437
200,711

—
—
—
832.6

35
3
2
783

—
—
—
311.5

9,947
568
1,307
265,426

—
—
—
316.0

3,122
338
150
40,143

—
—
—
1,643.1

80,035
5,135
2,783
810,180

—
—
—
596.8

188
2,459
63
73
2,783

—
—
—
—
31.9

22,684
115,289
3,565
803
142,341

—
—
—
—
787.2

9,365
34,215
1,350
264
45,194

—
—
—
—
189.7

25
123
0
2
150

—
—
—
—
60.3

12,648
26,577
633
490
40,348

—
—
—
—
46.2

2,953
8,735
388
88
12,163

—
—
—
—
471.0

48,194
188,033
6,015
1,736
243,979

—
—
—
—
172.0

61
39
100

—
—
3.5

697
146
843

—
—
11.8

180
12
192

—
—
1.4

3
0
3

—
—
2.6

141
41
182

—
—
0.7

106
11
117

—
—
4.6

1,194
250
1,444

—
—
2.8

Transmission categoryg
Male sex at birth (≥ 13 yrs at end of year)h
Male-to-male sexual contact
1,740
—
Injection drug use
227
—
Male-to-male sexual contact
302
—
and injection drug use
Heterosexual contacti
159
—
Perinatalj
5
—
Otherk
13
—
Subtotal
2,445
248.8
Female sex at birth (≥ 13 yrs at end of year)h
Injection drug use
267
—
Heterosexual contacti
510
—
Perinatalj
9
—
Otherk
10
—
Subtotal
796
77.2
Child (<13 yrs at end of year)
Perinatal
6
—
Otherk
1
—
Subtotal
7
1.7


HIV Surveillance Report

Table 16a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 pandemic)—United States (cont)
American Indian/
Alaska Native
No.
Rated
Region of residencel
Northeast
Midwest
South
West

144
397
793
1,914

Total

3,248

Native Hawaiian/
other Pacific
Islander
No.
Rated

Asiana
No.
Rated

Black/
African American
No.
Rated

Hispanic/Latinob
No.
Rated

111.9
96.0
97.0
178.5

3,466
1,596
3,419
7,717

88.8
66.0
72.8
92.4

89,494
54,193
253,184
33,144

1,413.6
751.9
1,043.7
913.0

73,061
16,018
84,830
72,188

869.9
283.9
361.6
303.2

64
50
163
659

282.6
128.7
161.2
146.1

53,710
48,040
117,902
86,304

149.0
93.9
166.5
222.6

15,055
6,515
22,034
8,819

1,487.6
450.6
870.4
343.4

235,337
126,929
482,479
210,858

421.4
185.8
380.9
268.1

133.5

16,198

83.6

430,015

1,038.0

246,097

401.4

936

152.6

305,956

155.5

52,423

693.7

1,055,603

320.4

White
No.
Rated

Multiracial
No.
Rated

Totalc
No.
Rated

119

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services,
and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b
Hispanic/Latino persons can be of any race.
c
Includes persons whose race/ethnicity is unknown.
d
Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
e
“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Transmission category is classified based on a hierarchy
of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not
sum to column subtotals and total.
h Data include transgender and additional gender identity persons.
i Sexual contact with a person known to have, or with a risk factor for, HIV infection.
j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
l Data are based on residence at the end of the specified year (i.e., most recent known address).

Vol. 33


HIV Surveillance Report

Table 16b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas

Gender
Male
Female
Transgender woman/girld
Transgender man/boyd
Additional gender identitye

120

Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

American Indian/
Alaska Native
No.

Vol. 33

Hispanic/Latinob
No.

Native Hawaiian/
other Pacific
Islander
No.

White
No.

Multiracial
No.

Totalc
No.

281,755
142,673
5,592
219
93

208,010
49,853
3,966
111
67

774
158
36
0
0

264,307
40,334
1,235
124
48

39,288
12,184
902
45
28

810,267
249,044
11,985
512
243

100
33
96
387
1,186
1,801
1,882
2,025
2,401
2,202
1,641
1,123
1,389

844
374
2,314
13,511
33,059
46,198
40,823
40,614
43,196
54,288
59,374
46,421
49,316

193
88
781
6,048
17,289
25,421
27,537
29,555
30,755
37,358
36,418
24,704
25,860

4
0
7
27
83
130
121
134
101
108
104
74
75

182
88
421
3,324
10,896
18,884
21,699
23,837
28,563
45,695
59,218
43,878
49,363

117
59
170
1,003
3,280
5,128
5,229
5,213
5,525
7,420
8,094
5,687
5,522

1,447
643
3,800
24,403
66,068
97,943
97,688
101,775
110,929
147,624
165,411
122,308
132,012

11,299
458
419

188,059
30,341
15,333

155,825
21,884
13,955

692
24
50

217,085
13,432
23,157

29,524
2,663
4,365

604,590
69,099
57,629

1,070
60
66
13,372

49,553
2,932
803
287,021

18,471
1,350
462
211,946

38
3
2
808

9,951
568
1,307
265,500

3,122
338
150
40,163

82,394
5,265
2,808
821,785

190
2,468
63
73
2,794

22,698
115,394
3,569
806
142,467

10,262
37,878
1,455
273
49,868

25
129
0
2
156

12,652
26,590
634
490
40,366

2,953
8,738
389
88
12,167

49,114
191,832
6,126
1,747
248,819

61
39
100

698
146
844

181
12
193

4
0
4

141
41
182

106
11
117

1,197
250
1,447

Asiana
No.

Black/
African American
No.

2,392
796
57
4
1

13,213
2,841
197
9
6

7
1
11
98
268
374
392
377
345
453
401
265
258

Transmission categoryf
Male sex at birth (≥ 13 yrs at end of year)g
Male-to-male sexual contact
1,741
Injection drug use
227
Male-to-male sexual contact and
302
injection drug use
Heterosexual contacth
160
Perinatali
5
Otherj
13
Subtotal
2,447
Female sex at birth (≥ 13 yrs at end of year)g
Injection drug use
267
Heterosexual contacth
510
Perinatali
9
Otherj
10
Subtotal
796
Child (<13 yrs at end of year)
Perinatal
6
Otherj
1
Subtotal
7


HIV Surveillance Report

Table 16b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas (cont)
American Indian/
Alaska Native
No.
Region of residencek
Northeast
Midwest
South
West
U.S. dependent areas
Total

Hispanic/Latinob
No.

Native Hawaiian/
other Pacific
Islander
No.

White
No.

Multiracial
No.

Totalc
No.

89,494
54,193
253,184
33,144
317

73,061
16,018
84,830
72,188
15,910

64
50
163
659
32

53,710
48,040
117,902
86,304
92

15,055
6,515
22,034
8,819
24

235,337
126,929
482,479
210,858
16,448

430,332

262,007

968

306,048

52,447

1,072,051

Asiana
No.

Black/
African American
No.

144
397
793
1,914
2

3,466
1,596
3,419
7,717
68

3,250

16,266

121

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services,
and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution.
a
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b
Hispanic/Latino persons can be of any race.
c
Includes persons whose race/ethnicity is unknown.
d
Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
e “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Transmission category is classified based on a hierarchy
of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not
sum to column subtotals and total.
h Data include transgender and additional gender identity persons.
i Sexual contact with a person known to have, or with a risk factor for, HIV infection.
j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
l Data are based on residence at the end of the specified year (i.e., most recent known address).

Vol. 33

Table 17a. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics,
2016–2020—United States
2016
No.

2017

Ratea

No.

2018

Ratea

No.

2020 (COVID-19
pandemic)

2019

Ratea

No.

Ratea

No.

Ratea

Male sex at birthb
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

312
7.5
2,970
27.5
24,180 210.5
56,654 485.5
62,180 565.4
65,199 627.8
68,340 699.6
100,825 973.6
127,883 1,194.2
104,044 975.7
67,133 722.0
60,766 279.0

301
7.1
2,975
27.6
23,116 204.3
58,961 495.6
66,146 596.9
67,959 641.3
67,682 696.4
95,155 919.4
124,711 1,189.4
110,687 1037.3
73,524 771.6
69,127 306.9

297
7.0
2,874
26.7
22,054 197.4
59,617 496.3
71,411 638.4
70,426 653.2
68,409 699.4
89,532 873.5
119,807 1,167.4
117,372 1,101.2
79,467 817.8
78,288 336.4

307
7.2
2,851
26.5
21,352 192.9
58,592 487.4
76,736 674.9
73,036 670.5
70,302 709.7
84,079 833.9
113,689 1,127.6
123,071 1,156.8
85,326 866.1
88,685 368.6

311
7.2
2,484
23.2
20,028 181.5
55,458 467.0
80,877 699.1
75,411 689.5
72,953 721.7
77,840 788.4
108,763 1,082.0
125,217 1,191.2
91,643 918.5
99,195 399.6

Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial

1,973 208.0
10,526 147.9
260,259 1,670.9
174,395 788.3
610 263.4
252,420 300.6
39,773 1,869.7

2,100 219.3
11,352 155.0
267,629 1,700.2
181,561 802.0
647 273.1
256,392 305.0
40,134 1,820.9

2,212 228.9
12,118 161.7
274,927 1,730.0
188,627 814.8
694 286.8
260,161 309.4
40,286 1,766.1

2,333 239.3
12,767 167.0
282,113 1,758.4
195,755 828.6
743 301.0
263,410 313.2
40,379 1,709.9

2,445 248.8
13,315 171.1
286,831 1,772.7
200,711 832.6
783 311.5
265,426 316.0
40,143 1,643.1

531,004
68,935
56,977

—
—
—

550,084
68,166
57,124

—
—
—

568,405
67,525
57,180

—
—
—

586,044
66,954
57,361

—
—
—

599,433
65,912
56,882

—
—
—

76,039
4,732
2,799

—
—
—

77,339
4,832
2,800

—
—
—

78,725
4,928
2,791

—
—
—

79,821
5,051
2,794

—
—
—

80,035
5,135
2,783

—
—
—

161,984
91,473
320,530
166,499
740,486

702.6
328.2
646.3
527.2
560.5

163,829
93,963
331,048
171,504
760,344

709.3
335.8
660.1
536.8
570.9

165,728
96,426
341,199
176,201
779,554

716.6
343.6
673.8
545.9
581.3

167,279
98,564
351,458
180,725
798,026

723.4
350.2
687.1
554.9
591.2

167,483
100,260
358,705
183,732
810,180

725.2
355.7
694.5
559.8
596.8

Transmission categorye
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactf
Perinatalg
Otherh
Region of residencei
Northeast
Midwest
South
West
Subtotal


HIV Surveillance Report

122

Vol. 33

Table 17a. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics,
2016–2020—United States (cont)
2016
No.

2017

Ratea

No.

2018

Ratea

No.

2020 (COVID-19
pandemic)

2019

Ratea

No.

Ratea

No.

Ratea

Female sex at birthb
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65

367
1,669
5,603
11,596
16,819
24,147
28,730
34,890
38,058
31,325
20,136
17,554

9.1
16.1
51.5
102.9
155.2
232.2
289.9
330.7
343.3
277.8
198.3
64.0

368
1,561
5,265
11,378
16,538
23,658
28,124
34,521
37,723
33,266
22,278
20,273

9.1
15.1
49.0
99.3
152.0
223.3
285.3
327.3
347.9
295.0
214.2
71.8

369
1,484
4,895
11,192
16,197
23,061
28,046
33,494
37,361
35,000
24,452
23,196

9.1
14.4
46.0
97.0
148.0
214.2
283.3
320.0
352.7
310.9
231.0
79.8

343
1,387
4,630
10,689
16,294
22,375
27,678
32,776
36,664
36,601
26,464
26,595

8.4
13.4
43.8
92.8
146.9
206.0
276.4
318.0
353.0
325.9
247.1
88.7

329
1,294
4,158
9,997
16,152
21,248
27,395
31,394
36,344
37,325
28,370
29,973

8.0
12.6
39.4
88.0
143.3
195.1
268.6
310.9
351.4
336.5
262.1
97.2

711
2,307
134,933
42,516
125
37,708
12,388

71.8
28.8
773.5
195.1
54.5
43.1
545.5

742
2,442
137,345
43,356
127
38,357
12,379

74.1
29.6
779.6
194.3
54.1
43.9
527.4

758
2,567
139,534
44,133
131
39,040
12,379

75.0
30.5
784.9
193.2
54.6
44.6
510.8

785
2,680
141,598
44,896
135
39,824
12,374

76.8
31.2
789.4
192.4
55.2
45.5
494.6

796
2,783
142,341
45,194
150
40,348
12,163

77.2
31.9
787.2
189.7
60.3
46.2
471.0

Transmission categorye
Injection drug use
Heterosexual contactf
Perinatalg
Otherh

49,201
174,674
5,351
1,668

—
—
—
—

48,995
178,746
5,532
1,680

—
—
—
—

48,837
182,501
5,713
1,697

—
—
—
—

48,727
186,172
5,876
1,722

—
—
—
—

48,195
188,033
6,015
1,736

—
—
—
—

Region of residencei
Northeast
Midwest
South
West
Subtotal
Total

67,698
23,871
115,016
24,309
230,894
971,380

274.5
82.3
219.5
75.8
167.1
359.4

67,871
24,552
117,550
24,980
234,953
995,297

274.9
84.4
221.8
77.0
168.8
365.4

68,097
25,206
119,722
25,722
238,747
1,018,301

275.7
86.4
223.6
78.5
170.3
371.3

68,067
25,908
122,102
26,419
242,496
1,040,522

275.7
88.6
225.7
80.0
171.9
376.9

67,648
26,319
123,110
26,902
243,979
1,054,159

274.5
89.9
225.3
80.8
172.0
379.7

Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the
COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Includes individuals aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on residence at the end of the specified year (i.e., most recent known address).


HIV Surveillance Report

123

Vol. 33

Table 17b. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics,
2016–2020—United States and 6 dependent areas

Male sex at birthb
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categorye
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and injection
drug use
Heterosexual contactf
Perinatalg
Otherh
Region of residencei
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal


HIV Surveillance Report

2016
No.
Ratea

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

2020 (COVID-19
pandemic)
No.
Ratea

314
7.4
2,996
27.4
24,444 210.3
57,254 485.5
62,890 566.3
66,170 630.3
69,468 703.0
102,504 978.6
130,000 1,200.5
105,775 981.3
68,354 727.0
62,041 281.0

303
7.1
2,997
27.5
23,344 203.9
59,521 495.1
66,826 597.5
68,860 643.2
68,767 699.6
96,658 923.6
126,774 1,195.6
112,500 1043.2
74,827 776.7
70,543 309.1

301
7.0
2,901
26.7
22,252 197.0
60,181 496.0
72,081 638.8
71,259 654.7
69,461 702.5
90,855 876.9
121,818 1,173.9
119,269 1,107.3
80,850 823.1
79,822 338.5

310
7.2
2,868
26.4
21,549 192.6
59,149 487.0
77,441 675.0
73,826 671.6
71,326 712.4
85,316 837.0
115,548 1,133.4
125,086 1,163.4
86,771 871.4
90,425 370.9

313
7.2
2,498
23.1
20,206 181.1
55,953 466.4
81,605 699.0
76,190 690.5
73,950 724.1
78,982 791.4
110,548 1,087.8
127,218 1,197.4
93,188 924.1
101,134 402.2

1,975
10,567
260,435
185,794
631
252,484
39,792

—
—
—
—
—
—
—

2,102
11,397
267,801
192,804
671
256,459
40,155

—
—
—
—
—
—
—

2,214
12,168
275,110
199,778
719
260,227
40,303

—
—
—
—
—
—
—

2,335
12,824
282,299
206,980
768
263,484
40,397

—
—
—
—
—
—
—

2,447
13,372
287,021
211,946
808
265,500
40,163

—
—
—
—
—
—
—

535,741
72,548
57,809

—
—
—

554,845
71,657
57,919

—
—
—

573,263
70,888
57,945

—
—
—

591,073
70,228
58,120

—
—
—

604,590
69,099
57,629

—
—
—

78,423
4,864
2,826

—
—
—

79,709
4,962
2,827

—
—
—

81,079
5,058
2,817

—
—
—

82,192
5,183
2,820

—
—
—

82,394
5,265
2,808

—
—
—

161,984
91,473
320,530
166,499
11,724
752,210

702.6
328.2
646.3
527.2
763.1
562.9

163,829
93,963
331,048
171,504
11,576
771,920

709.3
335.8
660.1
536.8
765.3
573.1

165,728
96,426
341,199
176,201
11,496
791,050

716.6
343.6
673.8
545.9
781.3
583.5

167,279
98,564
351,458
180,725
11,589
809,615

723.4
350.2
687.1
554.9
784.3
593.3

167,483
100,260
358,705
183,732
11,605
821,785

725.2
355.7
694.5
559.8
789.2
598.9

124

Vol. 33

Table 17b. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics,
2016–2020—United States and 6 dependent areas (cont)

Female sex at birthb
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categorye
Injection drug use
Heterosexual contactf
Perinatalg
Otherh
Region of residencei
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Total

2020 (COVID-19
pandemic)
No.
Ratea

2016
No.
Ratea

2017
No.
Ratea

2018
No.
Ratea

2019
No.
Ratea

368
1,690
5,687
11,759
17,074
24,579
29,273
35,627
38,965
32,164
20,649
18,143

9.0
16.1
51.6
103.2
155.9
233.6
291.7
333.6
347.1
281.9
200.9
65.2

372
1,584
5,333
11,524
16,769
24,043
28,626
35,206
38,586
34,106
22,827
20,924

9.1
15.2
49.0
99.4
152.6
224.4
286.9
329.8
351.5
299.0
216.9
73.1

373
1,499
4,964
11,323
16,404
23,405
28,513
34,151
38,163
35,845
25,091
23,905

9.1
14.4
46.1
97.1
148.4
215.1
284.6
322.6
355.9
314.8
234.3
81.1

344
1,396
4,683
10,817
16,495
22,665
28,112
33,406
37,413
37,486
27,156
27,407

8.3
13.4
43.8
92.9
147.3
206.6
277.5
320.3
355.8
329.9
250.7
90.2

330
1,302
4,197
10,115
16,338
21,498
27,825
31,947
37,076
38,193
29,120
30,878

7.9
12.5
39.3
88.1
143.6
195.5
269.8
312.7
354.2
340.3
266.0
98.8

711
2,318
135,060
47,433
132
37,725
12,392

—
—
—
—
—
—
—

742
2,453
137,470
48,136
134
38,376
12,383

—
—
—
—
—
—
—

758
2,578
139,659
48,857
136
39,058
12,384

—
—
—
—
—
—
—

785
2,691
141,725
49,613
141
39,843
12,377

—
—
—
—
—
—
—

796
2,794
142,467
49,868
156
40,366
12,167

—
—
—
—
—
—
—

50,248
178,573
5,477
1,680

—
—
—
—

49,985
182,568
5,655
1,692

—
—
—
—

49,792
186,307
5,829
1,708

—
—
—
—

49,670
189,994
5,984
1,732

—
—
—
—

49,114
191,832
6,126
1,747

—
—
—
—

67,698
23,871
115,016
24,309
5,084
235,978
988,188

274.5
82.3
219.5
75.8
297.3
168.7
361.3

67,871
24,552
117,550
24,980
4,947
239,900
1,011,820

274.9
84.4
221.8
77.0
293.9
170.3
367.1

68,097
25,206
119,722
25,722
4,889
243,636
1,034,686

275.7
86.4
223.6
78.5
298.8
171.8
373.0

68,067
25,908
122,102
26,419
4,884
247,380
1,056,995

275.7
88.6
225.7
80.0
296.9
173.3
378.6

67,648
26,319
123,110
26,902
4,840
248,819
1,070,604

274.5
89.9
225.3
80.8
295.1
173.4
381.4

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the
COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided
because U.S. census information is limited for U.S. dependent areas.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex
assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Includes individuals aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on residence at the end of the specified year (i.e., most recent known address).


HIV Surveillance Report

125

Vol. 33

Table 18a. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year
and selected characteristics, 2016–2020—United States

Transgender womana
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Perinatalf
Otherg
Region of residenceh
Northeast
Midwest
South
West
Subtotal
Transgender mana
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Perinatalf
Otherg
Region of residenceh
Northeast
Midwest
South
West


HIV Surveillance Report

2016
No.

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
103
853
1,861
1,602
1,373
1,098
1,096
905
557
268
137

0
93
798
1,904
1,816
1,466
1,125
1,091
991
611
307
174

0
68
770
1,904
2,012
1,583
1,197
1,106
1,034
693
343
206

0
66
738
1,814
2,266
1,705
1,272
1,153
1,031
785
376
258

1
49
710
1,718
2,494
1,784
1,410
1,145
1,076
816
446
299

40
143
4,592
3,183
24
1,018
853

42
162
4,857
3,342
26
1,078
869

49
170
5,118
3,542
29
1,122
886

53
182
5,368
3,756
33
1,182
890

57
197
5,592
3,931
35
1,235
901

8,095
16
1,572
22
148

8,590
19
1,583
22
162

9,103
23
1,597
22
171

9,624
24
1,613
21
182

10,102
24
1,595
20
207

2,627
1,324
3,521
2,381
9,853

2,751
1,403
3,729
2,493
10,376

2,898
1,496
3,885
2,637
10,916

2,999
1,546
4,095
2,824
11,464

3,091
1,624
4,314
2,919
11,948

1
6
16
44
54
53
42
44
46
28
16
11

1
7
19
59
44
64
42
47
47
28
20
11

0
7
22
71
61
65
51
50
46
25
26
12

0
5
29
74
82
67
54
52
44
34
22
15

1
3
39
69
92
75
57
48
47
38
24
16

4
4
166
76
0
75
36

4
6
174
81
0
86
38

4
8
194
89
0
102
39

4
9
211
101
0
111
42

4
9
219
108
0
124
45

257
5
64
18
17

282
6
63
18
20

325
8
60
18
25

359
9
61
17
32

382
10
62
19
36

71
104
105
81

74
109
117
89

78
119
134
105

87
124
150
117

91
125
173
120

126

Vol. 33

Table 18a. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year
and selected characteristics, 2016–2020—United States (cont)

Subtotal
Additional gender identityi
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Perinatalf
Otherg
Region of residenceh
Northeast
Midwest
South
West
Subtotal
Total

2020 (COVID-19
pandemic)
No.
509

2016
No.
361

2017
No.
389

2018
No.
436

2019
No.
478

0
4
13
34
24
15
24
14
12
15
6
5

0
2
15
34
27
28
16
23
13
14
7
5

0
5
19
34
31
34
15
21
13
15
8
7

0
5
24
33
45
38
12
20
18
14
7
10

0
2
27
36
53
34
16
25
17
10
12
11

0
1
66
47
0
31
21

0
2
73
53
0
34
22

1
5
78
55
0
39
24

1
5
85
63
0
44
28

1
6
93
67
0
48
28

138
1
24
2
1

156
1
23
2
2

175
1
22
2
2

197
1
23
2
3

211
1
24
2
5

88
20
44
14
166
10,380

107
22
40
15
184
10,949

128
21
39
14
202
11,554

136
31
42
17
226
12,168

139
38
43
23
243
12,700

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the
COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these
numbers, should be interpreted with caution.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented by using the exposure category classification, which is meant to convey all the
known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare
circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f Individuals aged ≥ 13 years at time of diagnosis of HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category;
therefore, case counts for “Other” might be high.
h Data are based on residence at the end of the specified year (i.e., most recent known address).
i Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”


HIV Surveillance Report

127

Vol. 33

Table 18b. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year and selected
characteristics, 2016–2020—United States and 6 dependent areas

Transgender womana
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Perinatalf
Otherg
Region of residenceh
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Transgender mana
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Perinatalf
Otherg
Region of residenceh
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal


HIV Surveillance Report

2016
No.

2017
No.

2018
No.

2019
No.

2020 (COVID-19
pandemic)
No.

0
103
856
1,866
1,607
1,379
1,100
1,098
910
561
269
139

0
93
801
1,907
1,824
1,471
1,127
1,093
994
617
308
176

0
68
774
1,906
2,019
1,586
1,202
1,106
1,035
699
344
208

0
66
743
1,816
2,272
1,707
1,278
1,154
1,034
790
378
259

1
49
715
1,719
2,500
1,789
1,417
1,147
1,077
821
449
300

40
143
4,592
3,218
24
1,018
853

42
162
4,857
3,377
26
1,078
869

49
170
5,118
3,573
29
1,122
886

53
182
5,368
3,788
34
1,182
890

57
197
5,592
3,966
36
1,235
901

8,123
16
1,579
22
148

8,618
19
1,590
22
162

9,128
23
1,603
22
171

9,652
24
1,618
21
182

10,133
24
1,600
20
207

2,627
1,324
3,521
2,381
35
9,888

2,751
1,403
3,729
2,493
35
10,411

2,898
1,496
3,885
2,637
31
10,947

2,999
1,546
4,095
2,824
33
11,497

3,091
1,624
4,314
2,919
36
11,984

1
7
16
44
54
53
42
44
46
28
16
11

1
8
19
59
44
64
42
47
47
28
20
11

0
8
22
71
61
65
52
50
46
25
26
12

0
5
30
74
82
67
55
52
44
34
22
15

1
3
40
69
92
75
58
48
47
38
24
17

4
4
166
77
0
75
36

4
6
174
82
0
86
38

4
8
194
91
0
102
39

4
9
211
103
0
111
42

4
9
219
111
0
124
45

257
5
64
19
17

282
6
63
19
20

326
8
60
19
25

360
9
61
18
32

383
10
63
20
36

71
104
105
81
1
362

74
109
117
89
1
390

78
119
134
105
2
438

87
124
150
117
2
480

91
125
173
120
3
512

128

Vol. 33

Table 18b. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year and selected
characteristics, 2016–2020—United States and 6 dependent areas (cont)

Additional gender identityi
Age at end of year
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
≥ 65
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Exposure categoryd
Sexual contacte
Injection drug use
Sexual contacte and injection drug use
Perinatalf
Otherg
Region of residenceh
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Total

2020 (COVID-19
pandemic)
No.

2016
No.

2017
No.

2018
No.

2019
No.

0
4
13
34
25
15
24
14
12
15
6
5

0
2
15
34
27
28
16
23
13
14
7
5

0
5
19
34
32
34
15
21
13
15
8
7

0
5
24
33
45
38
12
20
18
14
7
10

0
2
27
36
53
34
16
25
17
10
12
11

0
1
66
48
0
31
21

0
2
73
53
0
34
22

1
5
78
56
0
39
24

1
5
85
63
0
44
28

1
6
93
67
0
48
28

139
1
24
2
1

156
1
23
2
2

176
1
22
2
2

197
1
23
2
3

211
1
24
2
5

88
20
44
14
1
167
10,417

107
22
40
15
0
184
10,985

128
21
39
14
1
203
11,588

136
31
42
17
0
226
12,203

139
38
43
23
0
243
12,739

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the
COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these
numbers, should be interpreted with caution.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were
assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented by using the exposure category classification, which is meant to convey all the
known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare
circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f Individuals aged ≥ 13 years at time of diagnosis of HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category;
therefore, case counts for “Other” might be high.
h Data are based on residence at the end of the specified year (i.e., most recent known address).
i Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”


HIV Surveillance Report

129

Vol. 33

Table 19a. Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year, sex assigned at birth, and selected characteristics,
year-end 2020 (COVID-19 pandemic)—United States
13–14 years
No.
Ratea
Sex at birth
Male
Female
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categoryd
Male sex at birthe
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactf
Perinatalg
Otherh
Subtotal
Female sex at birthe
Injection drug use
Heterosexual contactf
Perinatalg
Otherh
Subtotal

15–17 years
No.
Ratea

18–19 years
No.
Ratea

20–22 years
No.
Ratea

23–24 years
No.
Ratea

No.

Total
Ratea

311
329

7.2
8.0

706
637

11.0
10.4

1,778
657

41.3
15.9

8,867
1,951

134.3
30.9

11,161
2,207

252.0
52.0

22,823
5,781

87.7
23.2

1
33
374
85
0
88
59

1.4
7.8
32.4
3.9
0.0
2.1
16.8

1
53
836
226
2
164
61

1.0
8.1
49.5
7.3
7.9
2.5
12.7

10
43
1,475
537
5
257
108

14.2
9.5
126.3
26.6
30.4
5.8
36.5

47
171
6,268
2,523
11
1,351
445

42.9
24.1
344.0
84.9
43.2
19.7
104.1

51
216
7,241
3,312
15
1,972
558

71.0
40.9
594.9
171.2
86.0
42.5
210.6

110
516
16,194
6,683
33
3,832
1,231

25.7
18.6
229.8
54.9
32.4
14.4
67.7

5
0
0

—
—
—

238
2
4

—
—
—

1,341
11
27

—
—
—

7,743
77
202

—
—
—

9,813
127
362

—
—
—

19,140
218
594

—
—
—

0
245
61
311

—
—
—
7.2

10
362
90
706

—
—
—
11.0

35
295
69
1,778

—
—
—
41.3

222
559
65
8,867

—
—
—
134.3

327
486
46
11,161

—
—
—
252.0

595
1,946
332
22,823

—
—
—
87.7

1
4
248
76
329

—
—
—
—
8.0

6
70
456
105
637

—
—
—
—
10.4

27
215
345
70
657

—
—
—
—
15.9

109
1,087
687
67
1,951

—
—
—
—
30.9

144
1,394
628
41
2,207

—
—
—
—
52.0

288
2,770
2,365
359
5,781

—
—
—
—
23.2

Region of residencei
Northeast
Midwest
South
West

99
148
282
111

7.6
8.4
8.5
5.4

264
225
609
245

13.2
8.5
12.5
8.1

382
364
1,353
336

26.5
20.5
41.7
17.0

1,637
1,627
5,978
1,576

75.9
58.9
120.5
51.8

2,141
1,919
7,016
2,292

151.4
106.9
211.7
106.6

4,523
4,283
15,238
4,560

54.4
39.9
77.4
37.3

Totalj

640

7.6

1,343

10.7

2,435

28.9

10,818

83.7

13,368

154.1

28,604

56.1

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic
on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated by gender, transmission category, or exposure category because of the lack of denominator data.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data
have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Data include transgender and additional gender identity persons.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on address of residence at the end of the specified year (i.e., most recent known address).
j Includes persons whose race/ethnicity is unknown.


HIV Surveillance Report

130

Vol. 33

Table 19b. Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year, sex assigned at birth, and selected characteristics,
year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas
13–14 years
No.
Gender
Male
Female
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/other Pacific Islander
White
Multiracial
Transmission categoryd
Male sex at birthe
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactf
Perinatalg
Otherh
Subtotal
Female sex at birthe
Injection drug use
Heterosexual contactf
Perinatalg
Otherh
Subtotal

15–17 years
No.

18–19 years
No.

20–22 years
No.

23–24 years
No.

Total
No.

313
330

712
642

1,786
660

8,926
1,975

11,280
2,222

23,017
5,829

1
33
374
88
0
88
59

1
53
838
234
2
164
62

10
43
1,476
547
5
257
108

47
171
6,270
2,602
12
1,352
445

51
216
7,241
3,446
15
1,972
558

110
516
16,199
6,917
34
3,833
1,232

5
0
0

240
2
4

1,347
11
27

7,784
77
205

9,908
128
363

19,284
219
598

0
247
61
313

10
366
90
712

35
297
69
1,786

223
572
66
8,926

335
498
47
11,280

604
1,979
334
23,017

1
4
249
76
330

6
70
461
105
642

27
216
347
70
660

109
1,100
697
69
1,975

144
1,405
632
41
2,222

288
2,794
2,386
361
5,829

Region of residencei
Northeast
Midwest
South
West
U.S. dependent areas

99
148
282
111
3

264
225
609
245
11

382
364
1,353
336
11

1,637
1,627
5,978
1,576
83

2,141
1,919
7,016
2,292
134

4,523
4,283
15,238
4,560
242

Totalj

643

1,354

2,446

10,901

13,502

28,846

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic
on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution.
a Rates are per 100,000 population. Rates are not calculated by gender, transmission category, or exposure category because of the lack of denominator data.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data
have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Data include transgender and additional gender identity persons.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g
Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on address of residence at the end of the specified year (i.e., most recent known address).
j Includes persons whose race/ethnicity is unknown.


HIV Surveillance Report

131

Vol. 33

Table 20. Diagnoses of HIV infection, 2020, and persons living with diagnosed HIV infection (prevalence), year-end 2020, by area of residence—
United States and 6 dependent areas

Area of residence
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Marylandc
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Subtotal
U.S. dependent areas
American Samoa
Guam
Northern Mariana Islands
Puerto Rico
Republic of Palau
U.S. Virgin Islands
Subtotal
Total

Diagnoses, 2020a (COVID-19 pandemic)
Persons aged ≥ 13 yrs
Children (< 13 yrs)
Total
No.
Rateb
No.
Rateb
No.
Rateb
585
14.1
6
0.8
591
12.0
29
4.8
1
0.8
30
4.1
662
10.6
2
0.2
664
8.9
242
9.6
0
0.0
242
8.0
3,924
11.9
6
0.1
3,930
10.0
324
6.6
0
0.0
324
5.6
171
5.6
0
0.0
171
4.8
93
11.1
0
0.0
93
9.4
197
32.3
0
0.0
197
27.6
3,408
18.2
7
0.2
3,415
15.7
1,977
22.1
1
0.1
1,978
18.5
51
4.3
0
0.0
51
3.6
32
2.1
1
0.3
33
1.8
1,096
10.3
3
0.2
1,099
8.7
433
7.7
1
0.1
434
6.4
100
3.8
0
0.0
100
3.2
138
5.7
0
0.0
138
4.7
300
8.0
1
0.1
301
6.7
722
18.7
1
0.1
723
15.6
16
1.4
1
0.6
17
1.3
706
13.8
1
0.1
707
11.7
434
7.3
0
0.0
434
6.3
519
6.1
0
0.0
519
5.2
229
4.8
0
0.0
229
4.0
402
16.2
0
0.0
402
13.6
359
6.9
2
0.2
361
5.9
14
1.5
0
0.0
14
1.3
73
4.6
0
0.0
73
3.8
392
14.9
0
0.0
392
12.5
33
2.8
0
0.0
33
2.4
805
10.7
4
0.3
809
9.1
131
7.4
0
0.0
131
6.2
1,963
11.9
1
0.0
1,964
10.2
1,079
12.0
0
0.0
1,079
10.2
36
5.7
0
0.0
36
4.7
888
9.0
2
0.1
890
7.6
333
10.1
1
0.1
334
8.4
180
5.0
0
0.0
180
4.2
775
7.1
2
0.1
777
6.1
53
5.8
1
0.7
54
5.1
655
14.8
3
0.4
658
12.6
34
4.6
0
0.0
34
3.8
647
11.1
0
0.0
647
9.4
3,548
14.8
7
0.1
3,555
12.1
131
5.1
0
0.0
131
4.0
12
2.2
0
0.0
12
1.9
628
8.7
0
0.0
628
7.3
421
6.5
1
0.1
422
5.5
139
9.1
0
0.0
139
7.8
213
4.3
1
0.1
214
3.7
14
2.9
0
0.0
14
2.4
30,346
10.9
57
0.1
30,403
9.2
0
0
0
286
0
3
289
30,635

0.0
0.0
0.0
10.2
0.0
3.4
9.3
10.9

0
0
0
0
0
0
0
57

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1

0
0
0
286
0
3
289
30,692

0.0
0.0
0.0
9.1
0.0
2.8
8.1
9.2

Prevalence of diagnosed HIV infection, year-end 2020 (COVID-19 pandemic)
Persons aged ≥ 13 yrs
Children (< 13 yrs)
Total
No.
Rateb
No.
Rateb
No.
Rateb
14,158
341.6
28
3.6
14,186
288.2
730
121.7
3
2.3
733
100.3
17,695
282.9
29
2.5
17,724
238.8
6,058
239.3
9
1.8
6,067
200.2
134,381
406.0
88
1.4
134,469
341.6
13,249
269.1
25
2.8
13,274
228.6
10,569
345.4
11
2.2
10,580
297.4
3,439
409.0
5
3.4
3,444
349.0
13,792 2,260.4
12
11.7
13,804 1,936.5
114,541
612.5
130
4.3
114,671
527.6
57,561
643.5
81
4.6
57,642
538.2
2,380
200.4
3
1.4
2,383
169.4
1,265
83.8
8
2.5
1,273
69.7
35,793
336.8
81
4.1
35,874
285.0
11,873
210.5
52
4.7
11,925
176.5
2,940
111.1
12
2.3
2,952
93.3
3,354
138.8
9
1.8
3,363
115.4
7,911
210.3
15
2.1
7,926
177.0
21,380
553.0
29
3.7
21,409
460.9
1,661
141.1
9
5.2
1,670
123.7
33,425
655.4
39
4.1
33,464
552.6
21,047
353.8
20
2.1
21,067
305.6
16,881
199.4
52
3.5
16,933
169.9
9,001
190.4
37
4.0
9,038
159.8
9,713
392.0
3
0.6
9,716
327.5
12,864
248.7
26
2.7
12,890
209.5
687
75.0
2
1.2
689
63.8
2,324
145.7
6
1.8
2,330
120.3
11,042
418.5
5
1.0
11,047
352.0
1,328
111.5
5
2.9
1,333
97.6
35,136
467.8
43
3.1
35,179
396.1
3,934
221.8
7
2.1
3,941
187.1
125,383
761.6
66
2.3
125,449
648.8
33,562
374.3
58
3.5
33,620
317.1
526
83.4
3
2.2
529
69.1
23,685
240.0
49
2.7
23,734
203.0
6,603
200.3
23
3.4
6,626
166.4
7,347
202.4
15
2.5
7,362
173.6
36,613
335.1
48
2.6
36,661
286.8
2,672
292.0
3
2.1
2,675
253.0
17,914
405.0
26
3.3
17,940
343.8
693
94.4
5
3.2
698
78.2
18,207
313.5
43
4.0
18,250
265.0
97,416
405.3
123
2.3
97,539
332.2
3,265
126.1
10
1.5
3,275
100.8
722
132.6
1
1.3
723
116.0
24,046
331.4
37
2.8
24,083
280.3
14,303
220.4
28
2.3
14,331
186.3
2,089
136.3
3
1.2
2,092
117.2
6,645
134.4
18
2.0
6,663
114.2
356
73.0
1
1.1
357
61.3
1,054,159
379.7
1,444
2.8
1,055,603
320.4
1
105
16
15,788
9
526
16,445
1,070,604

2.8
81.8
38.9
564.1
49.1
598.8
528.7
381.4

0
1
0
1
0
1
3
1,447

0.0
2.5
0.0
0.3
0.0
5.4
0.7
2.8

1
106
16
15,789
9
527
16,448
1,072,051

2.1
62.9
30.9
499.8
41.8
495.8
462.7
321.9

Abbreviations: yrs, years; CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Prevalence data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted
with caution.
a Data are based on residence at HIV diagnosis.
b Rates are per 100,000 population.
c Data for Maryland should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.


HIV Surveillance Report

132

Vol. 33


HIV Surveillance Report

Table 21. Persons aged ≥ 13 years living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas

American Indian/
Alaska Native
Area of residence

133
Vol. 33

Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Marylande
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma

No.
6
195
693
6
289
79
10
3
14
77
23
4
13
29
11
6
15
6
33
7
21
26
31
109
11
6
28
26
51
1
14
340
46
173
20
13
336

Asiana

Black/African
American

Hispanic/Latinob

Native Hawaiian/
other Pacific
Islander

White

Totalc

Multiracial

Rated

No.

Rated

No.

Rated

No.

Rated

No.

Rated

No.

Rated

No.

Rated

24.2
232.7
298.9
30.2
208.9
245.1
156.8
113.4
1,113.8
158.1
107.3
151.1
79.5
173.0
79.7
77.2
75.3
71.9
128.7
94.1
164.8
243.2
63.9
233.9
90.1
25.9
56.5
206.1
225.6
38.2
126.4
223.0
93.8
175.9
67.9
65.1
124.7

36
28
234
27
5,736
156
111
7
77
666
291
387
9
497
226
63
54
61
78
8
256
464
142
179
21
98
4
50
366
20
392
22
2,080
205
8
136
100

58.0
69.6
104.6
64.1
110.9
93.3
75.9
20.5
270.1
122.4
73.7
83.9
38.9
78.9
156.9
89.0
70.9
102.4
110.3
51.9
74.2
108.0
50.4
76.0
76.6
86.7
44.7
120.0
153.6
57.5
52.5
73.4
140.1
73.1
77.7
54.7
129.0

8,944
99
2,417
2,634
21,828
2,016
3,491
1,943
9,653
50,191
39,589
111
122
16,038
4,458
683
853
2,415
14,458
294
23,823
6,309
9,217
3,305
7,120
5,554
23
645
2,891
162
14,979
250
46,465
20,207
211
10,413
1,560

830.1
498.0
866.7
697.0
1,149.3
1,024.5
1,107.7
1,069.8
3,690.4
1,814.9
1,408.6
475.8
1,102.4
1,088.1
847.2
707.0
626.2
792.1
1,182.9
1,715.6
1,554.9
1,484.4
821.3
1,117.3
783.0
962.3
479.9
860.9
1,197.1
945.7
1,546.0
729.3
1,963.7
1,067.2
1,108.8
863.8
643.9

523
81
5,686
467
53,192
3,275
3,659
335
1,211
29,703
4,599
314
227
7,545
1,220
306
588
646
1,218
125
2,490
5,743
1,174
1,041
346
864
53
404
2,986
202
10,750
1,896
45,022
3,117
37
1,740
792

326.3
204.4
308.9
261.2
430.5
329.7
762.8
467.5
1,919.3
618.6
574.8
291.3
128.4
432.7
327.4
205.0
219.7
498.4
645.7
634.3
510.1
847.1
286.5
440.5
469.3
422.4
159.7
251.8
414.5
452.3
724.6
225.9
1,493.8
407.6
160.3
481.3
244.7

3
5
29
6
241
16
7
1
6
49
17
220
2
18
3
5
1
1
4
0
5
8
2
7
3
5
1
3
49
0
9
2
24
15
1
3
10

144.7
62.0
241.6
70.3
194.5
232.9
657.9
363.6
2,127.7
403.6
299.2
198.3
74.5
584.0
138.8
142.9
43.1
37.7
266.8
0.0
193.7
316.0
83.8
299.1
314.5
73.7
150.6
290.4
284.5
0.0
350.9
166.3
317.1
254.8
239.8
71.7
175.2

3,781
279
7,988
2,594
47,523
7,349
3,020
997
2,036
30,994
9,976
1,041
845
9,216
5,435
1,698
1,677
4,326
5,127
1,179
4,131
8,038
5,692
3,925
1,804
5,816
539
1,105
4,282
893
6,486
1,309
21,835
8,107
232
10,085
3,342

136.7
74.5
224.5
139.1
376.9
214.3
146.1
186.4
837.6
301.6
208.7
384.6
67.5
139.3
120.8
74.4
90.0
135.1
221.8
107.1
157.8
186.3
88.3
102.6
126.1
139.8
67.4
86.3
324.0
83.0
154.4
189.2
234.8
140.2
43.1
128.3
150.7

823
43
604
320
5,563
311
270
152
791
2,857
3,059
303
47
2,448
519
179
163
455
459
47
2,699
457
620
430
373
519
39
90
415
49
2,458
114
9,625
1,731
17
1,193
463

1,590.7
127.6
549.9
804.7
692.7
320.5
607.9
978.0
6,396.6
1,127.9
2,292.7
143.6
176.8
1,727.4
622.9
515.3
315.9
851.0
1013.9
288.8
2,679.2
509.7
397.0
506.9
1,639.4
583.2
197.1
370.4
538.0
316.9
2,569.2
474.3
3,968.1
1,239.6
167.4
715.5
289.4

No.

Rated

14,158
341.6
730
121.7
17,695
282.9
6,058
239.3
134,381
406.0
13,249
269.1
10,569
345.4
3,439
409.0
13,792 2,260.4
114,541
612.5
57,561
643.5
2,380
200.4
1,265
83.8
35,793
336.8
11,873
210.5
2,940
111.1
3,354
138.8
7,911
210.3
21,380
553.0
1,661
141.1
33,425
655.4
21,047
353.8
16,881
199.4
9,001
190.4
9,713
392.0
12,864
248.7
687
75.0
2,324
145.7
11,042
418.5
1,328
111.5
35,136
467.8
3,934
221.8
125,383
761.6
33,562
374.3
526
83.4
23,685
240.0
6,603
200.3


HIV Surveillance Report

Table 21. Persons aged ≥ 13 years living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2020 (COVID-19 pandemic)—United States and 6 dependent areas
(cont)
American Indian/
Alaska Native

Black/African
American

Asiana

Hispanic/Latinob

Native Hawaiian/
other Pacific
Islander

White

Totalc

Multiracial

134

No.

Rated

No.

Rated

No.

Rated

No.

Rated

No.

Rated

No.

Rated

No.

Rated

No.

Rated

Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Subtotal
U.S. dependent areasf
American Samoa
Guam
Northern Mariana Islands
Puerto Rico
Republic of Palau
U.S. Virgin Islands
Subtotal

54
35
5
12
102
10
40
34
0
18
118
3
28
11
3,241

134.9
216.3
132.9
71.6
190.3
57.6
48.1
138.5
0.0
89.3
147.0
86.8
65.9
113.8
160.9

155
321
41
55
5
93
1,058
72
17
356
516
12
99
3
16,098

88.1
79.4
129.7
68.0
41.4
84.0
83.4
102.7
160.6
70.2
81.0
91.7
69.2
58.9
97.5

556
16,998
611
11,554
156
9,867
34,905
310
75
13,518
2,403
381
2,449
18
429,172

807.8
1,476.4
1,119.9
1,015.1
1,028.1
1,048.0
1186.9
1027.7
1,097.1
980.4
931.3
705.2
836.5
348.6
1,252.6

1,170
6,683
769
1,078
70
1,114
34,516
839
61
2,503
2,362
102
994
67
245,905

265.3
861.4
567.4
454.8
264.3
387.2
380.4
240.2
560.2
381.5
311.7
413.9
319.9
148.6
513.0

20
14
2
5
1
3
23
13
0
11
59
0
1
0
933

137.1
428.1
364.3
197.3
243.9
95.3
105.7
50.6
0.0
201.6
129.1
0.0
54.3
0.0
186.5

5,135
10,541
1,158
4,198
324
6,329
22,123
1,900
535
6,491
7,835
1,461
2,796
246
305,774

184.4
125.1
172.1
145.3
52.8
145.0
213.8
93.0
105.8
143.3
174.7
103.1
68.4
59.2
178.4

257
2,017
86
1,004
35
789
4,744
94
34
1,124
1,003
126
277
11
52,306

247.3
1,388.6
533.3
1693.3
279.4
969.3
1,583.4
206.2
398.2
711.9
447.3
606.2
419.1
150.8
1,040.8

7,347
36,613
2,672
17,914
693
18,207
97,416
3,265
722
24,046
14,303
2,089
6,645
356
1,054,159

202.4
335.1
292.0
405.0
94.4
313.5
405.3
126.1
132.6
331.4
220.4
136.3
134.4
73.0
379.7

0
0
1
1
0
0
2

—
—
—
—
—
—
—

0
57
5
2
2
2
68

—
—
—
—
—
—
—

0
4
0
23
0
289
316

—
—
—
—
—
—
—

0
8
0
15,709
1
191
15,909

—
—
—
—
—
—
—

0
18
6
1
6
0
31

—
—
—
—
—
—
—

0
11
2
42
0
37
92

—
—
—
—
—
—
—

1
7
2
10
0
4
24

—
—
—
—
—
—
—

1
105
16
15,788
9
526
16,445

2.8
81.8
38.9
564.1
49.1
598.8
528.7

Total

3,243

—

16,166

—

429,488

—

261,814

—

964

—

305,866

—

52,330

—

1,070,604

381.4

Area of residence

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services,
and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Data are based on address of residence at the end of the specified year (i.e., most recent
known address).
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanic/Latino persons can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population.
e Data for Maryland should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
f Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

Vol. 33

Table 22. Diagnoses of HIV infection, 2020, and persons living with diagnosed HIV infection (prevalence), year-end 2020, by
metropolitan statistical area of residence—United States and Puerto Rico
Diagnoses, 2020a (COVID-19 pandemic)

Prevalence of diagnosed HIV infection,
year-end 2020b (COVID-19 pandemic)

MSA of residence

No.

Ratec

Rankd

No.

Ratec

Akron, OH
Albany–Schenectady–Troy, NY
Albuquerque, NM
Allentown–Bethlehem–Easton, PA–NJ
Atlanta–Sandy Springs–Alpharetta, GA
Augusta–Richmond County, GA–SC
Austin–Round Rock–Georgetown, TX
Bakersfield, CA
Baltimore–Columbia–Towson, MDe
Baton Rouge, LA
Birmingham–Hoover, AL
Boise City, ID
Boston–Cambridge–Newton, MA–NHf
Boston Division
Cambridge Division
Bridgeport–Stamford–Norwalk, CT
Buffalo–Cheektowaga, NY
Cape Coral–Fort Myers, FL
Charleston–North Charleston, SC
Charlotte–Concord–Gastonia, NC–SC
Chattanooga, TN–GA
Chicago–Naperville–Elgin, IL–IN–WI
Chicago Division
Elgin Division
Gary Division
Lake County Division
Cincinnati, OH–KY–IN
Cleveland–Elyria, OH
Colorado Springs, CO
Columbia, SC
Columbus, OH
Dallas–Fort Worth–Arlington, TX
Dallas Division
Fort Worth Division
Dayton–Kettering, OH
Deltona–Daytona Beach–Ormond Beach, FL
Denver–Aurora–Lakewood, CO
Des Moines–West Des Moines, IA
Detroit–Warren–Dearborn, MI
Detroit Division
Warren Division
Durham–Chapel Hill, NC
El Paso, TX
Fayetteville, NC
Fayetteville–Springdale–Rogers, AR–MO
Fresno, CA
Grand Rapids–Wyoming, MI
Greensboro–High Point, NC
Greenville–Anderson, SC
Harrisburg–Carlisle, PA
Hartford–East Hartford–Middletown, CT
Honolulu (Urban), HI

54
39
72
40
1,352
82
221
160
331
158
140
20
327
199
120
52
91
54
96
321
33
965
843
22
55
45
207
216
41
158
244
1,147
836
311
50
66
222
44
349
227
122
68
110
76
27
121
35
100
99
40
57
37

7.7
4.4
7.8
4.7
22.2
13.3
9.6
17.8
11.8
18.4
12.8
2.6
6.7
9.8
5.0
5.5
8.1
6.8
11.7
12.0
5.8
10.3
11.9
2.9
7.8
5.2
9.3
10.6
5.4
18.6
11.4
14.9
16.2
12.3
6.2
9.7
7.4
6.2
8.1
13.0
4.8
10.4
13.0
14.4
4.9
12.1
3.2
12.9
10.6
6.9
4.7
3.8

64
98
62
95
2
17
48
8
28
7
21
110
73
—
—
83
59
72
30
27
80
43
—
—
—
—
52
40
86
6
32
12
—
—
79
47
66
78
58
—
—
41
19
14
91
26
107
20
39
71
93
103

1,115
2,194
2,009
1,663
39,493
2,546
6,734
1,928
15,967
5,525
4,337
209
14,441
8,243
5,945
2,697
2,631
2,260
2,692
9,233
1,263
30,284
27,468
477
1,285
1,054
4,690
5,720
1,014
4,303
6,119
30,304
23,587
6,717
1,788
2,106
9,584
1,010
10,696
7,017
3,679
2,536
2,430
1,953
671
2,138
1,342
2,904
2,286
1,497
3,501
1,508

159.0
249.7
217.5
196.5
648.7
414.4
293.4
213.9
570.2
643.5
397.2
27.1
296.0
405.1
247.6
286.2
233.7
285.8
328.4
344.0
221.6
321.9
388.4
62.3
182.0
122.1
210.0
279.9
134.5
507.8
286.1
393.9
456.1
266.3
220.9
309.7
320.4
142.7
248.5
403.1
143.5
388.6
287.2
369.0
122.3
213.6
124.1
374.1
245.1
257.2
291.4
156.5


HIV Surveillance Report

135

Vol. 33

Table 22. Diagnoses of HIV infection, 2020, and persons living with diagnosed HIV infection (prevalence), year-end 2020, by
metropolitan statistical area of residence—United States and Puerto Rico (cont)
Diagnoses, 2020a (COVID-19 pandemic)
MSA of residence

No.

Ratec

Rankd

Houston–The Woodlands–Sugar Land, TX
Indianapolis–Carmel–Anderson, IN
Jackson, MS
Jacksonville, FL
Kansas City, MO–KS
Knoxville, TN
Lakeland–Winter Haven, FL
Lancaster, PA
Lansing–East Lansing, MI
Las Vegas–Henderson–Paradise, NV
Lexington–Fayette, KY
Little Rock–North Little Rock–Conway, AR
Los Angeles–Long Beach–Anaheim, CA
Anaheim Division
Los Angeles Division
Louisville/Jefferson County, KY–IN
Madison, WI
McAllen–Edinburg–Mission, TX
Memphis, TN–MS–AR
Miami–Fort Lauderdale–Pompano Beach, FL
Fort Lauderdale Division
Miami Division
West Palm Beach Division
Milwaukee–Waukesha, WI
Minneapolis–St. Paul–Bloomington, MN–WI
Modesto, CA
Myrtle Beach–Conway–North Myrtle Beach, SC–NC
Nashville–Davidson–Murfreesboro–Franklin, TN
New Haven–Milford, CT
New Orleans–Metairie, LA
New York–Newark–Jersey City, NY–NJ–PAf
Nassau County Division
New Brunswick Division
New York Division
Newark Division
North Port–Sarasota–Bradenton, FL
Ogden–Clearfield, UT
Oklahoma City, OK
Omaha–Council Bluffs, NE–IA
Orlando–Kissimmee–Sanford, FL
Oxnard–Thousand Oaks–Ventura, CA
Palm Bay–Melbourne–Titusville, FL
Pensacola–Ferry Pass–Brent, FL
Philadelphia–Camden–Wilmington, PA–NJ–DE–MDe
Camden Division
Montgomery County Division
Philadelphia Division
Wilmington Divisione
Phoenix–Mesa–Scottsdale, AZ
Pittsburgh, PA
Portland–South Portland, ME
Portland–Vancouver–Hillsboro, OR–WA

1,110
206
118
265
168
46
77
18
24
343
39
98
1,649
264
1,385
178
20
58
279
1,455
461
781
213
111
182
27
41
209
47
220
2,238
127
101
1,712
298
71
21
178
41
501
55
74
48
621
103
70
380
68
508
104
7
136

15.5
9.9
20.0
16.7
7.7
5.2
10.3
3.3
4.4
14.8
7.5
13.1
12.6
8.3
13.9
14.0
3.0
6.6
20.7
23.6
23.5
28.8
14.1
7.0
5.0
4.9
8.0
10.7
5.5
17.3
11.7
4.5
4.2
14.6
13.7
8.3
3.0
12.5
4.3
19.0
6.5
12.2
9.4
10.2
8.3
3.5
17.7
9.3
10.0
4.5
1.3
5.4

11
46
4
10
63
88
42
106
99
13
65
18
22
—
—
15
109
74
3
1
—
—
—
69
90
92
60
38
84
9
31
—
—
—
—
56
108
23
101
5
76
25
51
44
—
—
—
—
45
96
112
87


HIV Surveillance Report

136

Prevalence of diagnosed HIV infection,
year-end 2020b (COVID-19 pandemic)
No.
32,246
5,886
3,259
7,394
5,005
1,326
2,659
831
664
9,390
1,238
2,428
57,361
7,097
50,264
3,919
853
1,555
7,254
54,624
19,988
26,583
8,053
3,382
7,626
826
1,242
5,548
3,343
8,225
135,802
5,862
5,179
111,921
12,840
2,157
445
3,007
540
12,868
1,142
1,734
1,547
26,297
2,995
2,356
18,505
2,441
13,183
3,748
903
5,776

Ratec
450.7
281.5
553.2
465.6
230.3
151.0
357.1
152.1
121.1
405.4
237.9
325.2
437.5
224.1
505.5
308.8
127.2
177.7
537.9
884.9
1,020.8
981.9
534.2
214.4
208.5
150.2
241.4
282.9
392.4
646.5
710.1
207.5
217.2
952.8
592.3
252.4
64.4
211.0
56.6
487.5
135.7
285.0
302.4
430.5
240.2
118.5
862.6
335.6
260.5
162.3
166.2
230.1

Vol. 33

Table 22. Diagnoses of HIV infection, 2020, and persons living with diagnosed HIV infection (prevalence), year-end 2020, by
metropolitan statistical area of residence—United States and Puerto Rico (cont)
Diagnoses, 2020a (COVID-19 pandemic)
MSA of residence
Poughkeepsie–Newburgh–Middletown, NY
Providence–Warwick, RI–MA
Provo–Orem, UT
Raleigh–Cary, NC
Richmond, VA
Riverside–San Bernardino–Ontario, CA
Rochester, NY
Sacramento–Roseville–Folsom, CA
St. Louis, MO–IL
Salt Lake City, UT
San Antonio–New Braunfels, TX
San Diego–Chula Vista–Carlsbad, CA
San Francisco–Oakland–Berkeley, CA
Oakland Division
San Francisco Divisionf
San Jose–Sunnyvale–Santa Clara, CA
San Juan–Carolina–Caguas, PR
Scranton–Wilkes-Barre, PA
Seattle–Tacoma–Bellevue, WA
Seattle Division
Tacoma Division
Spokane–Spokane Valley, WA
Springfield, MA
Stockton, CA
Syracuse, NY
Tampa–St. Petersburg–Clearwater, FL
Toledo, OH
Tucson, AZ
Tulsa, OK
Virginia Beach–Norfolk–Newport News, VA–NC
Washington–Arlington–Alexandria, DC–VA–MDe–WV
Frederick Divisione
Washington Divisione
Wichita, KS
Winston-Salem, NC
Worcester, MA–CT
Youngstown–Warren–Boardman, OH–PA
Subtotal for MSAs (population of 500,000)

Prevalence of diagnosed HIV infection,
year-end 2020b (COVID-19 pandemic)

Ratec

Rankd

No.

Ratec

23
85
12
152
125
504
74
189
200
78
305
296
441
229
198
108
220
31
289
232
57
38
33
83
28
444
24
88
86
219
678
94
584
25
61
42
30

3.4
5.2
1.8
10.7
9.6
10.8
6.9
8.0
7.1
6.3
11.8
8.9
9.4
8.1
12.2
5.5
11.0
5.6
7.2
7.5
6.2
6.6
4.7
10.8
4.3
13.7
3.7
8.3
8.5
12.3
10.7
7.1
11.7
3.9
9.0
4.4
5.6

105
89
111
37
49
35
70
61
68
77
29
54
50
—
—
85
33
82
67
—
—
75
94
34
100
16
104
57
55
24
36
—
—
102
53
97
81

1,838
2,461
261
4,080
4,579
14,621
2,841
5,412
7,251
2,190
7,417
13,346
23,014
8,746
13,479
3,500
9,418
918
9,946
8,344
1,602
741
2,256
1,432
1,310
13,761
1,130
2,725
2,009
6,744
34,834
4,361
30,473
993
2,070
2,236
856

270.9
151.5
39.4
287.2
351.3
312.5
266.1
227.9
258.5
176.6
286.3
400.5
490.0
310.7
829.5
177.6
470.2
166.1
247.5
268.8
175.3
129.0
324.3
186.5
202.8
424.2
176.1
256.8
199.6
378.9
550.8
331.1
608.5
154.2
304.5
236.4
161.1

No.

24,724

10.8

—

872,744

381.5

Metropolitan areas (population of 50,000–499,999)

3,865

6.6

—

109,183

187.1

Nonmetropolitan areas

1,952

4.3

—

58,898

129.4

30,689

9.2

—

1,071,392

322.1

Totalg

Abbreviations: MSA, metropolitan statistical area; CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data on persons living with diagnosed HIV infection in 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with
caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12,
and rates based on these numbers, should be interpreted with caution. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the 50
states, the District of Columbia, and Puerto Rico.
MSA definitions for this report can be found at http://www.census.gov/programs-surveys/metro-micro.html.
a Data are based on residence at time of diagnosis of HIV infection.
b Data are based on address of residence at the end of the specified year (i.e., most recent known address).
c Rates are per 100,000 population.
d Based on rate.
e Data for Maryland should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
f Counts of diagnoses of HIV infection for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of < 500,000.
g Includes persons whose county of residence is unknown.


HIV Surveillance Report

137

Vol. 33

Web Addresses for Reports of State and Local HIV Surveillance
Alabama...................... http://www.alabamapublichealth.gov/hiv/publications.html
Alaska ......................... https://dhss.alaska.gov/dph/Epi/hivstd/Pages/hivdata.aspx
Arizona........................ http://www.azdhs.gov/phs/edc/odis/hiv-epidemiology/reports/index.php?pg=annual
Arkansas..................... https://www.healthy.arkansas.gov/programs-services/topics/hiv-aids-sti-surveillance
California..................... https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OAsre.aspx
Chicago....................... https://www.cityofchicago.org/city/en/depts/cdph/provdrs/health_data_and_reports/svcs/get_sti_hiv_datainchicago.html
Colorado ..................... https://cdphe.colorado.gov/sti-hiv-data-reporting
Connecticut................. https://portal.ct.gov/DPH/AIDS--Chronic-Diseases/Surveillance/Connecticut-HIV-Statistics
Delaware..................... http://www.dhss.delaware.gov/dhss/dph/epi/disstatshiv.html
District of Columbia..... https://dchealth.dc.gov/service/hiv-reports-and-publications
Florida......................... http://www.floridahealth.gov/diseases-and-conditions/aids/surveillance/index.html
Georgia ....................... https://dph.georgia.gov/data-fact-sheet-summaries#SurveillanceSummaries
Guam .......................... http://dphss.guam.gov/content/hiv-surveillance-program
Hawaii ......................... https://health.hawaii.gov/harmreduction/hiv-aids-surveillance/
Houston ...................... http://www.houstontx.gov/health/HIV-STD/
Idaho........................... http://healthandwelfare.idaho.gov/Health/FamilyPlanningSTDHIV/STDStatistics/tabid/393/Default.aspx
Illinois.......................... http://dph.illinois.gov/topics-services/diseases-and-conditions/hiv-aids/hiv-surveillance/update-reports
Indiana ........................ http://www.in.gov/isdh/23266.htm
Iowa ............................ http://idph.iowa.gov/hivstdhep/hiv/data
Kansas........................ https://www.kdhe.ks.gov/474/Kansas-STI-HIV-Statistics
Kentucky ..................... https://chfs.ky.gov/agencies/dph/dehp/hab/Pages/reportsstats.aspx
Los Angeles ................ http://publichealth.lacounty.gov/dhsp/Reports.htm
Louisiana .................... http://new.dhh.louisiana.gov/index.cfm/newsroom/category/63
Maine .......................... https://www.maine.gov/dhhs/mecdc/infectious-disease/hiv-std/data/index.shtml
Maryland ..................... https://health.maryland.gov/phpa/OIDEOR/CHSE/Pages/statistics.aspx
Massachusetts............ https://www.mass.gov/lists/hivaids-epidemiologic-profiles
Michigan ..................... https://www.michigan.gov/mdhhs/keep-mi-healthy/chronicdiseases/hivsti/data-and-statistics
Minnesota ................... https://www.health.state.mn.us/diseases/hiv/stats/index.html
Mississippi .................. https://msdh.ms.gov/msdhsite/_static/14,0,150.html
Missouri ...................... http://health.mo.gov/data/hivstdaids/data.php
Montana...................... https://dphhs.mt.gov/publichealth/cdepi/surveillance
Nebraska .................... https://dhhs.ne.gov/Pages/HIV-Prevention.aspx
Nevada ....................... http://dpbh.nv.gov/Programs/HIV-OPHIE/dta/Publications/HIV/AIDS_Surveillance_Program_(HIV-OPHIE)_-_Publications/
New Hampshire .......... https://www.dhhs.nh.gov/programs-services/disease-prevention/infectious-disease-control/hiv-prevention
New Jersey ................. http://www.nj.gov/health/hivstdtb/hiv-aids/statmap.shtml
New Mexico ................ http://nmhealth.org/data/infectious/20/
New York .................... https://www.health.ny.gov/diseases/aids/general/statistics/index.htm
New York City ............. http://www1.nyc.gov/site/doh/data/data-sets/hiv-aids-surveillance-and-epidemiology-reports.page
North Carolina............. http://epi.publichealth.nc.gov/cd/stds/figures.html
North Dakota............... https://www.ndhealth.gov/hiv/Data/
Ohio ............................ https://odh.ohio.gov/know-our-programs/hiv-aids-surveillance-program/data-and-statistics/
Oklahoma ................... https://oklahoma.gov/health/prevention-and-preparedness/sexual-health-and-harm-reduction-service/fact-sheets-ok-data.html
Oregon........................ https://www.oregon.gov/oha/ph/DiseasesConditions/CommunicableDisease/DiseaseSurveillanceData/HIVData/Pages/index.aspx
Pennsylvania .............. https://www.health.pa.gov/topics/programs/HIV/Pages/Annual-Summary.aspx
Philadelphia ................ https://www.phila.gov/documents/hiv-aids-data-and-research/
Puerto Rico ................. https://www.salud.gov.pr/CMS/471
Rhode Island............... http://health.ri.gov/publications/bytopic.php?parm=HIV
San Francisco............. http://www.sfdph.org/dph/files/reports/default.asp
South Carolina ............ http://www.dhec.sc.gov/Health/DiseasesandConditions/InfectiousDiseases/HIVandSTDs/DataandReports/
South Dakota .............. http://doh.sd.gov/diseases/infectious/HIV-AIDS/Prevention.aspx
Tennessee .................. https://www.tn.gov/health/health-program-areas/statistics/health-data/hiv-data.html
Texas .......................... http://www.dshs.state.tx.us/hivstd/reports/default.shtm
U.S. Virgin Islands ...... https://doh.vi.gov/programs/communicable-diseases
Utah ............................ http://health.utah.gov/epi/diseases/hivaids/surveillance/index.html
Vermont ...................... http://www.healthvermont.gov/immunizations-infectious-disease/hiv/surveillance
Virginia........................ http://www.vdh.virginia.gov/disease-prevention/disease-prevention/hiv-aids-sexually-transmitted-disease-std-hepatitis-reports/
Washington................. https://doh.wa.gov/data-statistical-reports/diseases-and-chronic-conditions/hiv-data
West Virginia............... https://oeps.wv.gov/hiv-aids/pages/default.aspx#box
Wisconsin ................... http://dhs.wisconsin.gov/aids-hiv/Stats/index.htm
Wyoming..................... https://health.wyo.gov/publichealth/communicable-disease-unit/hivaids-surveillance-program/
Note. Electronic reports are not available for the following areas: American Samoa, the Northern Mariana Islands, and the Republic of Palau.


HIV Surveillance Report

138

Vol. 33

ENDING THE HIV EPIDEMIC: A PLAN FOR AMERICA INITIATIVE, PHASE
I AREAS
To accelerate action to end the HIV epidemic, the U.S. Department of Health and Human Services (HHS) has
proposed a plan to reduce new HIV infections in the United States. The Ending the HIV Epidemic: A Plan for
America (EHE) initiative, Phase I, will implement high-impact HIV prevention, care, treatment, and outbreak
response strategies in 48 counties, the District of Columbia, San Juan, Puerto Rico, and 7 states with a substantial rural HIV burden. The goal of the initiative is to reduce new HIV infections by 75% in 5 years, and by 90%
in 10 years.
The EHE Phase I jurisdictions include the District of Columbia, San Juan, Puerto Rico, and 48 counties:
Arizona—Maricopa County; California—Alameda County, Los Angeles County, Orange County, Riverside
County, Sacramento County, San Bernardino County, San Diego County, San Francisco County; 
Florida—Broward County, Duval County, Hillsborough County, Miami-Dade County, Orange County, Palm
Beach County, Pinellas County; Georgia—Cobb County, DeKalb County, Fulton County, Gwinnett County;
Illinois—Cook County; Indiana—Marion County; Louisiana—East Baton Rouge Parish, Orleans Parish;
Maryland—Baltimore City, Montgomery County, Prince George’s County; Massachusetts—Suffolk County;
Michigan—Wayne County; Nevada—Clark County; New Jersey—Essex County, Hudson County; New
York—Bronx County, Kings County, New York County, Queens County; North Carolina—Mecklenburg
County; Ohio—Cuyahoga County, Franklin County, Hamilton County; Pennsylvania—Philadelphia County;
Tennessee—Shelby County; Texas—Bexar County, Dallas County, Harris County, Tarrant County, Travis
County; Washington—King County.
EHE Phase I jurisdictions also include the following 7 states with substantial rural HIV burden: Alabama,
Arkansas, Kentucky, Mississippi, Missouri, Oklahoma, and South Carolina.


HIV Surveillance Report

139

Vol. 33

Table A1. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2019 and 2020—Ending the HIV Epidemic
Phase I jurisdictions
2019

2020 (COVID-19 pandemic)

Persons aged ≥ 13 years
Area of residence
Arizona
Maricopa County

No.

a

Rate

Total
No.

Persons aged ≥ 13 years
a

Rate

No.

a

Rate

Total
No.

Ratea

505

13.5

506

11.3

477

12.5

479

10.5

District of Columbia

217
1,537
247
266
147
295
383
208
250

15.3
18.1
9.2
13.1
11.4
16.7
13.6
26.3
41.2

218
1,539
247
266
147
295
384
208
252

13.1
15.4
7.8
10.8
9.5
13.5
11.5
23.7
35.6

157
1,382
264
239
153
263
296
153
197

11.1
16.4
9.8
11.6
11.8
14.7
10.5
19.6
32.3

157
1,385
264
241
153
263
296
153
197

9.4
13.9
8.3
9.7
9.8
12.0
8.9
17.7
27.6

Florida
Broward County
Duval County
Hillsborough County
Miami-Dade County
Orange County
Palm Beach County
Pinellas County

597
279
265
1,134
464
236
182

36.0
34.9
21.4
49.0
39.5
18.2
21.0

597
279
266
1,135
465
237
182

30.5
29.1
18.0
41.9
33.3
15.8
18.7

460
229
247
781
369
213
152

27.6
28.4
19.6
33.7
31.1
16.3
17.5

461
230
247
781
370
213
153

23.5
23.8
16.5
28.8
26.3
14.1
15.7

Georgia
Cobb County
DeKalb County
Fulton County
Gwinnett County

178
343
532
211

28.0
54.4
58.9
27.6

178
343
533
211

23.4
45.1
50.0
22.5

135
269
477
149

21.1
42.4
52.0
19.3

135
270
477
149

17.7
35.4
44.3
15.8

Illinois
Cook County

882

20.3

884

17.2

774

17.9

776

15.2

Indiana
Marion County

205

26.0

206

21.4

167

21.1

168

17.4

Louisiana
East Baton Rouge Parish
Orleans Parish

155
158

42.1
47.3

155
158

35.1
40.4

124
105

33.8
31.5

124
105

28.2
27.0

Marylandb
Baltimore City
Montgomery County
Prince George's County

197
131
278

39.0
14.9
36.5

197
131
278

33.1
12.5
30.5

175
80
214

35.1
9.1
28.1

176
80
214

30.0
7.6
23.5

Massachusetts
Suffolk County

133

18.7

133

16.5

135

19.1

135

16.8

Michigan
Wayne County

289

19.9

289

16.5

227

15.7

227

13.0

Nevada
Clark County

451

23.7

451

19.8

343

17.7

343

14.8

New Jersey
Essex County
Hudson County

233
150

35.1
26.3

233
150

29.0
22.3

199
123

30.0
21.7

199
124

24.9
18.5

New York
Bronx County
Kings County
New York County
Queens County

502
474
333
354

43.2
22.3
22.9
18.4

503
474
334
355

35.5
18.5
20.5
15.8

338
444
296
316

29.4
21.0
20.6
16.7

339
444
296
316

24.2
17.5
18.4
14.2

California
Alameda County
Los Angeles County
Orange County
Riverside County
Sacramento County
San Bernardino County
San Diego County
San Francisco County


HIV Surveillance Report

140

Vol. 33

Table A1. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2019 and 2020—Ending the HIV Epidemic
Phase I jurisdictions (cont)
2019

2020 (COVID-19 pandemic)

Persons aged ≥ 13 years
Area of residence

No.

Ratea

Total
No.

Persons aged ≥ 13 years
Ratea

No.

Ratea

Total
No.

Ratea

North Carolina
Mecklenburg County

267

28.8

268

24.1

209

22.2

209

18.5

Ohio
Cuyahoga County
Franklin County
Hamilton County

159
215
172

15.1
19.7
25.2

159
215
172

12.9
16.3
21.0

185
204
132

17.6
18.6
19.3

185
205
132

15.1
15.5
16.1

Pennsylvania
Philadelphia County

445

33.5

445

28.1

331

24.9

332

21.0

Puerto Rico
San Juan Municipio

88

31.1

88

27.6

71

25.5

71

22.7

Tennessee
Shelby County

261

34.0

261

27.9

235

30.6

235

25.1

Texas
Bexar County
Dallas County
Harris County
Tarrant County
Travis County

331
748
1,218
312
177

20.2
35.0
32.0
18.2
16.4

331
749
1,219
315
177

16.5
28.4
25.9
15.0
13.9

282
658
921
292
162

17.0
30.6
24.0
16.8
14.7

282
659
924
292
162

13.9
25.0
19.5
13.8
12.5

242

12.6

242

10.8

198

10.2

198

8.7

Washington
King County

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in
state/local jurisdictions. Data are based on residence at time of diagnosis of HIV infection.
a Rates are per 100,000 population.
b Data for Maryland should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.


HIV Surveillance Report

141

Vol. 33


HIV Surveillance Report

Table A2. Persons aged ≥ 13 years living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2020 (COVID-19 pandemic)—Ending the HIV Epidemic Phase I
jurisdictions

142
Vol. 33

Area of residence
Arizona
Maricopa County
California
Alameda County
Los Angeles County
Orange County
Riverside County
Sacramento County
San Bernardino County
San Diego County
San Francisco County
District of Columbia
Florida
Broward County
Duval County
Hillsborough County
Miami-Dade County
Orange County
Palm Beach County
Pinellas County
Georgia
Cobb County
DeKalb County
Fulton County
Gwinnett County
Illinois
Cook County
Indiana
Marion County
Louisiana
East Baton Rouge Parish
Orleans Parish
Marylande
Baltimore City
Montgomery County
Prince George's County
Massachusetts
Suffolk County
Michigan
Wayne County

American Indian/
Alaska Native
No.
Rated

Asiana
No.
Rated

Black/African
American
No.
Rated

Hispanic/Latinob
No.
Rated

Native Hawaiian/
other Pacific Islander
No.
Rated

White
No.
Rated

Multiracial
No.
Rated

Totalc
No.
Rated

318

513.3

179

102.8

1,891

890.0

3,685

331.9

18

235.6

5,546

253.0

432

604.6

12,101

316.0

11
51
8
23
20
15
31
35
14

319.3
308.9
143.9
232.4
299.8
211.9
255.0
2,280.4
1,113.8

410
1,813
543
170
174
105
411
785
77

88.3
138.4
91.4
117.3
79.2
73.6
116.0
276.2
270.1

2,239
9,502
378
843
1,107
1,004
1,585
1,502
9,653

1,541.9
1,379.5
815.3
635.0
874.7
686.1
1,179.3
3,846.6
3,690.4

1,355
23,584
3,535
2,688
1,034
2,419
5,413
2,844
1,211

456.9
599.4
411.9
271.3
358.5
256.4
595.4
2,542.9
1,919.3

27
50
10
7
16
5
19
27
6

235.4
261.2
132.8
111.7
103.5
90.8
158.5
948.2
2,127.7

1,707
12,752
2,431
5,706
1,976
1,134
5,427
6,046
2,036

380.1
551.1
218.9
777.7
335.7
223.9
412.5
1,912.4
837.6

280
2,488
187
328
192
163
445
564
791

560.1
1,548.1
299.0
802.0
358.8
506.0
548.4
2,408.6
6,396.6

6,030
50,243
7,092
9,765
4,519
4,845
13,331
11,803
13,792

424.6
595.0
264.2
474.2
347.9
271.6
472.9
1,515.0
2,260.4

14
4
4
7
6
5
2

427.1
153.5
137.1
351.7
230.7
238.2
97.7

136
55
64
75
69
34
47

216.2
135.3
113.9
206.1
101.8
90.0
154.7

9,198
4,219
3,174
10,533
3,807
4,676
1,454

2,011.3
1,827.6
1,611.8
3,101.7
1,639.7
2,032.3
1,740.9

4,101
447
1,676
13,045
2,514
1,371
575

789.4
537.4
457.7
802.6
661.4
472.1
696.8

5
2
3
7
10
2
0

441.9
297.3
343.2
1,279.6
727.1
310.7
0.0

5,924
1,395
2,122
2,515
2,346
1,771
2,596

989.7
322.8
343.5
848.0
485.9
242.4
395.8

597
213
190
376
221
188
152

2,605.3
1,331.1
910.0
2,614.4
1,166.3
1,292.8
1,156.1

19,975
6,335
7,233
26,559
8,973
8,047
4,826

1,199.3
785.9
573.3
1,147.4
756.7
616.0
555.8

0
2
10
0

0.0
209.7
776.8
0.0

16
70
54
61

44.4
173.1
75.8
59.6

2,126
6,590
11,495
1,815

1,202.9
1,932.2
2,933.2
833.3

408
705
1,012
613

529.6
1,545.7
1,665.4
394.4

1
3
7
1

410.1
889.6
4,126.5
308.5

718
1,162
2,592
511

212.5
592.8
688.2
183.0

209
459
833
181

1,816.2
4,676.6
5,537.4
1,262.2

3,478
8,992
16,004
3,182

542.9
1,417.8
1,745.2
412.9

24

465.4

348

100.2

12,587

1,277.6

5,813

556.0

11

1,347.9

5,296

281.2

1,849

3,314.8

25,929

599.8

2

130.7

137

464.8

2,357

1,070.1

504

668.0

3

1,519.9

1,569

349.6

223

1,381.9

4,795

605.6

3
4

367.2
506.1

10
23

78.8
226.8

3,519
3,340

2,112.5
1,729.1

84
296

594.1
1,740.7

0
0

0.0
0.0

432
1,152

255.6
1,061.8

55
131

1,373.5
3,403.5

4,103
4,948

1,116.9
1,483.6

9
3
4

650.4
200.6
211.2

21
75
41

148.1
53.2
122.5

8,137
2,285
6,084

2,658.1
1,399.1
1,261.6

390
627
671

1,640.6
384.7
503.5

0
2
0

0.0
468.4
0.0

774
573
366

532.1
146.5
375.1

569
300
898

7,352.9
1,530.5
6,828.2

9,900
3,865
8,064

1,984.7
439.3
1,058.4

6

463.8

123

180.3

2,156

1,583.8

1,506

989.4

1

248.8

1,806

539.0

115

889.2

5,713

808.9

8

160.2

27

52.4

5,409

999.4

331

403.0

0

0.0

1,007

136.6

225

776.0

7,007

484.6


HIV Surveillance Report

Table A2. Persons aged ≥ 13 years living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2020 (COVID-19 pandemic)—Ending the HIV Epidemic Phase I
jurisdictions (cont)

143

Area of residence
Nevada
Clark County
New Jersey
Essex County
Hudson County
New York
Bronx County
Kings County
New York County
Queens County
North Carolina
Mecklenburg County
Ohio
Cuyahoga County
Franklin County
Hamilton County
Pennsylvania
Philadelphia County
Puerto Ricof
San Juan Municipio
Tennessee
Shelby County
Texas
Bexar County
Dallas County
Harris County
Tarrant County
Travis County
Washington
King County

American Indian/
Alaska Native
No.
Rated

Asiana
No.
Rated

Black/African
American
No.
Rated

Hispanic/Latinob
No.
Rated

Native Hawaiian/
other Pacific Islander
No.
Rated

White
No.
Rated

Multiracial
No.
Rated

Totalc
No.
Rated

35

382.5

337

160.8

2,688

1,185.6

2,620

455.1

49

347.4

3,298

391.1

358

587.1

9,385

483.9

0
3

0.0
347.1

29
95

74.3
100.6

5,967
1,325

2,330.1
2,191.5

1,812
2,280

1,206.6
972.0

3
0

1,136.0
0.0

514
834

247.5
488.6

630
331

7,585.3
4947.4

8,973
4,874

1,353.6
858.1

6
6
8
12

187.2
149.3
395.1
179.0

98
371
567
790

201.8
137.4
305.4
153.5

11,641
14,295
7,318
5,016

3,413.5
2,241.9
4,153.9
1,459.2

13,697
7,104
8,869
6,960

2,149.9
1,828.9
2,497.5
1,356.8

2
5
6
9

344.3
811.4
1,039.4
381.7

852
2,706
7,908
1,972

781.7
349.5
1,139.1
407.9

1,339
1,719
1,655
1,273

13,358.9
5,013.6
6,646.7
3,806.7

27,676
26,236
26,448
16,064

2,407.7
1,243.8
1,838.4
846.6

8

289.8

47

79.0

4,200

1,421.2

582

504.5

1

261.6

1,007

222.5

338

2,133.7

6,186

656.7

2
7
0

123.0
334.4
0.0

19
37
19

54.2
57.7
95.6

2,810
2,312
1,805

938.2
948.4
1,051.1

561
343
115

906.5
608.4
557.7

0
1
1

0.0
220.8
147.9

1,254
2,200
994

198.0
312.0
217.9

248
283
173

1,474.9
1,083.8
1,399.9

4,920
5,204
3,115

469.3
473.9
456.4

29

1,015.8

166

158.4

10,847

2,059.3

2,807

1,514.5

5

1,553.8

2,577

532.0

587

2,608.7

17,019

1282.6

0

—

0

—

4

—

3,408

—

0

—

18

—

3

—

3,433

1,231.0

2

155.3

13

58.9

5,136

1,260.9

238

564.0

1

791.0

609

213.6

283

3,258.8

6,283

819.4

3
8
6
2
4

73.3
124.1
79.2
30.1
142.6

46
217
366
95
69

88.4
147.1
126.0
92.5
82.7

957
8,101
12,760
2,705
1,141

758.8
1,640.6
1,741.8
914.3
1,271.2

4,386
5,113
8,616
1,516
1,917

444.7
622.9
536.6
316.0
555.2

0
8
3
4
1

0.0
810.7
151.3
119.5
125.5

1,061
4,486
4,196
1,568
1,807

226.2
687.2
362.8
191.6
321.4

303
1,050
1,119
318
221

1,436.2
4,113.0
2,538.4
1,133.5
1164.4

6,756
18,983
27,068
6,208
5,160

406.8
883.8
705.1
357.9
467.7

37

325.2

321

81.4

1,430

1,132.5

1,146

651.5

27

182.3

3,639

316.1

517

715.8

7,117

365.7

Vol. 33

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services,
and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Data are based on residence at the end of the specified year (i.e., most recent known address).
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanic/Latino persons can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population.
e Data for Maryland should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
f Rates by race/ethnicity are not provided because U.S. census information is limited for Puerto Rico.